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Abstract 
 
Natural killer cells are large, granular, innate lymphoid cells that lie at the interface 
between innate and adaptive immunity and facilitate bidirectional crosstalk 
between the two systems. This has led to an abundance of research into 
vaccination induced priming of ‘adaptive’ or memory-like NK cell responses. 
Using human peripheral blood mononuclear cells for cross-sectional and 
vaccination studies in two distinct virus models, cytokine-dependent NK cell 
activation, and the effect of vaccination on these responses was investigated.  
Very low concentrations of IL-15 enhanced NK cell activation in response to 
inactivated influenza virus stimulation in vitro via augmented innate cytokine 
secretion from accessory cells, in particular IL-12 from myeloid dendritic cells. 
Similarly, after seasonal influenza vaccination, both accessory cell cytokine 
secretion and NK cell activation were enhanced compared to before vaccination 
in response to low dose IL-15 stimulation in vitro. This suggested that together 
with a vaccination-induced enhanced responsiveness to innate cytokines at the 
NK cell level (the generation of cytokine-induced memory like NK cells), an 
increased production of innate cytokines at the accessory cell level contributed 
to the overall enhancement in NK cell response post-vaccination. 
The effect of vaccination on NK cell effector function was further investigated in 
PBMC from heathy volunteers vaccinated with an Ebola glycoprotein expressing, 
vectored, prime-boost regimen vaccine (Ad26.ZEBOV/MVA-BN-Filo). Both 
inactivated influenza vaccination and Ebola vaccination increased the frequency 
and proliferation of less differentiated, CD56bright NK cells. Data described in this 
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thesis also demonstrate for the first time that NK cells were activated indirectly 
by Ebola glycoprotein induced IL-12 and IL-18, independently of Ebola 
vaccination, and in contrast to influenza vaccination, there was no evidence of 
vaccine induced boosting of these responses. NK cell responses to Ebola GP 
were dependent on accessory cell TLR-4 engagement but were tightly regulated 
by CD14+ monocyte-derived IL-10. In addition to soluble antigen driven cytokine-
dependent activation, 21-day post-boost vaccination serum induced robust 
antibody-dependent NK cell activation of more differentiated subsets that varied 
with vaccine arm and correlated with antibody titre.  
Together, these studies demonstrate that two different types of vaccines against 
distinct viruses have similar impacts on the activation of less differentiated NK 
cells. Priming of both NK cells and myeloid cells for enhanced cytokine-
dependent NK cell responses after vaccination was not replicated across different 
vaccination models and may be a function dependent on the unique cytokine 
signatures induced by the respective antigens. These studies further our 
understanding of NK cells in post-vaccination effector responses, and may 
represent an avenue for improving future design of vaccines and adjuvants. 
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1.1 The Immune System 
 
The human immune system is traditionally divided into two arms, innate and 
adaptive. Innate immune cells of myeloid lineage, including monocytes, 
macrophages and dendritic cells (DCs), and of lymphoid lineage, such as innate 
lymphoid cells (ILC) including natural killer (NK) cells, react within hours of 
infection. The innate immune system responds to conserved pathogen 
associated molecular patterns (PAMP) present on viral, bacterial and fungal 
pathogens via pattern-recognition receptor (PRR) engagement. Activation of 
these cells leads to non-specific, antigen-independent targeting and elimination 
of infected cells and extracellular pathogens. Downstream secretion of pro and 
anti-inflammatory cytokines and chemokines conducts recruitment of immune 
cells to the site of infection and enables the orchestration of subsequent immune 
responses. The adaptive arm, consisting of T and B lymphocytes, develops later 
in the course of an infection and is capable of targeting specific pathogens via 
rearrangement of genes encoding antigen receptors to produce a diverse array 
of T and B cell receptors. This response forms the basis of immunological 
memory and the ability to mount a more robust response upon secondary 
exposure.  
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1.2 Natural Killer Cells 
 
NK cells are large, granular, ILCs that express a wide variety of germ line 
encoded receptors on their surface. Derived from the bone marrow, but along a 
distinct lineage from B and T cells, they make up 5-15% of human peripheral 
blood mononuclear cells (PBMC). NK cells are characterised phenotypically by 
the lack of T cell marker CD3 and/or B cell marker CD19 and the expression of 
CD56 (neural cell adhesion molecule; NCAM) (1). They are among the first cells 
to respond during primary infections and are important in the early control of viral 
infections including herpesviruses and influenza infections (2-5). The role of NK 
cells as early producers of inflammatory cytokines (such as interferon (IFN)-γ), 
controllers of viral load and modulators of the bidirectional cross-talk between 
innate and adaptive immunity has led to an abundance of research into ‘adaptive’ 
or memory-like NK cell responses and their function after vaccination. 
 
1.2.1 Human NK cell Subsets and Differentiation 
 
ILC1, 2 and 3 and NK cells derive from common lymphoid progenitor (CLP) cells, 
however, NK cells are said to derive from a distinct progenitor (NKP vs ILCP) and 
can be distinguished from ILC1 by the expression of transcription factor Eomes 
(6). NKP cells, having gained expression of the IL-15 receptor β-chain (IL-15Rβ; 
CD122), give rise to immature NK cells (iNK) expressing CD56, which develop 
into mature NK cells (mNK) and gain expression of CD94 (a component of killer 
lectin-like receptors; KLR) and CD16 (7, 8). The bone marrow and several 
secondary lymphoid tissues are thought to be the sites of NK cell development 
CHAPTER 1. INTRODUCTION 
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as suggested by the identification of NKP in human tissues (9). IL-15 is critical for 
NK cell development; IL-15-/- mice (or mice deficient in any chain of the IL-15R - 
α, β or γ chain) lack NK cells, highlighting the definitive role for this cytokine (10). 
Group 2 and 3 ILCs are phenotypically and functionally different from ILC1 and 
NK cells; ILC2, distinguished by transcription factor GATA-3 expression, release 
type 2 cytokines (IL-5 and IL-13) and ILC3, dependent on transcription factor 
RORγt, release IL-17 (8). ILC phenotypes are summarised in Table 1.  
 
 NK cells ILC1 ILC2 ILC3 
Lineage - - - - 
CD16 +/- - - - 
CD56 + +/- - +/- 
CD94 + - - - 
CD117 - - +/- + 
CD127 - +/- + + 
NKp44 +/- +/- - +/- 
IL-1βR - +/- + + 
IL-12Rβ + + - +/- 
IL-17Rβ - - + - 
Table 1: Phenotypes of human ILC subsets. Adapted from (11). 
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In human peripheral blood, mature NK cells are subtyped in to CD56dim and 
CD56bright subsets depending on the density of CD56 expression on the cell 
surface. The classification, first made in 1986 by Lanier et al., demonstrated that 
low CD56 expressing NK cells (CD56dim) are CD16 positive (or high) and more 
cytotoxic than high CD56 expressing NK cells (CD56bright) that produce cytokines 
more efficiently (12). CD56bright NK cells that make up around 8% of NK cells in 
human peripheral blood also become cytotoxic and CD56dim cells that make up 
the majority of NK cells in peripheral blood (>95%) also release cytokines, 
blurring the distinction between the roles (1, 13). It is thought that CD56bright NK 
cells are precursors to more differentiated CD56dim NK cells, however this is still 
debated and under investigation (14, 15).  
CD57, which is only expressed on a proportion of CD56dim NK cells, is another 
surface marker by which human peripheral blood NK cells are categorised. First 
recognised as a marker of terminal T cell differentiation, CD57 is a terminally 
sulphated glycan carbohydrate carried on adhesion molecules (16). CD57+ NK 
cells are thought to differentiate from CD56dimCD57- cells (via intermediate CD57 
expression) during normal ageing and activation, which is accelerated by viral 
infections such as human cytomegalovirus (HCMV) (discussed later) (17, 18). 
Less differentiated CD56dimCD57- NK cells are more responsive to exogenous 
cytokines and produce more IFN-γ than the more differentiated CD56dimCD57+ 
NK cell subset (16). CD56dimCD57+ NK cells express the highest levels of CD16 
making them specialised for antibody-dependent activation, but respond less well 
to cytokine stimulation (17, 19). CD56bright and CD56dimCD57- NK cells are also 
more proliferative, measured by Ki67 expression, and express higher levels and 
percentages of cytokine receptors such as IL-2Rα-chain (CD25), IL-12Rβ2 and 
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IL-18Rα than CD56dimCD57+ NK cells. (18, 19). Figure 1 shows the phenotypic 
and functional differences between NK cell differentiation subsets. 
NK cells are widely distributed in tissues including the liver, lungs and the uterus; 
tissue resident NK cells, in the liver for example, can make up 50% of total 
lymphocytes (1). NK cells in secondary lymphoid tissues such as lymph nodes 
and tonsils are predominantly CD56bright, whereas the majority of splenic NK cells 
are CD56dim (1, 20). ‘Tissue residency’ markers of human NK cells, such as 
integrins involved in retaining lymphocytes in tissues, have recently been 
deduced, such as CD103+ and CD49a+ subsets in the liver, lung and uterus (1, 
20-23).  
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Figure 1: NK cell differentiation subsets. 
The phenotype and function of less differentiated CD56bright, and more differentiated CD56dim NK 
cell subsets, which are further subtyped by CD57 expression. Expression of cytokine receptors 
(for IL-12, IL-18 and IL-2 (CD25)), and activating receptor CD16, IFN-γ secretion and cytotoxicity 
differs between subsets. Adapted from (18). 
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1.2.2 NK Cell Activation  
 
NK cells are activated by several distinct but synergistic signals: direct activation 
by an imbalance in activating and inhibitory receptor engagement, antibody-
dependent activation via CD16 crosslinking, and indirect activation by soluble 
cytokines and chemokines. Figure 2 shows a schematic of how NK cells integrate 
innate and adaptive signals for activation. This thesis primarily focuses on 
antibody and cytokine-dependent NK cell activation. 
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Figure 2: Integration of innate and adaptive signals for NK cell activation. 
NK cells can be activated by soluble or contact-dependent signals from innate antigen 
presentating cells (APCs) such as macrophages (M) or dendritic cells (DC), or by 
adaptive signals such as antibody-antigen immune complxes or T cell-derrived IL-2. 
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1.2.2.1 Direct Activation 
 
NK cells form contacts with myeloid accessory cells and target cells via adhesion 
molecules such as lymphocyte function-associated antigen 1 (LFA-1) (24). An 
initial activating receptor signal, such as NKG2D-mediated recognition of 
upregulated stress ligands can induce a conformational change in LFA-1, 
allowing binding to intracellular adhesion molecule (ICAM)-1 on target cells (25). 
This conjugate formation is essential for cellular polarisation and is important for 
NK cell lytic granule delivery and cytotoxicity (26, 27). Cell-cell contact is also 
important for cytokine mediated NK cell responses, for example trans-
presentation of IL-15 by DC at the interface of DC-NK cell interactions is important 
for NK cell survival, proliferation and activation (28-30). IL-12 may also be 
delivered in a targeted way for inducing NK cell IFN-γ secretion (31).  
NK cells express germ line encoded receptors such as KLR, highly polymorphic 
killer immunoglobulin-like receptors (KIR) and natural cytotoxicity receptors 
(NCR). KLR, for example NKG2A (inhibitory receptor) and NKG2C (activating 
receptor), form heterodimers with CD94 and bind non-classical HLA-E molecules 
(32). KIR bind classical HLA-A, B and C molecules, for example KIR2DL1 
(inhibitory receptor) and KIR2DS1 (activating receptor) bind HLA-C2 molecules 
(33). NCRs NKp30, NKp44 and NKp46 are known for inducing cytotoxicity after 
recognition of self-antigens upregulated in response to cellular stress and 
transformation (34). Contact with cells lacking ligands for inhibitory receptors or 
contact with cells expressing ligands for activating receptors enables direct NK 
cell activation. Under homeostatic conditions, the balance of these receptor 
interactions favours NK inhibition, stalling the killing of healthy self-cells. 
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However, following infection or transformation, down regulation of HLA class I 
and induced expression of stress ligands on the target cell tips the balance in 
favour of NK cell activation, a phenomenon known as missing-self (35, 36).  
This cytotoxic effector mechanism is important in anti-viral immunity as many viral 
proteins, for example human immunodeficiency virus (HIV) Nef and Vpu proteins, 
mediate downregulation of HLA molecules rendering the infected cell open to NK 
cell killing (37-39). Alternatively, in the case of murine cytomegalovirus (MCMV), 
viral protein m157 can act as a ligand for NK cell inhibitory receptor Ly49C stalling 
NK cell activation and evading killing (40, 41). In addition to activation and 
inhibition of NK cell functions in the effector phase of an infection, the level of 
activation and requirement for additional co-stimulation is determined by a prior 
‘education’ process whereby functional receptor-ligand interactions (KIR/HLA 
and NKG2A/HLA) determine NK cell sensitivity for inhibition (42). The presence 
or absence of KIR and their ligands has been linked to the outcome of viral 
infections in humans, for example KIR2DL3 with HLA-C1 (‘educated’ genotype) 
is associated with increased resolution of hepatitis C virus (HCV) infection (43, 
44).   
Direct interaction between human NK cell receptors and pathogen-derived 
molecules demonstrate modulation of NK cell activation in an antigen-specific 
manner. HCV and Flavivirus peptides in combination with HLA-C molecules are 
recognised by KIR2DS2 leading to NK cell activation and target cell lysis (45). 
HCMV-derived peptides stabilise HLA-E on the cell surface acting as a ligand for 
NKG2C, which enables activation and proliferation of NKG2C+ NK cells (46). 
Influenza haemagglutinin (HA) was identified as a ligand for NK cell NKp46 and 
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NKp44 in humans, and shown to trigger cytotoxicity (47, 48). This interaction was 
dependent on sialyation of NKp46 and was demonstrated with HA from H1, H3 
and H5 influenza viruses with different sites and degrees of binding (49, 50). The 
interaction in a mouse model, also dependent on sialic acid residues, was shown 
to be critical for preventing lethal influenza virus infection suggesting an important 
anti-viral mechanism (51, 52). NCRs have also been suggested to bind other 
viral, bacterial and parasite-derived ligands resulting in both activating and 
inhibitory signals (53). Recently, Aspergillus fumigatus hyphae was shown to be 
directly recognised by NK cells involving binding of CD56 inducing NK cell 
cytokine secretion and cytotoxicity (54, 55).  
 
1.2.2.2 Antibody-Dependent Activation 
 
Target cells coated with pathogen-specific antibodies or antibody-antigen 
immune complexes can induce NK cell antibody-dependent cellular cytotoxicity 
(ADCC). The constant (Fc) portion of antigen-specific antibodies (typically IgG1 
and IgG3 in humans) engage activating or inhibitory Fc receptors (FcR), FcγRI 
and FcγRIIIa or FcγRIIa respectively. NK cells express the low affinity, activating 
FcR FcγRIIIa (CD16), predominantly expressed by more differentiated CD56dim 
NK cell subsets. Crosslinking of CD16 leads to signal transduction via 
immunoreceptor tyrosine-based activating motifs (ITAM) and intracellular adaptor 
molecules CD3ζ and/or FcεR1γ (56, 57). This leads to the release of cytolytic 
granules containing lytic proteins such as granzyme B and perforin, a process 
termed degranulation (57). During degranulation, lysosome associated 
membrane protein-1 (LAMP-1; CD107a) within the membrane of the granule is 
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exposed on the surface of the cell and therefore is often used as a marker of NK 
cell degranulation (58). Following activation and vaccination, CD16 is cleaved 
from the surface of NK cells through matrix metalloprotease ADAM17 cleavage, 
which is thought to be a regulation mechanism limiting further antibody and 
cytokine-dependent activation (59-61). 
Antibodies are important effector molecules that facilitate cellular immune 
mechanisms for killing of infected or transformed cells. Many studies are 
shedding light on the importance of ADCC inducing antibodies (with weak 
neutralising ability) in vaccine-induced protection against influenza, Ebola and 
HIV (62-64). NK cell function and ADCC may be utilised as a parameter for the 
evaluation of vaccine responses and in the design of new vaccines or post-
exposure monoclonal antibody (mAb) therapies in the future.  
 
1.2.2.3 Cytokine-Dependent Activation and Regulation 
 
Optimal NK cell activation and regulation requires innate cytokines released from 
accessory cells after antigen recognition by PRRs or pathogen phagocytosis; 
both pro and anti-inflammatory cytokine signalling is indispensable for anti-viral 
immunity (65). In vitro studies have demonstrated unique but synergistic roles of 
IL-12, IL-15, IL-18 and type I IFN, as well as T cell derived IL-2 in NK cell 
activation. Whole PBMC or purified NK cell stimulation with cocktails of IL-12, IL-
15 and IL-18 are well known to induce significant NK cell IFN-γ secretion, 
degranulation and CD25 upregulation (66-68). 
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Type I IFNs, consisting of IFN-α, IFN-β, IFN-ε, IFN-κ, and IFN-ω are produced in 
abundance by DCs after viral infection, predominantly by plasmacytoid DCs. 
Human IFN-α (of which there are 13 subtypes in humans) and IFN-β are critical 
during viral infection; both bind the heterodimeric IFN-α/β (IFNAR) receptor (two 
subunits, IFNAR1 and IFNAR2), expressed on all nucleated cells (69). Receptor 
binding results in signal transduction and phosphorylation of STAT1 and 2 and 
ultimately leads to transcription of IFN-stimulated genes (ISGs) (70). Type I IFN 
is particularly important for NK cell cytotoxicity,  whether that is by binding IFNAR 
on NK cells directly or by indirectly promoting further pro-inflammatory cytokine 
release (such as IL-15 and IL-12) from DCs (71, 72). Many viruses have evolved 
type I IFN evasion mechanisms, highlighting the significance of type I IFN in anti-
viral immune responses. Influenza virus non-structural (NS) 1 protein, for 
example, blocks type I IFN transcription and mRNA processing, and Ebola virus 
encoded VP24 and VP35 proteins use several different mechanisms to strongly 
antagonise host IFN responses (73, 74).  
IL-12, produced by monocytes, macrophages and DCs, is a potent inducer of NK 
cell activation, in particular IFN-γ secretion (75, 76). Engagement with the IL-12 
receptor (a dimer of IL-12Rβ1 and IL-12Rβ2) induces intracellular signalling 
resulting in phosphorylation of STAT4 and transcription of genes for effector 
function (77). Neutralisation of IL-12 has been shown to reduce NK cell IFN-γ 
production in many different infection models in mice and in human in vitro culture 
systems (78-80). Exogenous IL-12 therapy restored NK cell function in HIV 
exposed infants with impaired accessory cell cytokine secretion highlighting the 
importance of this cytokine in the immune response to viral infection (81).  
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IL-18, a member of the IL-1 family, is synthesised as a precursor protein (pro-IL-
18) that is constitutively expressed in macrophages. Pro-IL-18 is cleaved in an 
inflammasome dependent manner by caspase-1 function forming biologically 
active IL-18 that is secreted (82). IL-18 binding to the IL-18R complex (IL-18Rα 
and IL-18Rβ) induces rapid NK cell CD25 upregulation; IL-18 also synergises 
with IL-12 and IL-15 for robust IFN-γ secretion (66-68, 83). 
IL-2 and IL-15, produced by different arms of the immune system, have well 
known importance in NK cell differentiation and survival and have differential 
roles in NK cell activation. They have unique alpha chain receptors (IL-2Rα and 
IL-15Rα) but share a beta chain (IL-2Rβ/IL-15Rβ) and common gamma chain 
(γc) which together make up high affinity trimeric receptors on the surface of NK 
cells (84). IL-2 has been shown to reduce expression of CD25, γc and IL-15Rα, 
whereas IL-15 sustains IL-15Rα expression (85). Evidence for models where IL-
2 secretion from T cells limits further IL-15 signalling after adaptive responses are 
mounted describe a feedback mechanism between these two cytokines (68, 85).  
IL-15 trans-presentation, where IL-15 bound to IL-15Rα is presented by DC at 
the DC-NK cell interface, is gaining in interest as a NK cell ‘priming’ tool, and is 
being utilised for NK cell immunotherapy (86-91). The IL-15 superagonist 
complex ALT-803 has been shown to induce NK cell activation and was well 
tolerated in cancer patients in phase 1 clinical studies (90-92). Increased NK cell 
numbers correlated with a reduction in simian immunodeficiency virus (SIV) viral 
load in non-human primates treated with ALT-803, suggesting an ability to control 
viral replication in chronic infections (89). IL-15 complex treatment prevented the 
development of cerebral malaria in mice, synergy between IL-15 and IL-12/IL-21 
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induced immunomodulatory, IL-10-secreting NK cells perhaps reducing 
pathogenic T cell activity (93). Vaccines combined with IL-15 have been shown 
to elicit superior immune responses in mice; in these studies, enhanced DC 
maturation correlated with NK cell activation, although the role of NK cells in 
protective immunity was not evaluated (94-97). 
Synergistic effects of innate cytokines and synergy between cytokines and direct 
or antibody-mediated activation are important for optimal NK cell responses and 
regulation of effector functions. IL-12, IL-15 and IL-18 independently and 
synergistically drive the upregulation of CD25 on NK cells, increasing 
responsiveness to IL-2 (68, 98). IL-12 and IL-18 independently synergise with IL-
2 for increased CD25 expression and IFN-γ secretion (68). IL-12 and type I IFN 
each synergise to enhance antibody-dependent induction of NK cell cytotoxicity 
towards antibody-coated tumour cells and virally infected cells (99-101). It is 
suggested that co-localisation of CD16 and the IL-12 receptor on the surface of 
activated NK cells allows enhanced downstream signalling functions (102). IL-18 
also synergises with CD16 signalling to drive NK cell degranulation (68). Cytokine 
stimulation has also been shown to reduce the threshold for receptor-mediated 
direct activation of NK cells (24). 
Negative regulation of NK cell function by soluble mediators has been widely 
demonstrated and has an important role in optimising immune responses to 
infection and limiting pathology (103). TGF-β and IL-10 can inhibit NK cell function 
directly or indirectly via suppression of accessory cell cytokine secretion. TGF-β 
signalling has been shown to block the mammalian target of rapamycin (mTOR) 
signalling pathway, important for NK cell development and activation and leads 
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to downregulation of CD25 and type I IFN receptor expression (104, 105). IL-10 
can also indirectly limit NK cell function by supressing cytokine secretion; DCs 
from IL10-/- mice secrete more IL-12 during MCMV infection and IL-10R blockade 
increased TLR-induced IL-12 secretion in monocytes in vitro (106, 107). 
 
1.2.2.4 NK Cell Activation in Viral Infections 
 
PRRs such as members of the TLR family sense both the extracellular and 
intracellular environments for PAMPs. TLRs are expressed on many innate 
immune cells and recognise different pathogen-derived PAMPs. TLR-3, 7, 8 and 
9 are important in recognising viral products and become exposed to viral double 
stranded (ds)-RNA or single stranded (ss)-RNA, for example, during endosomal 
internalisation of virus particles or after cell lysis (70). Cell surface expressed 
TLR-4, typically known for recognising bacterial LPS, has also been shown to 
recognise viral GPs (108, 109). TLR ligation induces signalling cascades 
(typically via adaptor molecules TIR domain–containing adaptor inducing IFN-β 
(TRIF) or myeloid differentiation primary response protein 88 (MyD88)) ultimately 
leading to promotion of gene transcription for pro and anti-inflammatory cytokine 
production, including type I IFN, IL-12, IL-15 and IL-18, with distinct kinetics 
relating to the viral pathogen (70, 110). These cytokines modulate the NK cell 
response via receptor engagement and/or cell-cell contact and signal 
transduction, resulting in STAT phosphorylation and transcriptional control of 
target genes such as ISGs (70). 
NK cells shape the subsequent adaptive response by secretion of cytokines and 
chemokines. IFN-γ is important for T cell expansion and recruitment, memory 
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formation and B cell isotype class-switching (111), whereas IL-10 produced by 
NK cells is reported to limit T cell proliferation and effector functions (112, 113). 
NK cell cytotoxic functions reduce viral loads by eliminating infected cells, which 
modulates the amount of antigen available for T cell activation (114). Direct lysis 
of CD4+ T cells by NK cells has also been demonstrated in viral infections, 
eliciting indirect effects on the CD8+ T cell compartment and regulating the 
balance between viral clearance and immunopathology (113). The absence of 
NK cells in mice increases CD4+ T cell activation, T follicular helper cell 
responses and the number of germinal centre B cells in response to lymphocytic 
choriomeningitis virus (LCMV) infection, demonstrating NK cells can constrain 
antibody generation and affinity maturation (115, 116). NK cell production of CC-
chemokines (such as CCL3, CCL4 and CCL5) can inhibit viral entry and 
replication, for example, by competing for HIV co-receptor CCR5 (117, 118).  
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1.3 NK Cell Memory 
 
Several studies have shown that NK cells can acquire some features of adaptive 
lymphocytes; early examples of NK cell adaptive features arose from mouse 
studies of hapten-induced contact hypersensitivity and MCMV. NK cells from 
Rag2-/- mice were shown to transfer hapten-specific memory-like responses 
(lasting up to 4 weeks) to naive mice despite the absence of T and B cell immunity 
(119). The MCMV viral protein m157 on the surface of infected cells was shown 
to recognise the murine NK cell activating receptor Ly49H and lead to clonal 
expansion of effector NK cells and generation of a pool of self-renewing m157-
responsive NK cells; these cells respond robustly to subsequent MCMV infection 
when transferred to naive mice (120). More recently, virus antigen-specific NK 
cell killing has been reported in rhesus macaques with characteristics of memory 
like NK cells. Purified splenic NK cells from rhesus macaques chronically infected 
with SIV demonstrated specific lysis of DCs pulsed with SIV antigens; DCs pulsed 
with unrelated antigens or NK cells from uninfected animals were not reactive 
(121).  
Further to the MCMV model, as mentioned previously, a human counterpart has 
been proposed to involve NK cell recognition of HCMV infected host cells via the 
HLA-E-binding receptor NKG2C. Expanded populations of highly differentiated 
(NKG2C expressing) NK cells in individuals chronically infected with HCMV were 
first described more than a decade ago (122). Increased frequencies of NKG2C+ 
NK cells after solid organ transplant from HCMV seropositive donors were 
measured after HCMV reactivation in the transplant recipient (123). This 
expansion is thought to be mediated by stabilisation of HLA-E and increased 
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surface expression (46), being associated with enhanced IFN-γ production, 
acquisition of CD57 and KIR and a reduction in NKG2A expression (4). Further, 
HCMV expanded NK cells that have lost expression of several key signalling 
molecules, in particular FcεR1γ, SYK and EAT-2, have been described as 
‘adaptive’ NK cells (124). The loss of these signalling molecules is associated 
with stable epigenetic changes of the promotor regions of key genes involved in 
NK cell function, including IFN-γ production (124, 125). Another phenotype of 
these cells is the loss of a transcription factor involved in IL-12 and IL-18 receptor 
expression, PLZF, leading to a reduction of these receptors on the surface (124). 
Adaptive NK cells show reduced responsiveness to IL-12 and IL-18 and produce 
less IFN-γ compared to other NK cell subsets (124). However, these NK cells do 
display enhanced ADCC activity towards HCMV-infected target cells, involving a 
shift to an FcεR1γ independent signalling pathway, suggesting they are 
specialised for controlling virus reinfection or reactivation (126-129). IL-12 was 
found to be important in both MCMV and HCMV expansions of adaptive NK cells 
and IL-2 was shown to be important in their maintenance (130, 131). 
Cytokine induced memory-like (CIML) NK cells have been described in mouse 
and human in vitro models (132-135), and there is evidence supporting the 
generation of these NK cells in vivo after vaccination. This is introduced further in 
section 1.6. 
  
CHAPTER 1. INTRODUCTION 
41 
 
1.4 Influenza Virus 
 
In this thesis, the NK cell response to two viral vaccines will be characterised; the 
two viruses, influenza and Ebola, will be introduced here. 
Influenza virus is a member of the Orthomyxoviridae family and consists of an 
enveloped, single stranded, segmented RNA genome. Eight segments encode 
RNA dependent RNA polymerase (PB1, PB2 and PA), nucleoprotein (NP), matrix 
(M), non-structural (NS), HA and neuraminidase (NA) (136) (Figure 3). There are 
3 main types of influenza virus, A, B and C, which are classified by properties 
such as host preference, NP and M protein expression. More recently a new 
influenza genus, influenza D, has been identified (137). Influenza A viruses, 
responsible for a large majority of human disease, are further subtyped 
depending on the expression of HA and NA proteins located on the surface of the 
viral particle (138). These two highly expressed proteins are responsible for cell 
attachment and the release of new virions respectively and are primary targets 
for neutralising antibodies (136). Influenza A has the ability to escape any pre-
existing immunity by mutating the genes for HA and NA, a process called 
antigenic drift, or by reassortment of gene segments between human and non-
human strains, antigenic shift (138). 
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Figure 3: A schematic of Influenza A virus. 
Influenza A virus has 8 segments of RNA genome expressing viral proteins RNA dependent RNA 
polymerase (PB1, PB2 and PA), nucleoprotein (NP), matrix (M), non-structural (NS), 
haemagglutinin (HA) and neuraminidase (NA). The viral particle is made up of HA and NA proteins 
on the surface, internal NP and matrix proteins M1 and M2. Adapted from (136).  
 
Influenza pandemics (caused by influenza A only), such as the 1918 ‘Spanish flu’ 
and 2009 ‘swine flu’ occur when a new stain is introduced into the human 
population. Pandemic viruses then continue to circulate as seasonal epidemics 
(138). Influenza A seasonal epidemics result in 3 to 5 million cases and up to 
650,000 deaths per year globally, as well as putting intolerable pressure on health 
systems and causing major economic losses (139). Annual variation in the 
predominant circulating strains of influenza viruses mitigates vaccine-induced or 
naturally acquired cross-protective immunity, necessitating annual revaccination 
of high risk groups (such as pregnant women, children of 6 months to 5 years 
and the elderly) (139). The effectiveness of the current seasonal influenza 
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vaccines depend on whether the vaccine strains, recommended by WHO 
biannually, are matched or mismatched to the circulating strains that season. 
Currently available vaccines include inactivated (delivered intramuscularly) or live 
attenuated (via nasal spray) tri, or quadrivalent vaccines (TIV/QIV), containing 
two influenza A plus one or two influenza B strains.  
The influenza vaccines used for the studies in Chapter 3 were as follows: 
inactivated TIV from the 2015-2016 season (A/California/7/2009 (H1N1), 
A/Switzerland/9715293/2013 (H3N2), B/Phuket/3073/2013) or inactivated QIV 
from the 2017-2018 season (A/Michigan/45/2015 (H1N1), A/Hong 
Kong/4801/2014 (H3N2), and B/Brisbane/60/2008) (both non-adjuvant, Split 
Virion BP, Sanofi Pasteur). The viruses were propagated in fertilised hens’ eggs 
from healthy chicken flocks and may contain very small amounts of ovalbumin, 
chicken proteins, neomycin, formaldehyde or octoxinol-9. Buffer solution contains 
sodium chloride, potassium chloride, disodium phosphate dihydrate, potassium 
dihydrogen phosphate and water for injections. 
Influenza virus infection of the lung epithelia and lung resident macrophages and 
DCs is recognised by PRRs such as retinoic inducible gene 1 (RIG-1), TLR-3, 
TLR-7 and nucleotide oligomerisation domain (NOD)-like receptor (NLR) sensing 
of ssRNA (140). This stimulates the release of cytokines and chemokines 
including type I IFN which leads to antigen presentation, further 
cytokine/chemokine release and modulation of apoptosis and proliferation of 
effector cells in the lung (69). NK cells and T cells are recruited to the lung as a 
result of local accumulation of IL-15 and CXCL10 (IP-10) (5, 140). Murine lung 
NK cells become cytotoxic, secrete IFN-γ and upregulate CD25 after influenza 
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infection (141). DCs act as APCs to cytotoxic T lymphocytes (CTL) and T helper 
cells and aid recruitment to the lung where they can mediate viral clearance (142).  
Cross-reactive antibodies (with neutralising and/or ADCC function) and cross-
protection mediated by T cells (predominantly CD8+ T cells) has been 
demonstrated across influenza A strains (and across influenza B strains) and 
forms the basis for new improved ‘universal’ influenza vaccine development (143-
146). The leading strategy involves targeting more conserved epitopes of 
influenza virus proteins, for example the HA ‘stalk’ region (more highly conserved 
compared to the more accessible HA ‘head’ region), the M proteins or NP (147-
151). Development of multivalent vaccines (combinations of HA from different 
strains or combinations of HA + NP/M/NA) have also shown broad protection 
against heterologous viruses (152). Adding adjuvants, using conserved antigenic 
domains of the HA gene in DNA vaccines and passive mAb immunisation are 
among other strategies employed. Vaccine platforms engaged include peptide 
and recombinant protein vaccines, virus-like particle (VLP) vaccines, DNA 
vaccines and viral vectored vaccines (153, 154). 
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1.5 Ebola Virus 
 
Ebola virus is a member of the Filoviridae family, an enveloped, negative 
stranded RNA virus with a genome containing just seven genes (155). Ebola virus 
infection causes Ebola virus disease (EVD), a severe acute haemorrhagic fever 
with rapid onset of symptoms such as muscle pain and headache, leading to 
vomiting, damage to liver and kidney function, bleeding and death in 25% to 90% 
of cases depending on the outbreak (156). Since the first recoded outbreak in 
1976, five species have been isolated, Zaire ebolavirus (ZEBOV), Sudan 
ebolavirus (SEBOV), Tai Forest ebolavirus, Bundibugyo ebolavirus (BEBOV) and 
Reston ebolavirus (155). During the West African outbreak of 2014 to 2016 
(ZEBOV), over 28,000 cases were reported with more than 11,000 deaths (157). 
Since 2017, there has been a series of smaller outbreaks of the ZEBOV species 
in the Democratic Republic of the Congo that continue to be of considerable 
global health concern (155). 
During Ebola virus infection of macrophages and DCs, dsRNA triggers 
intracellular RIG-I and melanoma differentiation–associated protein 5 (MDA5) 
receptor signalling, which leads to an initial type I IFN response. Despite high 
levels of IFN-α detected in the serum of infected patients and non-human 
primates (NHPs), viral loads continue to rise, failing to resolve infection (158). 
Innate immune dysregulation, including impaired DC maturation, inhibition of type 
I IFN signalling and excessive secretion of inflammatory cytokines such as TNF-
α, IL-6 and IL-10 are hallmarks of EVD (158-160). This leads to a failure to 
activate effector cells, failure to control viral replication, and enables systemic 
dissemination and inflammation (158, 161). The most immunogenic Ebola virus 
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protein, the surface glycoprotein (GP) (that is shed or cleaved from the surface 
of infected cells) can activate non-infected monocytes and macrophages to 
produce inflammatory cytokines such as TNF-α, IL-1β, IL-10, IL-6, IFN-β and IL-
12 in vitro, this perhaps exacerbates inflammation further (108, 162, 163).  
Several vaccines are in development for the prevention of EVD. The most 
advanced of these utilise viral vectors for the expression of Ebola GP. Vectored 
vaccines expressing ZEBOV GP use the recombinant vesicular stomatitis virus 
(VSV) (rVSV-ZEBOV) and Chimp Adenovirus type 3 (ChAd3-ZEBOV) vectors. 
ChAd3-ZEBOV and a third viral vector expressing ZEBOV GP, adenovirus type 
26 (Ad26-ZEBOV), are being tested as a prime-boost regimen combined with a 
multivalent Modified Vaccinia Ankara (MVA) vectored vaccine expressing 
ZEBOV, SEBOV, Marburg Virus GP (related Filovirus) and Tai Forest Ebola virus 
NP (MVA-BN-Filo). The Ad26-ZEBOV, MVA-BN-Filo vaccine, a 2-dose 
heterologous vaccine regimen (currently being tested by the EBOVAC 
consortium, Innovative Medicines Initiative) was used for the studies in chapters 
4 and 5 of this thesis. Ad26-ZEBOV (Janssen Vaccines and Prevention B.V., The 
Netherlands) is a recombinant, replication-defective, Ad26-vectored vaccine 
produced in PER.C6 human cells (5x1010 virus particles/dose). MVA-BN-Filo 
(Bavarian Nordic, Denmark) is a recombinant, replication-defective, MVA-
vectored vaccine manufactured in chicken embryo fibroblasts (1x108 
TCID50/dose), both are delivered intramuscularly. These vaccines have been 
shown to be safe and immunogenic in humans in phase 1, 2 and 3 trials, however, 
challenges remain in optimising regimen interval, determining correlates of 
protection and the durability of efficacy (164-166). Table 2 details the most 
advanced Ebola vaccines currently in human trials. 
  
Vaccine Company Design Phase Study Population Reference 
rVSV-ZEBOV Merck Zaire Ebola virus GP Phase 1 USA (167) 
Phase 1 Germany, 
Switzerland, Gabon, 
Kenya 
(168, 169) 
Phase 1/2 Switzerland (170) 
Phase 3 Guinea, Sierra 
Leone 
(171) 
ChAd3-ZEBOV GSK Zaire (and Sudan) Ebola 
virus GP 
Phase 1 USA (172) 
Phase 1/2 Switzerland (173) 
ChAd3-
ZEBOV/MVA-BN-
Filo 
GSK, BN Zaire (and Sudan) Ebola 
virus GP (ChAd3), 
Zaire/Sudan Ebola virus 
GP/Marburg GP/ Tai Forest 
Ebola virus NP (MVA) 
Phase 1 Mali (174) 
Phase 1 U.K. (175) 
Phase 1 U.K., Senegal (176) 
Ad26-
ZEBOV/MVA-BN-
Filo * 
J&J 
(Janssen), 
BN 
Zaire Ebola virus GP (Ad26), 
Zaire/Sudan Ebola virus 
GP/Marburg GP/ Tai Forest 
Ebola virus NP (MVA) 
Phase 1  U.K. (166) 
Phase 1 Tanzania, Uganda (177) 
Phase 1 Kenya (178) 
Table 2: The most advanced Ebola vaccines currently in human trials. 
Information gathered and updated from (164, 165), * EBOVAC consortium vaccine used in this thesis. GSK; GlaxoSmithKline, BN; Bavarian Nordic, J&J; 
Johnson and Johnson. 
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1.6 NK Cells and Vaccination 
 
Vaccination is a cost-effective way of reducing the burden of, eliminating, and - 
in exceptional cases - eradicating infectious diseases. Whilst a number of 
effective vaccines are currently licenced, many highly prevalent and complex 
diseases remain without effective prophylactic vaccines. Protective titres of 
neutralising antibodies and expanded populations of effector and memory B and 
T lymphocytes are viewed as measures of protection for many vaccines. 
Currently, the generation of durable antigen-specific memory forms the basis of 
vaccine development and evaluation of vaccine efficacy (166, 179). Developing 
vaccines to overcome pathogen polymorphism and complexity demands new 
approaches to vaccine design and evaluation; this in turn requires the 
identification of novel correlates of protection and determination of optimal dosing 
schedules. The activation of NK cells represents a potential route for further 
optimisation of vaccination strategies by harnessing their role as anti-pathogen 
effector cells which integrate innate and acquired immune responses.  
An increasing number of studies in humans demonstrate activation of NK cells 
during recall responses to pathogens in vaccinated subjects. In vitro NK cell 
responses to components of the DTP vaccine (diphtheria toxoid, tetanus toxoid 
and whole cell inactivated pertussis), Bacille Calmette-Guérin (BCG) and 
influenza vaccine are enhanced after vaccination (18, 180-182) and heightened 
NK cell IFN-γ and degranulation responses have been detected after vaccination 
against rabies, malaria, influenza and BCG (133, 183-185). These post-
vaccination responses are dependent on vaccine-specific CD4+ memory T cells 
and, in particular, their rapid secretion of IL-2. 
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Although the ‘antigen-specificity’ of these post-vaccination NK cell responses 
resides in the CD4+ T cell pool, the NK cells are also modified as a result of 
vaccination. Innate cytokines, which can be induced by live or killed whole 
pathogen vaccines or by adjuvants, are potent NK cell activators and can induce 
their differentiation into CIML NK cells. First described as being generated by 
cytokine co-culture in vitro, CIML NK cells have an enhanced ability to secrete 
IFN-γ and become cytotoxic in response to cytokine and MHC-devoid K562 cell 
restimulation for up to 21 days after the initial stimulation (132, 133, 135, 186). In 
vitro cytokine activation with IL-18 and IL-12 and/or IL-15 induces prolonged 
expression of CD25, thereby generating CIML NK cells with enhanced 
responsiveness (demonstrated by IFN-γ production and cytotoxicity) to picomolar 
concentrations of IL-2 (67). More importantly perhaps, CIML NK cells can be 
induced by vaccination in response to CD4+ T cell-derived IL-2 and myeloid cell-
derived IL-12 and type I IFN, and have been implicated in the enhancement of 
NK cell function ex vivo (133, 183-185, 187-189). Vaccination-induced CIML NK 
cells can be detected for up to 12 weeks post-vaccination in European subjects 
(133) and up to 6 months in west African vaccines (189) but are not well 
understood. Table 3 summarises the evidence for vaccination induced CIML NK 
cells.  
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Pathogen Species Vaccine Increased 
Responsive-
ness In vitro 
Duration 
of 
Response 
Reference 
Influenza Human TIV IL-12, IL-15, 
IL-18 
3 months 
(UK) or  
6 months 
(Gambia) 
(133, 189) 
Yellow 
fever 
virus 
Human YF-17D IL-12 15 days (187) 
SIV Macaque Ad26 
HIV-1,  
DNA-
Ad26 
IL-12, IL-15 38 weeks (190) 
TB Human BCG IL-12, IL-18 ND (184) 
Table 3: Evidence of induction of human cytokine-induced memory-like (CIML) NK cells 
by vaccination. 
SIV; simian immunodeficiency virus, TB; Tuberculosis, TIV; trivalent influenza vaccine, YF-17D; 
yellow fever 17D vaccine, BCG; Bacille Calmette-Guérin, ND, not determined.  
 
Vaccination-induced CIML NK cells are restricted to the less-differentiated 
subsets of NK cells and their induction is accompanied by proliferative expansion 
of the least mature CD56bright NK cells and CD56dimCD57- subsets (133, 189). 
Enrichment of less differentiated NK cells in lymph nodes and effector tissues 
could influence the impact of CIML NK cells induced by vaccination. The highest 
proportion of human immature CD56bright (CD16-) NK cells are found in the lymph 
nodes (191, 192) and produce IFN-γ in response to CD4+ T cell derived IL-2, 
thereby potentially influencing subsequent adaptive responses (192). A higher 
percentage of adoptively transferred pre-activated CIML NK cells were found in 
the lymph nodes of mice compared to control NK cells (132) and localised in the 
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bone marrow, spleen and blood of mice and in the bone marrow of patients with 
acute myeloid leukaemia (186).  
The tissue localisation of NK cells amenable to cytokine mediated pre-activation 
may also be crucial to functional outcomes. Human liver is enriched for resident 
CD56bright NK cells with high NCR and NKG2D expression, with strong target cell 
mediated degranulation but poor IFN-γ production (193). Tissue resident ILCs 
may also be sensitive to pre-activation by vaccine-induced cytokines. Murine liver 
ILC1, for example, are highly sensitive to IL-12 stimulation and produce more 
IFN-γ at the sites of MCMV infection than peripheral sites (194). When taken 
together with the emerging literature on the impact of persistent viral infections 
such as HCMV on NK cell function (180), it is possible that differences between 
or within human populations in proportions of CIML NK cells and ‘adaptive’ NK 
cells (due to differences in recent infection and vaccination history) may 
contribute to differences in vaccine immunogenicity and effectiveness (189, 195, 
196). 
Despite the likely dominance of ‘HCMV-adaptive’ cells (described in section 1.3) 
in populations with endemic HCMV infection, the generation of CIML from less 
differentiated NK cells persists after vaccination (189) (reviewed in reference 
(197)). It appears, therefore, that there is a balance of CIML and highly 
differentiated NK cell effectors which may be altered by vaccination. Less 
differentiated NK cells are shorter lived, possess higher levels of cytokine 
receptors and higher intrinsic proliferative capacity; vaccination may simply 
contribute to the homeostatic maintenance of these cells. The benefits of 
preferentially expanding and generating CIML NK cells from these subsets is 
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unknown but could be more functionally significant in young infants where highly 
differentiated cytotoxic effectors are lacking (18). On the other hand, loss of IL-
12 responsiveness and independence of this cytokine for IFN-γ production is a 
well-known feature of more differentiated NK cell effectors; more focused 
antibody driven responses may be advantageous in restricting the potential for 
inflammation associated damage in older individuals. 
In the remainder of the introduction, I will explore in more detail the potential role 
of NK cells, activated by myeloid cell-derived cytokines or by components of 
adaptive immunity (CD4+ T cell IL-2 or pathogen-specific antibodies), as effectors 
of vaccination against a number of globally important infectious diseases.  
 
1.6.1 Influenza 
 
In vitro restimulation of PBMC from TIV-vaccinated volunteers with inactivated 
influenza virus induces higher frequencies of IFN-γ producing and degranulating 
NK cells compared to restimulation of pre-vaccination PBMC from the same 
people (133, 182, 198, 199). The heightened NK cell response becomes evident 
as early as 2 weeks post-vaccination but is normally lost by 12 weeks. Post-
vaccination enhancement of NK cell IFN-γ production was dependent on IL-2 
produced from CD4+ T cells, whilst degranulation responses were dependent on 
IL-2 and on the presence of anti-influenza antibody (133, 182). A co-stimulatory 
role for innate myeloid cell-derived cytokines was also demonstrated by partial 
inhibition of TIV restimulation responses with IL-12, IL-18 and IFN-αβR2 blockade 
(133). 
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Consistent with the generation of CIML NK cells, antigen-independent in vitro 
responses to exogenous IL-12, IL-15 and IL-18 were also elevated for up to 3 
months after influenza vaccination in a U.K. study (133), and for up to 6 months 
in African subjects (189). Enhancement of NK cell responses after influenza 
vaccination is therefore mediated by indirect mechanisms involving antigen-
specific cellular CD4+ T cell and humoral responses combined with a shorter-
lived CIML component. Such enhanced NK cell function after seasonal influenza 
vaccination may contribute to protective immunity to influenza, but, given the 
dependence on antigen-specific T cells and antibodies, does not in itself 
overcome the issue of variation in the predominant circulating strains of influenza 
viruses and the need for annual re-vaccination. 
Development of a ‘universal’, cross-protective influenza vaccine is a major priority 
for many groups working in the influenza vaccine field, NK cell function may yet 
play a role. Conserved HA stalk-specific antibodies that mediate NK cell ADCC 
are present after natural infection and after vaccination with TIV or monovalent 
adjuvanted H1N1 vaccines (200). NP-specific ADCC-mediating antibodies 
induced by seasonal influenza vaccination demonstrate cross-reactivity with 
H7N9 avian influenza NP (149). As mature CD56dimCD57+ NK cells and HCMV-
induced ‘adaptive’ NK cells are both potent mediators of ADCC and preferentially 
respond to influenza antigens after vaccination (60), NK cells may be of particular 
importance as effectors of the next generation of universal influenza vaccines. 
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1.6.2 Ebola 
 
Little is known about the role of NK cells in Ebola virus infection or vaccination, in 
vitro studies show IFN-inhibiting domains (IIDs) within Ebola viral proteins VP24 
and VP35 interrupt DC maturation and type I IFN signalling impairing NK cell 
activation and cytotoxicity (159). Disrupting either of these IIDs restores DC 
maturation and NK cell activation as measured by NKp46 and CD38 expression 
(159). Another study showed that Ebola VLPs lacking IIDs activated NK cells and 
led to lysis of Filovirus infected autologous human DCs in culture and pro-
inflammatory cytokine release (201). Mice can be protected against Ebola virus 
infection by adoptive transfer of NK cells from VP40-containing VLP treated mice 
(161). Increased survival of mice after post-exposure vaccination with the 
candidate vaccine rVSV∆G-EBOV  is reversed by NK cell depletion (202); post-
exposure vaccination stimulated a burst of IFN-γ release and type I IFN secretion 
from accessory cells, potentially kick-starting the antiviral response and 
overcoming the blockade caused by IIDs (202).  
In humans, increased levels of NK cell activation markers were measured at day 
2 and 3 after vaccination with rVSV-ZEBOV (203). Post-exposure antibody 
therapy has also been shown to give effective protection in animal models via 
ADCC activity and anti-Ebola GP mAbs induced human NK cell activation in vitro 
(204-206). These studies implicate NK cells as important effectors in protection 
against Ebola virus infection and in vaccine-induced immunity and raise the 
potential for indirect cytokine activation of NK cells to restrict virus dissemination 
after therapeutic vaccination. 
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1.6.3 Other Pathogens 
1.6.3.1 Yellow Fever 
 
The live attenuated yellow fever virus (YFV) vaccine 17D is one of the most 
effective vaccines developed to date; 99% of recipients are protected for more 
than 10 years after a single vaccination (207). For this reason, YF-17D has been 
used as a tool to identify highly effective early (innate) immune responses to 
acute viral infection in humans (187, 208). YFV infects and induces TLR-
mediated signalling in hepatocytes and cells of the innate immune system such 
as monocytes and DCs. In mouse models of YFV infection or YF-17D 
vaccination, NK cells accumulate in the spleen and are major producers of IFN-γ 
(209, 210). Induction of innate cytokines such as IL-1α and chemokine IP-10, and 
up-regulation of the early activation and proliferation markers CD69 and Ki67 on 
NK cells is detected as early as 3 days post-vaccination in humans (187, 208, 
211). NK cell activation peaks at the same time as viral load, 6 days post-
vaccination, and correlates directly with a rise in plasma type I and type III IFN. 
Thereafter, viral load and NK cell responses decline rapidly, returning to baseline 
by day 10 and 15 post-vaccination respectively (187, 211).  
In a study in Uganda, pre-existing IFN-γ producing NK cells in an activated 
immune microenvironment were associated with lower viral loads and 
subsequently reduced antibody titres after YF-17D vaccination (195). NK cell 
IFN-γ responses to YFV correlated with increased in vitro responsiveness of less 
differentiated NK cells to innate cytokines such as IL-12 after vaccination (187) 
suggesting that, as for influenza vaccines, YF-17D-induced accessory cell-
derived cytokines may also induce development of CIML NK cells. As in influenza 
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vaccination, this pre-activation state is short-lived suggesting that there is no 
lasting imprint on the NK cell repertoire. These transient innate responses 
(including NK cells) may, however, synergise with antigen-specific vaccine-
induced responses resulting in the formation of particularly durable and effective 
T and B cell-mediated immunity to YFV (187, 211). A more robust mechanistic 
understanding of the induction and function of CIML NK cells during infection or 
vaccination with YFV and other Flaviviruses will help to define their role. 
 
1.6.3.2 HIV 
 
HIV remains highly prevalent across the world with 1.8 million new infections 
estimated in 2017; lifelong treatment is required to prevent disease and death, 
which places a considerable burden on health systems worldwide (212). A 
prophylactic HIV vaccine is of utmost priority. HLA class I and KIR genotype and 
NK cell education influence direct killing of HIV-1 infected CD4+ T cells and are 
associated with the rate of progression of HIV infection (213, 214). In the partially 
successful RV144 vaccine trial, IgG against variable regions 1 and 2 of the HIV-
1 envelope GP were inversely correlated with the rate of infection (215). Indeed, 
RV144 induced isotypes IgG1 and IgG3 targeting the crown of the V2 loop and 
ADCC activity of anti-V2 antibodies has been demonstrated in human PBMC 
cultures (216-218). 
NK cells from KIR3DL1/HLA-Bw4+ or KIR2DL1/HLA-C2+ donors show higher 
antibody-dependent cytotoxicity against HIV infected targets in the presence of 
anti-HIV GP120 antibody (219, 220). These studies could demonstrate an effect 
of NK cell education on HIV vaccine-induced effector NK cells, potentially 
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contributing to individual variability in vaccine outcomes. CD57+NKG2C+ 
memory-like NK cells are expanded in HIV-1/HCMV co-infected individuals and 
these cells make a potential contribution to control of viremia during primary HIV 
infection (221, 222). Similarly, expanded populations of peripheral blood KLRC2+ 
NK cells (NKG2A/C) were shown in macaques infected with SIV and rhesus 
macaque (rh)CMV (223). Together with evidence that individuals with a degree 
of inherent resistance to HIV - so-called ‘elite controllers’ or slow progressors - 
mount stronger antibody-mediated NK cell activation and ADCC responses than 
more susceptible individuals, these studies suggest that NK cells may contribute 
to HIV protection and control (224). 
NK cells have been implicated as antigen-specific effector cells after vaccination 
or infection of non-human primates with SIV. Target cells pulsed with SIV 
vaccine-antigen but not heterologous antigens can be lysed in vitro by splenic 
and hepatic NK cells from infected but not from uninfected animals (121). These 
antigen-specific responses could be detected for at least 5 years after SIV 
DNA/adenovirus prime-boost vaccination, suggesting that this memory-like 
response is long lived (121). By contrast, no significant potentiation of circulating 
NK cell function was observed after SIV infection or vaccination; rather, SIV 
infection impaired the cytotoxic response of peripheral blood NK cells (190). 
However, a trend towards increasing in vitro NK cell CD107a expression in 
response to IL-15 and IL-12 post-vaccination suggests that memory-like NK cells 
with enhanced cytokine responsiveness may have been induced in this study 
(190). 
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In HIV patients, therapeutic HIV vaccination or IL-2 treatment sustains or 
enhances NK cell activity (188, 225). Immunisation of chronically-infected 
patients with an adjuvanted HIV-1 GP120/NefTat subunit protein vaccine induces 
IL-2 from T helper cells and an increase in NK cell IFN-γ production in vitro. NK 
cell IFN-γ production was reduced by depletion of CD4+ T cells and almost 
completely abrogated after blocking both IL-2 and IL-12, suggesting a role for 
accessory cells in full NK cell effector functions after vaccination (188). These, 
and other, studies highlight the potential of therapeutic vaccination to restore NK 
cell function during chronic HIV infection (188, 226). 
 
1.6.3.3 Malaria 
 
The role of NK cells in natural immunity or vaccine-induced protection against 
malaria infection has not been fully established (227). NK cell activation has been 
described to varying degrees in different experimental murine models (228, 229) 
and NK cells have been shown to contribute directly to the elimination of 
Plasmodium (P.) falciparum infected red blood cells (RBC) and protect against 
experimental cerebral malaria in mice (93, 230). In vitro studies of human PBMC 
show NK cells are readily activated by P. falciparum infected RBC; the resulting 
NK cell proliferation, IFN-γ production, CD25 and CD69 expression were further 
demonstrated to be dependent on IL-2, accessory cell IL-12 and IL-18 production 
and on cell-cell contact (83, 231-234). Long lasting NK cell activation has been 
reported in controlled human malaria infection (CHMI) studies, and a decrease in 
peripheral blood NK cell frequency early after infection suggests migration of NK 
cells into the tissues, possibly the liver (235-237). 
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RTS,S/AS01 is the most promising vaccine tested to date for human P. 
falciparum malaria. RTS,S consists of recombinant circumsporozoite surface 
protein (CSP) of P. falciparum fused to the hepatitis B virus surface antigen (HBs) 
and adjuvant delivery system (AS)01 formed into VLPs. PBMC collected from a 
RTS,S randomised controlled trial revealed post-vaccination IL-2 secretion with 
IFN-γ and CD69 upregulation on NK cells in response to in vitro restimulation with 
HBs or CSP. All responses were significantly higher in RTS,S vaccinees 
compared to control rabies vaccinated subjects (185). A weak association has 
been reported between IL-2 secreting CD4+ T cells and time to parasitaemia, 
accompanied by an increase in the proportion of CD56bright NK cells. Higher IFN-
γ and perforin expression and protection against malaria challenge in vaccine 
recipients has also been reported (238). Interestingly, peripheral blood NK cell 
gene expression signatures were negatively correlated with RTS,S induced 
malaria protection, consistent with migration of activated blood NK cells to the 
tissues (239). In vitro, human NK cells also mediate ADCC against infected RBC 
in response to antibodies isolated from humans in malaria endemic regions, 
potentially indicating a role for NK cells in the presence of vaccine-induced 
antibody (240). 
 
1.6.3.4 Tuberculosis 
 
The live attenuated BCG vaccine is the only vaccine currently licensed for the 
prevention of tuberculosis (TB) disease caused by Mycobacterium tuberculosis 
(MTB) and is administered to over 120 million infants each year (241). NK cells 
are an important component of the cellular immune response to BCG, producing 
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more than half of the total IFN-γ after vaccination in new-borns and two-month 
old infants (241).  
BCG, and other live vaccines such as measles vaccine, have been shown to 
induce non-specific effects that are beneficial to the recipient and reduce overall 
mortality in a community (242, 243). Potential underlying mechanisms include T 
cell mediated cross-reactivity and/or ‘training’ or ‘priming’ of innate immune cells, 
including monocytes and NK cells. Increased expression of PRR in monocytes 
and higher levels of IFN-γ, TNF-α and IL-1β secretion have been observed when 
PBMC from BCG-vaccinated individuals are restimulated with mycobacterial or 
unrelated antigens compared to pre-vaccination PBMCs (181). These effects 
persisted for up to 12 months after BCG vaccination and were partly attributed to 
epigenetic remodelling of key cytokine gene loci and has been termed ‘trained 
immunity’. Similarly, increased NK cell CD69 expression in response to Pam3Cys 
(heterologous stimulation) in vitro (that correlated with higher concentrations of 
IL-12) and in vivo in humans after experimental malaria challenge has been 
reported post-BCG vaccination (244, 245). Interestingly, no changes in NK cell 
phenotype, maturation or IFN-γ production were reported in BCG trained NK cells 
(246), suggesting that they are not equivalent to CIML NK cells.  
Enhancement of NK cell IFN-γ responses to BCG has been reported after BCG 
vaccination of patients with latent TB (184) and in 5-week-old infants who were 
BCG vaccinated at birth compared to unvaccinated controls (184); NK cell 
responses were completely abrogated by neutralisation of IL-12 and IL-18 (184). 
Consistent with studies of other whole organism vaccines, as described above, 
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these studies indicate that enhanced responsiveness to cytokines is a key feature 
of vaccine-mediated effects on NK cells. 
 
1.6.4 The Role of Vaccine Adjuvants in Promoting NK Cell 
Responses 
 
Killed whole organism or live attenuated vaccines are both highly immunogenic 
and particularly effective at potentiating NK cell responses; both of these traits 
likely reflect the presence of potent PAMPs for PRR-mediated accessory cell 
activation. PAMP-containing adjuvants are typically required to improve the 
immunogenicity of subunit or vectored vaccines, which lack these ligands. 
Several studies have documented enhancement of NK cell activation by 
adjuvants (188, 247, 248). IL-15-matured DCs exposed in vitro to the TLR-4 
agonist AS04-adjuvanted human papilloma virus (HPV) VLP vaccine can 
potentiate NK cell activation and killing of HPV-infected cells compared to either 
IL-4 matured DCs or VLP alone; this effect was attributed to the superior cytokine-
producing ability of the DCs (95). Similarly, vaccination in the presence of 
exogenous IL-15 enhances DC maturation and protection against lethal 
Staphylococcal enterotoxin B challenge in mice compared to vaccine alone (94).  
AS03, a squalene-based adjuvant, promotes recruitment of APCs and antigen 
processing. A system-wide analysis of the response to AS03 adjuvanted 
inactivated H5N1 influenza vaccine revealed a direct correlation between  IP-10, 
type I and II IFN production, and enhanced NK cell activation and proliferation 
(249, 250). Similarly, a bursin-like peptide shown to stimulate immune cells 
induced higher levels of IL-2 and IL-4 and increased NK cell frequencies and IFN-
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γ secretion in mice vaccinated with inactivated influenza H9N2 compared to 
vaccine alone (251). Taken together, these studies indicate that PRR-mediated 
activation and maturation of accessory cells such as DCs by vaccine adjuvants 
increase the production of co-stimulatory cytokines leading to heightened NK cell 
activation. Whether these NK cells share features of CIML NK cells has not yet 
been formally tested. 
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1.7 Concluding Remarks 
 
Although there is now considerable evidence of enhanced NK cell responses 
after vaccination, the functional importance of NK cells in vaccination-induced 
immunity is rather difficult to evaluate. The NK cell response to vaccination varies 
depending on the type of vaccine, the cytokine signature induced by the 
vaccine/adjuvant combination and subsequent accessory cell activation (Figure 
4). The ability of NK cells to respond to signals from both innate and adaptive 
immune cells suggests that when one arm of the immune response is impaired, 
such as T cell responses in HIV infection or innate cell dysregulation in EVD, NK 
cells may play an important immune effector role, maximising the impact of the 
remaining arm of the immune system. Successful activation of APCs and 
induction of an early inflammatory response by a vaccine correlates with 
enhanced and sustained NK cell activation and function. Importantly, NK cell 
education by HLA-KIR or other receptor-ligand combinations may well calibrate 
functional capacity on induction by both adaptive and innate pathways thereby 
driving individual variability in vaccine induced responses. The addition of 
adjuvant systems to vaccines to increase accessory cell activation and therefore 
augmenting NK cell function including ADCC activity could play a role in the future 
design of new vaccines, post-exposure therapy, therapeutic cancer vaccines, 
regimen optimisation and evaluation of vaccine efficacy. 
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Figure 4: Accessory cell-dependent NK cell activation after vaccination. 
Activation of APCs by live attenuated or inactivated whole organism vaccines induces the release 
of co-stimulatory cytokines which in turn leads to NK cell activation including IFN-γ release, 
degranulation and CD25 upregulation (a). Adjuvants promote accessory cell function for subunit 
or vectored vaccines in the absence of vaccine derived PAMPs (b). Upon secondary exposure, 
IL-2 from memory CD4+ T cells, antibody and the presence of CIML NK cells enable an enhanced 
response (c).  
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1.8 Aims and Hypothesis 
 
The overall aim of this thesis was to investigate the effect of vaccination against 
viral pathogens on human NK cell phenotype and effector function upon 
restimulation with vaccine antigen and/or cytokines. 
The central hypothesis was that vaccination primes NK cells for enhanced 
responsiveness to innate cytokines, leading to more robust NK cell activation 
upon secondary exposure to either viral innate cytokines or viral stimuli. 
Objectives: 
1. To determine the effect of very low doses of IL-15 on NK cell activation in 
response to vaccine antigens, and mechanisms involved. 
2. To characterise the early effects of influenza vaccination on NK cell 
phenotype and activation, and cytokine-dependent enhancement of NK 
cell function after vaccination. 
3. To analyse NK cell phenotype and function to test the hypothesis in fully 
naïve recipients after vaccination with a novel prime-boost Ebola vaccine 
regimen. 
4. To examine the role of vaccine-induced antibody in the induction of NK 
cell responses.  
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2.1 Abstract 
 
IL-15 is a key regulator of NK cell maintenance and proliferation and synergises 
with other myeloid cell-derived cytokines to enhance NK cell effector function. At 
low concentration, trans-presentation of IL-15 by dendritic cells can activate NK 
cells, whilst at higher concentrations IL-15 can act directly on NK cells, 
independently of accessory cells. In this study, we investigate the potential for IL-
15 to boost responses to influenza virus by promoting accessory cell function. 
We find that co-culture of human peripheral blood mononuclear cells with 
inactivated influenza H3N2 virus in the presence of very low concentrations of IL-
15 results in increased production of myeloid cell-derived cytokines, including IL-
12, IFN-.    * 0 -CSF and IL-     D Q G  D Q  L Q F U H D V H G  I U H T X H Q F \  R I  S R O \ I X Q F W L R Q D O  1 . 
cells (defined by expression of two or more of CD107a, IFN-   D Q G   & ’      
Neutralisation experiments demonstrate that IL-15 mediated enhancement of NK 
cell responses is primarily dependent on IL-12 and partially dependent on IFN-
.  5    V L J Q D O O L Q J    & U L W L F D O O \    , /-15 boosted the production of IL-12 in influenza-
stimulated blood myeloid dendritic cells. IL-15 co-stimulation also restored the 
ability of less differentiated NK cells from human cytomegalovirus seropositive 
individuals to respond to influenza virus. These data suggest that very low 
concentrations of IL-15 play an important role in boosting accessory cell function 
to support NK cell effector functions. 
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2.2 Introduction 
 
IL-15 is essential for the survival, proliferation and functional integrity of NK cells 
and is being exploited to enhance NK cell-mediated immunotherapies (1, 2). IL-
15 augments NK cell expression of perforin, granzyme B, natural cytotoxicity 
receptors NKp30 and NKp44 (3) and the activating receptor NKG2D (4). The 
potency of IL-15, even at very low concentrations, is partly due to its presentation 
 D W   W K H   V X U I D F H   R I   D Q W L J H Q   S U H V H Q W L Q J   F H O O V    $ 3 & V    D V   D   F R P S O H [   Z L W K   W K H  .-chain 
of its own receptor (IL-     5.   (5). Here, it can be presented to the same cell (cis-
presentation) or to neighbouring cells (trans-presentation) such as NK cells and 
CD8+ T cells that express IL-     5  D Q G  W K H  F R P P R Q  -chain receptor (IL-     5 F  
(6).  
Dendritic cells (DCs) can be induced to present IL-15 at their surface by microbial 
ligands signalling through TLR and by innate cytokines such as granulocyte-
macrophage colony-stimulating factor (GM-CSF) and type I IFN (7, 8). DC-
mediated NK cell activation is, in part, dependent on IL-15 that polarises to the 
DC-NK cell synapse during conjugate formation (9). Although IL-15 is believed to 
mediate the majority of its effects via trans-presentation by IL-   5.    D W   K L J K 
concentrations it can bind directly to IL-    5 F   D Q G   W K H U H E \   D F W L Y D We NK cells 
(10). Furthermore, at very high concentrations, free IL-15 may bind to IL-     5.  R Q 
neighbouring cells for cis- or trans-presentation (5, 11). Low concentrations of IL-
15 alone induce negligible NK cell activation but IL-15 is highly synergistic with 
other cytokines and with recall antigens such as influenza for NK cell CD25 and 
IFN-  H [ S U H V V L R Q (12, 13). 
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IL-15 trans-presentation is being explored for cancer immunotherapy; induction 
of constitutive expression of IL-15 and IL-     5.  E \  ’ & V  R U  use of soluble IL-15/IL-
     5.  F R P S O H [ H V  K D V  E H H Q  V K R Z Q  W R  H Q K D Q F H  1 .  F H O O  D Q W L-tumour activity in vitro 
and in preclinical mouse studies (reviewed in (14)). Another strategy for NK cell 
immunotherapy includes activation of NK cells with IL-12, IL-15 and IL-18 prior to 
adoptive transfer where they reduce tumour growth in mice (15). Pre-activation 
of peripheral blood mononuclear cells (PBMC) with high concentrations of IL-15 
can also restore impaired NK cell cytotoxicity of simian immunodeficiency virus 
(SIV)-infected macaques (16). Although these studies are consistent with direct 
NK cell priming by IL-15 at high concentration, or synergy with myeloid cell-
derived cytokines at low concentration, the potential for IL-15 to amplify the 
myeloid cell response has not been thoroughly explored. However, one study has 
shown that TLR-induced maturation of DCs is enhanced in the presence of IL-
15, leading to increased NK cell cytotoxicity towards human papilloma virus-
(HPV) infected cells (17). 
We hypothesised that, in addition to NK cell activation by trans-presentation and 
other direct effects, IL-15 could have indirect effects on the response of human 
NK cells to viruses by promoting NK cell activating cytokines from accessory 
cells. We show that very low concentrations of IL-15 (0.75ng/ml) dramatically 
enhance the production of IL-12, IFN-.    , / -      D Q G   * 0 -CSF from myeloid 
accessory cells in response to influenza H3N2 and that increased production of 
IFN-.   D Q G, in particular IL-12, is associated with (i) heightened and sustained 
activation of NK cells and (ii) polyfunctionality of the responding NK cells. 
Furthermore, IL-15-mediated enhancement preferentially boosts IL-12 
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production in myeloid DCs (mDC) compared to other blood DC populations and 
monocytes. These studies suggest that IL-15 enhanced accessory cell function 
may potentiate NK cell responses, providing an additional avenue of interest for 
boosting NK cell effector responses in vaccination and NK cell-mediated 
immunotherapy.  
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2.3 Materials and Methods 
 
2.3.1 Study participants 
 
Volunteers were recruited from among staff and students at the London School 
of Hygiene and Tropical Medicine (LSHTM) (n=84) using an anonymised 
volunteer database. The study was approved by the LSHTM Research Ethics 
Committee (reference numbers 6237 and 6324). HCMV serostatus was 
determined for each donor by HCMV IgG ELISA (BioKit, Barcelona, Spain) using 
plasma collected from heparinised whole blood. Donors ranged in age from 20 to 
77 years with a median age of 32 years. Twenty-nine (35%) of the donors were 
male, and 48% were HCMV seropositive.  
 
2.3.2 PBMC isolation and in vitro culture assays 
 
PBMC were isolated from heparinised whole blood using Histopaque 1077 
(Sigma-Aldrich, Gillingham, U.K.) gradient centrifugation. Cells were rested for 2 
hours and either used fresh (blocking experiments and IL-12 intracellular 
staining) or cryopreserved in liquid nitrogen (all other experiments). Before use, 
frozen cells were thawed and washed in RPMI 1640 supplemented with 100U/ml 
penicillin/streptomycin and 20mM L-glutamine (Gibco, ThermoFisher). Cells were 
counted using Countess II FL Automated Cell Counter (Invitrogen, 
ThermoFisher); average viability after thaw was 86%. 3x105 cells/well were 
cultured in RPMI 1640 supplemented as above with 5% pooled human AB serum 
 I R U        R U      K R X U V  D W     Û &  L Q    -well round- E R W W R P  S O D W H V  Z L W K    J  P O  L Q D F W L Y D W H G 
whole H3N2 influenza virus (influenza A/Victoria/361/2011 (H3N2) (IVR-165) 
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National Institute for Biological Standards and Control, Potters Bar, U.K.), with or 
without recombinant human IL-15 at 0.75ng/ml (PeproTech, London, U.K.). 
 & R Q F H Q W U D W L R Q V  Z H U H  G H W H U P L Q H G  E \  S U L R U  W L W U D W L R Q   +  1   D W    J  P O  Z D V  W K H  O R Z H V W 
concentration to induce significant NK cell IFN-   X S U H J X O D W L R Q   Z L W K R X W   W K H 
presence of additional cytokines, 0.75ng/ml IL-15 was previously shown to be the 
lowest concentration to synergise with other cytokines for NK cell activation, 
without significant NK cell activation alone (13). Additional cultures were also 
stimulated with a high concentration of cytokines (HCC) consisting of IL-12 
(PeproTech, London, U.K.; 5ng/ml) and IL-18 (R&D Systems, Oxford U.K.; 
50ng/ml).  
For blocking experiments the following antibodies were used; anti-IL-     D W    J  P O 
(Becton Dickinson (BD) Biosciences, Oxford, U.K.), rat IgG2a isotype control at 
    J  P O    H % L R V F L H Q F H V    7 K H U P R ) L V K H U     D Qti-IL-       D W     J  P O    % ’   % L R V F L H Q F H V   
anti-IFN-.  5    D W     J  P O    0 H U F N   0 L O O L S R U H    : D W I R U G    8  .     D Q G   F R P E L Q H G   P R X V H 
 , J *    D Q G   , J *  D   L V R W \ S H   F R Q W U R O V   D W     J  P O   I L Q D O    H % L R V F L H Q F H V     * R O J L 6 W R S 
(Monensin; 1/1500 concentration; BD Biosciences) and GolgiPlug (Brefeldin A; 
1/1000 final concentration; BD Biosciences) were added for the final 3 hours of 
culture. Culture supernatants were collected and stored at -80°C. For control 
experiments, NK cells were purified (mean purity 87%) using an NK Cell Isolation 
Kit (Miltenyi Biotec) and 2x105 NK cells were stimulated for 18 hours under the 
conditions described above for PBMC cultures (n=5). For IL-12 intracellular 
staining experiments, 2x106 cells/well were cultured as above for 18 hours with 
GolgiStop and GolgiPlug for the final 5 hours. 
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2.3.3 Flow cytometry and Luminex 
 
Cells were stained in 96-well round-bottom plates for surface markers including 
viability marker (Fixable Viability Dye eFluor780; eBioscience) in FACS buffer 
(PBS containing 0.5% FCS, 0.05% sodium azide and 2mM EDTA) for 30 minutes 
after blocking Fc receptors for 5 minutes with Fc Receptor (FcR) Blocking 
Reagent (Miltenyi Biotec). Cells were then washed in FACS buffer, fixed and 
 S H U P H D E L O L V H G   X V L Q J   % ’   & \ W R I L [  & \ W R S H U P   . L W   D F F R U G L Q J   W R   W K H   P D Q X I D F W X U H U ¶ V 
instructions. Cells were then stained for intracellular markers with FcR blocking 
 I R U      P L Q X W H V  D Q G  Z D V K H G  D J D L Q   I L Q D O O \  F H O O V  Z H U H  U H V X V S H Q G H G  L Q         O  ) $ &S 
buffer and transferred to alpha tubes for acquisition on a BD LSRII flow cytometer. 
Fluorophore labelled antibodies used were: anti-CD3-V500 (clone UCHT1), anti-
CD56-PECy7 (clone NCAM16.2), anti-CD107a-FITC (clone H4A3), anti-HLA-
DR-PE (clone TU36) (all BD Biosciences), anti-IFN-  –APC (clone 45.B3), anti-
CD86-AF488 (clone IT2.2), anti-CD11c-PerCPCy5.5 (clone 3.1), anti-CD16-
PEDazzle (clone 3G8), anti-CD14-AF700 (clone 63D3) (all Biolegend, London, 
U.K.), anti-CD25-PerCPCy5.5 (clone BC96), anti-CD57-e450 (clone TB01), anti-
CD19-PECy5 (clone HIB19), anti-CD123-e450 (clone 6H6), anti-IL-12(p40)-e660 
(clone C17.8) (all eBiosciences). Cells were acquired using FACSDiva software, 
data were analysed using FlowJo V10 (Tree Star, Oregon, U.S.A). FACS gates 
were set using unstimulated cells or FMO controls, samples with less than 100 
NK cell events were excluded. Concentrations of GM-CSF, IFN-.     , ) 1 -    7 1 ) -
.    , 3 -10, IL-      , / -10, IL-12p70 in cell culture supernatants were determined by 
Luminex technology (Merck Millipore) and Bio-Plex software (Bio-Rad, Watford, 
U.K.).  
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2.3.4 Statistics 
 
Statistical analysis was performed using GraphPad Prism version 7.01 
(GraphPad, California, U.S.A.). Functional responses were compared using 
Wilcoxon signed-rank test and intergroup comparisons between HCMV 
seropositive and HCMV seronegative individuals were performed using Mann  –
Whitney U test. Correlation analysis was performed using linear regression. 
Significance levels are assigned as *p, 0.05, **p, 0.01, ***p, 0.001, and ****p, 
0.0001 for all tests. Analysis and presentation of polyfunctional NK cell data was 
performed using SPICE version 5.1 (downloaded from 
http://niaid.github.io/spice/).  
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2.4 Results 
 
2.4.1 Nanogram concentrations of IL-15 boost and sustain functional NK 
cell responses to influenza H3N2. 
 
To determine the effect of a low concentration of exogenous IL-15 on the 
frequency and kinetics of NK cell responses to influenza, IFN-    & ’      D   D Q G 
CD25 were measured at 6, 9 and 18 hours after stimulation of human PBMC with 
inactivated H3N2 virus in the presence or absence of 0.75ng/ml recombinant 
human IL-15. The flow cytometry gating strategy is shown in Figure 1A-D. H3N2 
alone induced high frequencies of NK cells expressing each of the three 
activation markers, but there was no significant response to IL-15 alone. At all 
time points, the percentage of expression of all markers was significantly higher 
when cells were cultured with H3N2 plus IL-15 compared to cells cultured with 
H3N2 alone (Figure 1E-G), with each marker displaying distinctly different 
kinetics (frequencies of cells expressing CD107a, IFN-   D Q G  & ’     S H D N L Q J  D W    
9 and 18 hours respectively). A low frequency of NK cells showed spontaneous 
degranulation (CD107a expression) at early time points (Figure 1E) whereas 
there was little or no IFN-  S U R G X F W L R Q  R U  & ’     L Q G X F W L R Q  L Q  X Q V W L P X O D W H G  F X O W X U H V 
(Figure 1F, 1G). Increased responses to H3N2 in the presence of IL-15 were 
reflected in increased mean fluorescence intensities (MFI) for all NK cell 
functional markers at their optimal time points. A small, but significant, increase 
was observed in CD107a MFI at 6 hours (H3N2 median 747 units, interquartile 
range (IQR) 718  –776; H3N2 + IL-15 median 768 units, IQR 735  –813, p=0.0001), 
IFN-  0 ) ,  L Q F U H D V H G substantially by 9 hours (H3N2 median 681 units, IQR 523 –
814; H3N2 + IL-15 median 1037 units, IQR 864  –1179, p=0.0001), and a 
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significant shift in CD25 MFI was observed by 18 hours (H3N2 median 72.5 units, 
IQR 34.7 –153.8; H3N2 + IL-15 median 371.5 units, IQR 249  –508, p=0.0001). 
Thus, very low concentrations of IL-15 boost the NK cell response to H3N2 
stimulation and lead to sustained CD107a and IFN-   S U R G X F W L R Q   F R P S D U H G with 
untreated cultures. 
NK cells are a heterogeneous population of cells, CD56bright subsets are highly 
responsive to cytokines whereas the more mature CD56dimCD57+ subset are 
known to be less responsive to cytokines but maintain cytotoxic function (18). We 
therefore analysed the response of each of these subsets to IL-15 (flow cytometry 
gating strategy shown in Supplementary Figure 1A). As expected, the early 
degranulation response was highest in the most mature (CD56dimCD57+) subset 
and IFN-   S U R G X F W L R Q  Z D V highest in the less mature (CD56dimCD57-) subsets at 
the peak of each response (Supplementary Figure 1B, 1F). However, at 6 hours, 
IL-15 had little effect on degranulation in the CD56dimCD57+ NK cell population, 
but by 9 hours, the heightened response in the presence of IL-15 was pronounced 
within the CD56bright and CD56dim subsets (Supplementary Figure 1B, 1E). 
Enhancement of NK cell IFN-   D Q G   & ’     responses to influenza by low 
concentrations of IL-15 was evident to a similar extent in all NK cell subsets 
(Supplementary Figure 1C-J). 
 
2.4.2 IL-15 enhances NK cell polyfunctionality. 
 
As IL-15 appeared to enhance all three NK cell functions to a similar degree, we 
considered the possibility that this was due to a fraction of NK cells being highly 
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sensitive to the effects of IL-15 and responding in a polyfunctional manner. We 
examined co-expression of IFN-   Z L W K  & ’     D    & ’     R U  E R W K  D W  H D F K  W L P H  S R L Q W 
(flow cytometry gating strategy shown in Figure 2A-C). No polyfunctional NK cells 
were detected in unstimulated cultures or in cultures containing only IL-15 
(Supplementary Figure 2A-C).  When cells were cultured with H3N2 alone, very 
few double or triple positive NK cells were detectable (Figure 2D-F). However, 
after 6 or 9 hours of culture with H3N2 plus IL-15, a considerable population of 
NK cells were double positive for IFN-  D Q G  & ’      D   ) L J X U H   ’   D Q G  E \      K R X U V 
cells co-expressing IFN-  and CD25 (Figure 2E) together with a small but 
statistically significant population of triple positive NK cells (Figure 2F), were 
detectable. Importantly, influenza virus stimulation in the presence of as little as 
0.75ng/ml of IL-15 was almost as effective at inducing polyfunctional NK cells as 
much higher concentrations of a combination of IL-12 and IL-18 (5ng/ml and 
50ng/ml respectively) (Supplementary Figure 2A-C). Polyfunctionality of NK cells 
was also evident from the statistically significant correlation between expression 
of the different functional markers among NK cells cultured with H3N2 plus IL-15 
compared to those cultured with H3N2 alone (Supplementary Figure 2D-I). 
Overall, therefore, IL-15 significantly increased the frequency of polyfunctional 
NK cells responding to influenza virus.   
 
2.4.3 IL-15 enhances in vitro production of myeloid cell-derived 
cytokines. 
 
Because NK cells respond to cytokines released from activated accessory cells 
such as DCs and monocytes, supernatants were collected from cultures at 18 
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hours and cytokine concentrations were measured by Luminex. H3N2 influenza 
virus alone induced secretion of significant concentrations of IL-12(p70), IFN-.   
IFN-   * 0 -CSF, IL-     7 1 ) -.  D Q G  , / -10 (Figure 3A-G). However, addition of low 
concentrations of IL-15 to H3N2 resulted in further significant increases in the 
secretion of all of these cytokines (with the exception of IL-10) (Figure 3G). IL-15-
mediated enhancement of IL-12 secretion was observed in 42 of 73 donors 
(57.5%) with an average 2.1 fold increase in these individuals (Figure 3A). IL-15 
co-stimulation increased IFN-.    V H F U H W L R Q   L Q         R I   L Q G L Y L G X D O V   F R P S D U H G   W R 
H3N2 alone with a median 1.2 fold increase (Figure 3B) and also enhanced IFN-
   E \   D Q   D Y H U D J H         I R O G    ) L J X U H    &     F R Q V L V W H Q W   Z L W K   , /-15 boosting of NK cell 
IFN-   U H V S R Q V H V    ) L J X U H          , Q   F R Q W U D V W    , /-15 alone only induced modest 
increases in IFN-   D Q G   * 0 -CSF production (median increase of only 8.18pg/ml 
for IFN-   D Q G   L Q F U H D V H in GM-CSF in only 3 of 20 donors) compared with 
unstimulated cells (Figure 3C, 3D), and there was no effect of IL-15 alone on IL-
12(p70), IFN-.    , / -     7 1 ) -.  R U  , / -10 secretion (Figure 3A, 3B, 3E-G). 
In the presence of H3N2 and IL-15, the percentage of NK cells producing IFN- 
at 18 hours was significantly correlated with secreted concentrations of both IL-
12 and type I IFN (Figure 3H-M). However, there was no enhanced correlation 
between NK cells producing IFN-  D Q G  * 0 -CSF, TNF-.  R U  , / -    Z L W K  , / -15 (GM-
CSF: r=+0.385, r=+0.391 with IL-15; TNF-.    U                U               Z L W K   , / -15; IL-
      r=+0.197, r=+0.331 with IL-15) suggesting that IL-12 and/or IFN-.   P L J K W  E H 
driving the enhanced NK cell IFN-   U H V S R Q V H    , Q   V X P P D U \    , / -15 dramatically 
enhances the secretion of myeloid cell-derived cytokines and the secretion of two 
of these cytokines (IL-12 and IFN-.    L V  V W U R Q J O \  F R U U H O D W H G  Z L W K  1 .  F H O O  I X Q F W L R Q   
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2.4.4 IL-12 is critical for IL-15-mediated enhancement of NK cell 
responses and generation of polyfunctional NK cells. 
 
As IL-12 and IFN-.    Z H U H   L Q G X F H G   E \   F R-culturing PBMC with influenza H3N2 
and IL-15, and because enhanced NK cell function was correlated with the 
concentrations of these two monokines, we tested the hypothesis that the effects 
of IL-15 on NK cells were mediated via IL-12 and/or type I IFNs. Neutralising 
antibodies against IL-12, IFN-.  5    D Q G   , / -2 were added to cultures stimulated 
with H3N2 (with and without IL-15) for 6, 9 and 18 hours. All three NK cell 
functional responses were reduced in the presence of blocking antibody to IL-12 
by 18 hours (Figure 4A-F) and at the earlier time point of 9 hours (not shown); in 
particular the frequencies of CD107a or IFN-  producing cells induced by H3N2 
plus IL-15 were reduced to those observed in the absence of IL-15 (Figure 4A-
E). Degranulation was also dependent partially on type I IFNs as blockade of the 
IFN-.  5    U H F H S W R U   O H G   W R   S D U W L D O   U H G X F W L R Q   L Q   & ’      D   H [ S U H V V L R Q in both IL-15 
treated and untreated cultures (Figure 4A, 4D). Blocking IL-2 also reduced 
CD107a upregulation after H3N2 stimulation, irrespective of the presence or 
absence of IL-15 (Figure 4A, 4D). However, although anti-IL-2 reduced the NK 
cell IFN-   U H V S R Q V H   W R   +  1    Q R   V X F K   U H G X F W L R Q   Z D V   V H H Q   L Q   U H V S R Q V H   W R   +  1  
plus IL-15, suggesting that IL-15 may be substituting for IL-2 in this assay. 
In addition to reducing the overall frequencies of CD107a+, IFN- + and CD25+ NK 
cells, IL-12 blockade had a marked effect on the induction of polyfunctional NK 
cells. IL-12 neutralisation reduced the frequencies of double and triple positive 
NK cells to the levels observed without IL-15 (Figure 4G-J). These data suggest 
that both the heightened NK cell response to H3N2 and the generation of 
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polyfunctional NK cells in response to IL-15 is dependent on accessory cell IL-
12. Furthermore, correlations between different NK cell functional markers (as 
seen in Supplementary Figure 2D-I) are also seen when NK cells are stimulated 
with high concentrations of IL-12 and IL-18 (data not shown). Stimulation of 
purified NK cells with H3N2 alone or with IL-15 induced no significant NK cell 
activation confirming an accessory cell requirement for both the virus induced 
response and IL-15 mediated enhancement (IFN- percentage at 18 hours: H3N2 
median 0.29%, IQR 0.25-0.368%, H3N2 + IL-15 median 0.465%, IQR 0.308-0.84; 
CD107a percentage at 18 hours: H3N2 median 0.93%, IQR 0.605-1.293%, H3N2 
+ IL-15 median 1.68%, IQR 0.75-2.475%; see Figure for reviewers only, appendix 
page 317). 
 
2.4.5 IL-15 enhances IL-12 production by mDCs. 
 
To determine the source of IL-15-induced IL-12, PBMC were stimulated with 
H3N2 in the presence or absence of IL-15 for 18 hours and stained for 
DC/monocyte phenotypic markers and for intracellular IL-12(p40). DC 
populations were gated as lineage-, CD14-, HLA-DR+ cells, and further split in to 
CD123-CD11c+ mDC, and CD123+CD11c- plasmacytoid DC (pDC) populations. 
The majority of IL-12-producing cells were mDCs rather than pDCs, classical 
(CD14+CD16-) or non-classical (CD14-CD16+) monocytes (figure 5A). Up to 3.1% 
of mDCs expressed IL-12 in response to H3N2 and a significantly higher 
proportion (4.5%) were IL-12 positive with the combination of H3N2 and IL-15 (a 
median 1.9 fold increase) (Figure 5A). Furthermore, IL-15-mediated 
enhancement of IL-12 production was observed only in DCs and was associated 
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with increased expression (MFI) of CD86 (Figure 5B). Little to no IL-12 was 
detected in unstimulated and IL-15 alone treated mDCs (Figure 5C). Of the 14 
individuals tested, 8 (57.1%) showed an increase in IL-12 production from mDCs 
with H3N2 plus IL-15 compared to H3N2 alone, corresponding with the proportion 
of responders determined by Luminex detection of IL-12 in supernatant (Figure 
   ’     $ P R Q J  W K H V H    µ U H V S R Q G H U V ¶   W K H U H  Z D V  D O V R  D Q  L Q F U H D V H  L Q  W K H  0 ) ,  R I  , /-12 
staining of mDCs cultured with H3N2 plus IL-15 compared to H3N2 alone (Figure 
5E). These data suggest that IL-15 potentiates NK cell responses to H3N2 by 
enhancing maturation (CD86 expression) and IL-12 production specifically from 
mDCs. 
 
2.4.6 Enhancement in NK cell function by IL-15 is observed in both HCMV 
seropositive and seronegative individuals. 
 
We, and others, have reported altered NK cell functions in HCMV seropositive 
individuals (19-22). HCMV seropositive individuals respond less well to 
exogenous cytokines and vaccine antigens (including influenza H3N2), and this 
is only partially explained by accelerated NK cell differentiation (21, 22). Here, we 
again observed lower NK cell CD107a, IFN-   D Q G   & ’      U H V S R Q V H V   W R   +  1  
among HCMV seropositive donors than among HCMV seronegative donors 
(Figure 6). Low concentrations of IL-15 enhanced the responses of both HCMV 
seropositive and seronegative subjects but could not fully restore the NK cell 
response of HCMV seropositive subjects to levels seen in HCMV seronegative 
subjects (Figure 6A-C). Interestingly, however, IL-15 was able to completely 
restore the IFN-   U H V S R Q V H   R I   & ’   bright and CD56dimCD57- NK cells, but not 
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CD56dimCD57+ cells, in HCMV seropositive individuals (Figure 6E, 6H). This 
suggests that IL-15 preferentially affects immature NK cells, normalising their 
IFN-   U H V S R Q V H  W R  +  1   to levels seen in HCMV seronegative individuals. Apart 
from a reduced IFN-   U H V S R Q V H    Z K L F K   P D \   E H   D F F R X Q W H G   I R U   E \   U H G X F H G 
production from NK cells in seropositive individuals, there was no difference in 
the in vitro production of lymphoid or myeloid cell-derived cytokines in response 
to H3N2 between HCMV positive and negative donors, irrespective of the 
presence or absence of IL-15 (Supplementary Figure 3).  
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2.5 Discussion 
 
Many studies of the effect of IL-15 on NK cell activation focus on IL-15 trans-
presentation or direct activation of NK cells with high concentrations of IL-15 
(typically between 5 and 50ng/ml) in combination with other cytokines (5, 10). 
Moreover, the synergy between cytokines and pathogen-derived signals for NK 
cell activation has typically been studied only for high concentrations of cytokines 
acting on isolated NK cells, precluding consideration of potential indirect effects 
of the pathogen, the cytokines, or both. To characterise more deeply the potential 
for synergy between IL-15 and pathogen-derived signals in NK cell activation, we 
have conducted a comprehensive analysis of NK cell CD107a, IFN-   D Q G   & ’   
expression and myeloid cell-derived cytokine secretion in response to influenza 
virus H3N2 in the presence or absence of an extremely low concentration of IL-
15. 
Low concentrations of IL-15 enhanced the innate cytokine response to influenza 
virus and this increased cytokine (primarily IL-12) was associated with 
potentiation of NK cell function. Importantly, the concentrations of IL-12 induced 
by this synergistic interaction between influenza virus and IL-15 are of the same 
order of magnitude as the lowest concentrations of IL-12 that we have previously 
shown to effectively synergise with IL-15 and other common  -chain family 
cytokines for NK cell activation in vitro (13). This concentration of IL-12 and the 
low concentration of IL-       X V H G   L Q   W K L V   V W X G \   D U H   D W   O H D V W    -fold lower than 
described effective concentrations for NK cell activation with single cytokines, 
these may be more physiologically relevant than previously used concentrations 
that are unlikely to be reached in vivo. The low in vitro concentration used in this 
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study is within the range for the maximal serum concentration achieved 
therapeutically in patients with metastatic malignant melanoma or renal cancer 
after a low-dose transfusion of 0.3mg/kg/day recombinant human IL-15 and 
which resulted in increases in innate cytokines (23). 
In this article, we have shown that IL-15 preferentially enhances virus-induced 
mDC maturation (measured by upregulation of costimulatory marker CD86) as 
well as cytokine secretion compared to other DC subsets and monocytes, and 
that, together, this heightens and sustains NK cell activation. This role for mDCs 
is fully in line with the known pathogen recognition repertoire and cytokine 
production profile of mDCs (24, 25). Similarly, the essential role of DC-derived IL-
12 in NK cell activation is in line with published data, including data showing that 
IL-12 synergises with specific antibody for NK cell-mediated ADCC of tumours 
(26, 27), that NK cell activation by HPV virus-like particle (VLP)-matured DCs is 
reversed by IL-12 blocking antibodies (28) and that exogenous IL-12 can restore 
NK cell function in HIV-exposed but uninfected infants (29). Interestingly, IL-15 
synergizes well in vitro with IL-12 and IL-     E X W  Q R W  Z L W K  R W K H U -chain –dependent 
cytokines, including IL-2 and IL-21, suggesting some redundancy between the 
latter pathways (13). This is also consistent with our observation that 
neutralization of endogenous IL-2 did not reduce NK cell IFN-  in response to 
H3N2 plus IL-15. 
Enhancement of NK cell function by IL-15 is well established (30). IL-15 has also 
been reported to enhance DC maturation (measured by upregulation of CD40, 
CD86 and MHC class II expression) in mice (17, 31). In line with our observations 
in humans, DCs cultured with HPV-VLP matured more efficiently in the presence 
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of IL-15 and this correlated with enhanced NK cell activation and killing of HPV 
infected tumour cells (17). However, the role of IL-15 enhancement of IL-12 
production by peripheral DCs has not been previously appreciated or linked to 
enhanced NK cell responses. Interestingly, one study demonstrated IL-15 
enhancement of IL-12 secretion by a PMA-activated U937 monocytic cell line was 
associated with increased ability to kill intracellular Leishmania parasites, 
suggestive of a potential role of such mechanisms in protection against infection 
(32). 
The cytotoxic and cytokine-producing roles of NK cells have traditionally been 
ascribed to distinct NK cell subsets (CD56dim and CD56bright, respectively) and 
this dichotomy has rather obscured the potential for NK cells to perform both 
functions simultaneously (i.e. to be polyfunctional). Nevertheless, polyfunctional 
CD56dimCD62L+ NK cells (with dual ability to produce IFN-   D Q G   E H F R P H 
cytotoxic) can be induced by stimulation with high concentrations (50ng/ml) of IL-
12 and IL-18 (33) and TLR stimulation induced polyfunctional NK cells 
(expressing 2 or more of CD107a, IFN-   D Q G   7 1 ) -.    L Q  HIV-1-exposed 
seronegative but not seropositive individuals (34). We defined polyfunctionality 
as simultaneous expression of two or more of IFN- , CD107a and CD25 by any 
NK cell subset; no polyfunctional cells were induced by IL-15 alone and very few 
were detected in response to influenza virus alone. However, stimulation with IL-
15 and virus induced significant numbers of both double and triple-positive NK 
cells suggesting that synergy (likely at the level of mDCs) between IL-15 and 
pattern recognition receptor (PRR) signalling may be necessary for the induction 
of polyfunctional NK cells. This may be due, in part, to the dependence of NK 
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cells on IL-12 to drive IFN-   S U R G X F W L R Q   D Q G on IFN-.  and IL-15 to drive 
cytotoxicity (2, 35).  
Our observation that IL-15 restored the impaired responses of HCMV 
seropositive individuals only among the less differentiated CD56bright and 
CD56dimCD57- NK cell subsets, and that (apart from IFN-  production) there were 
no differences in cytokine production by PBMCs from HCMV seropositive and 
seronegative donors, suggests that polyfunctionality may arise from broadening 
the effector function of less mature NK subsets rather than any effect on mature 
NK subsets. This effect is entirely consistent with IL-12 mediating IL-15 
enhancement of NK cell responses, IL-12 receptor expression, and therefore 
responsiveness, being progressively lost during NK cell differentiation and in 
 µ D G D S W L Y H ¶   1 .   F H O O   V X E V H W V (18, 36). Moreover, these data suggest that reduced 
NK cell responses in HCMV seropositive individuals are not due to an accessory 
cell defect but may result from intrinsic changes in more differentiated NK cells 
(18, 22). This hypothesis, that IL-15 broadens the functional response of 
immature NK cells, is further supported by evidence that degranulation, IFN-  
and TNF-.  production from CD56bright NK cells are potently enhanced by 
exposure to multiple myeloma or acute myeloid leukaemia target cells after in 
vivo therapy with the IL-15R agonist ALT803 (37). The use of an IL-15/IL-    5. 
superagonist may further boost NK cell responses to H3N2 virus, however, this 
would be expected to act on NK cells directly, as IL-15 is already complexed to 
its receptor, therefore potentially bypassing the accessory-dependent effects. 
In summary, we have revealed an unexpected impact of very low concentrations 
of IL-15 on the production of cytokines, in particular IL-12 from mDCs, which, in 
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turn, plays a vital role in boosting NK cell responses to influenza virus 
(summarised in Supplementary Figure 4). In addition to increasing the overall 
frequencies of responding NK cells, IL-15 also promotes the generation of 
polyfunctional NK cells. These studies suggest that use of very low dose IL-15 
may be a strategy for enhancing and broadening NK cell effector function in 
immunotherapy and in enhancing vaccine responses.   
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2.7 Figures 
 
 
Figure 1: Nanogram concentrations of IL-15 boost and sustain functional NK cell 
responses to influenza H3N2. 
PBMC were cultured in vitro for 6, 9 and 18 hours in medium alone (unstimulated; n=12) or IL-15 
alone (n=12), H3N2 (n=62) or H3N2 plus IL-15 (n=62). NK cells are gated as CD56+CD3- 
lymphocytes (A). Flow cytometry gating strategy for NK cell CD107a (B), IFN-       &     D Q G   & ’   
(D) responses after 18 hours in vitro culture in one representative individual. Numbers shown are 
the percentage of total NK cells positive for each marker. Graphs show percentage of total NK 
cell population expressing CD107a (E), IFN-       )    D Q G   & ’       *    Z L W K   W K H   P H G L D Q   D Q d 95% 
confidence interval. ***p < 0.001, ****p < 0.0001 H3N2 alone versus H3N2 plus IL-15 by the 
Wilcoxon signed-rank test.  
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Figure 2: IL-15 enhances NK cell polyfunctionality. 
CD107a and CD25 expression of IFN-     V H F U H W L Q J   1 .   F H O O V   Z H U H   J D W H G   D W        $           %    R U          &  
hours. Plots show NK cell function in one representative donor, numbers shown are percentage 
of parent population after stimulation with H3N2 plus IL-15. Frequencies of IFN-  +CD107a+ (D), 
IFN-  +CD25+ (E) double positive and IFN-  +CD25+CD107a+ (F) triple positive NK cells after 
antigen stimulation with IL-15 or without IL-15 are shown for each time point (n=62). Graphs are 
box and whisker plots with 10-90th percentile. Median distribution of triple, double and single 
positive NK cells after stimulation with H3N2 alone or H3N2 with IL-15 for 18 hours are also shown 
in pie charts as percentage of total NK cells (pie slice) and  proportion expressing each marker 
(pie arc) (G). ****p < 0.0001, Wilcoxon signed-rank test.  
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Figure 3: IL-15 enhances in vitro production of myeloid cell derived cytokines. 
Supernatants were collected from whole PBMC cultured with medium alone (n=20) or IL-15 alone 
(n=20), H3N2 (n=73) or H3N2 with IL-15 (n=73) for 18 hours, and concentrations of IL-12p70 (A), 
IFN- .      %     , ) 1 -   (C), GM-CSF (D), IL-       (     7 1 ) -.     )    D Q G   , / -10 (G) were determined by 
Luminex technology. The correlation between NK cell IFN-     S U R G X F W L R Q   G H W H U P L Q H G   E \ 
intracellular cytokine staining and the concentration of IL-12(p70) (H, K), IFN- .      ,    /     , ) 1 -      -  
M) determined by Luminex after stimulation with H3N2 (H-J) and H3N2 with IL-15 was also 
determined (K-M). Graphs are before and after plots. *p < 0.05, ****p < 0.0001, Wilcoxon signed-
rank test (A-G). Correlations were measured by linear regression with statistical significance 
determined as a p value < 0.05 (H-M). 
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Figure 4: IL-12 is critical for IL-15-mediated enhancement of NK cell responses and 
generation of polyfunctional NK cells. 
PBMC were cultured for 6, 9 and 18 hours with H3N2 (A-C) and H3N2 plus IL-15 (D-F) in the 
presence of IL-12, IFN- .  5    D Q G   , / -2 blocking antibodies or the appropriate isotype control. 
Graphs show CD107a (A,D), IFN-       %  (    D Q G   & ’        &  )    U H V S R Q V H V   D I W H U       K R X U V   F X O W X U H   D Q G 
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frequencies of IFN-  +CD107a+ (G), IFN-  +CD25+ (H) double positive and IFN-  +CD25+CD107a+ 
(I) triple positive NK cells after 9 (peak of IFN-     U H V S R Q V H    R U       K R X U V   S H D N  R I   & ’     U H V S R Q V H  
(n=11). Graphs are box and whisker plots with 10-90th percentile. Median distribution of triple, 
double and single positive NK cells after stimulation with H3N2 and IL-15 for 18 hours are also 
shown in pie charts as percentage of total NK cells (pie slice) and proportion expressing each 
marker (pie arc) (J). *p < 0.05, **p < 0.01, ***p < 0.001, Wilcoxon signed-rank test. 
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Figure 5: IL-15 enhances IL-12 production by mDCs. 
PBMC were cultured with H3N2 or H3N2 with IL-15 (n=14) for 18 hours, cells were stained for 
DC and monocyte phenotypic markers and intracellular IL-12. Single, live cells were further gated 
as lineage (CD3, CD19, CD56) negative, classical (CD14+CD16-) and non-classical (CD14-
CD16+) monocytes, all CD14+ and CD14- cells, all CD14-HLA-DR+ DCs, mDCs (CD123-CD11c+) 
and pDCs (CD123+CD11c-). IL-12+ events (A) and CD86 MFI (B) for each cell type was gated 
using fluorescence minus one controls and shown as one data point per donor; the horizontal line 
represents the median. Flow cytometry gating strategy for IL-12+ mDCs is shown in one 
representative individual; numbers denote percentage IL-12+ mDCs (C). Before and after plots 
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show percentage of mDCs expressing IL-12 for each individual when stimulated with H3N2 +/- 
IL-15 (D) and the corresponding IL-12 MFI for each responder and non-responder with IL-15 co-
stimulation (E). *p < 0.05, Wilcoxon signed-rank test. 
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Figure 6: Enhancement in NK cell 
function by IL-15 is observed in both 
HCMV seropositive and seronegative 
individuals. 
HCMV serostatus for each individual was 
determined (n=35 seropositive and n=38 
seronegative). CD107a (A), IFN-       %    D Q G  
CD25 (C) expression within each group 
after stimulation with H3N2 and H3N2 plus 
IL-15 for 6, 9 and 18 hours. NK cell 
responses attributed to each differentiation 
subset determined by the expression of 
CD56 and CD57, CD56bright, 
CD56dimCD57- CD56dimCD57+ were 
analysed (flow cytometry gating strategy in 
Supplementary Figure 1A). Graphs show 
median with 95% confidence interval. 
CD107a (D, G), IFN-      (    +   D Q G  & ’       )  
I) expression within each subset is shown 
for HCMV seropositive and seronegative 
individuals, only the peak time point for each response is shown. Each dot represents an individual donor; the horizontal line represents the median. *p < 0.05, 
**p < 0.01, ***p < 0.001, ****p < 0.0001, H3N2 versus H3N2 plus IL-15, Wilcoxon signed-rank test (A-C), unpaired Mann-Whitney U tests (D-I). ns, not significant.
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2.8 Supplementary Figures
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Supplementary Figure 1: IL-15 
boosts NK cell functional 
responses to H3N2 vaccine antigen 
in all NK cell differentiation 
subsets. 
Gating strategy for NK cell 
differentiation subsets CD56bright, 
CD56dimCD57- CD56dimCD57+ (A). 
CD107a (B, E, H), IFN-       &    )    ,    D Q G 
CD25 (D, G, J) expression within 
these subsets after stimulation with 
H3N2 and H3N2 plus IL-15 for 6 (B-D), 
9 (E-G) and 18 hours (H-J), (n=62) are 
shown. Graphs are box and whisker 
plots with 10-90th percentile. *p < 
0.05, ****p < 0.0001, Wilcoxon signed-
rank test.
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Supplementary Figure 2: No detection of polyfunctional NK cells in cultures containing IL-
15 alone, the relationship between NK cell functional responses becomes more positively 
correlated with the presence of IL-15. 
Frequencies of IFN-  +CD107a+ (A), IFN-  +CD25+ (B) double positive and IFN-  +CD25+CD107a+ 
(C) triple positive NK cells after H3N2 stimulation with and without IL-15 or HCC (IL-12 5ng/ml 
and IL-18 50ng/ml) are shown for each time point (unstimulated and IL-15 alone; n=12, H3N2, 
H3N2 plus IL-15 and HCC; n=62). Each dot represents an individual donor; the horizontal line 
represents the median. Correlations between NK cell IFN-     S U R G X F W L R Q   D Q G   & ’    D   R U   & ’    
expression after 6 (D, G), 9 (E, H) or 18 (F, I) hours stimulation with H3N2 (D-F) or H3N2 with IL-
15 (G-I) (n=62) are shown. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, one-way ANOVA 
Kruskal-Wallis test with Dunns multiple comparisons. Correlations were measured by linear 
regression with statistical significance determined as a p value < 0.05. ns, not significant. 
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Supplementary Figure 3: Cytokine release is not significantly different between HCMV 
seropositive and seronegative groups. 
Concentrations of IL-12p70 (A), IFN- .    %    , ) 1 -      &    * 0 -CSF (D), IL-      (    7 1 ) - .    )   D Q G  , / -
10 (G) in supernatants after 18 hours stimulation were determined by Luminex technology and 
split in to HCMV seropositive (n=35) and seronegative (n=38) groups. Each dot represents an 
individual donor; the horizontal line represents the median. Not significant by unpaired Mann-
Whitney U tests.  
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Supplementary Figure 4: A schematic representation of the effect of IL-15 on NK cell 
responses to H3N2. 
H3N2 induced IL-12 secretion from mDCs is enhanced in the presence of very low concentrations 
of IL-15, leading to enhanced NK cell responses and higher frequencies of polyfunctional NK cells 
independently of trans-presentation or direct NK cell IL-15R binding. 
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3.1 Abstract 
 
Cytokine-induced memory like (CIML) NK cells generated in response to pro-
inflammatory cytokine activation, in vitro and in vivo, can also be generated by 
vaccination, exhibiting heightened responses to cytokine stimulation for months 
after their initial induction. Our previous study demonstrated that in vitro NK cell 
responses to inactivated influenza virus were also indirectly augmented by very 
low doses of IL-15 which increased induction of myeloid cell-derived cytokine 
secretion. These findings led us to hypothesise that IL-15 stimulation could reveal 
a similar effect for active influenza vaccination and influence CIML NK cell 
effector functions. In this study, 51 healthy adults were vaccinated with seasonal 
influenza vaccine and PBMC were collected before and up to 30 days after 
vaccination. Myeloid and lymphoid cell cytokine secretion was measured after in 
vitro PBMC restimulation with low dose IL-15, alone or in combination with 
inactivated H3N2 virus; the associated NK cell response was assessed by flow 
cytometry. PBMCs collected 30 days post-vaccination showed heightened 
cytokine production in response to IL-15 compared to PBMCs collected at 
baseline, these responses were further enhanced when IL-15 was combined with 
H3N2. NK cell activation in response to IL-15 alone (CD25) and H3N2 plus IL-15 
(CD25 and IFN-    Z D V   H Q K D Q F H G   S R V W-vaccination. We also observed 
proliferation of less differentiated NK cells with downregulation of cytokine 
receptors as early as 3 days after vaccination, suggesting cytokine stimulation in 
vivo. We conclude that vaccination-induced  µ training ¶ of accessory cells combines 
with the generation of CIML NK cells to enhance the overall NK cell response 
post-vaccination.  
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3.2 Introduction 
 
NK cells are large, granular, lymphoid cells, classically categorised as cells of the 
innate immune system as they express activating and inhibitory receptors from 
germline encoded genes. The balance of activating and inhibitory signals 
transduced by these receptors controls the direct activation of NK cells, and this 
is fine-tuned by signals from innate cytokines such as IL-12, IL-15 and type I 
interferon (IFN) produced by myeloid accessory cells. NK cells can also augment 
and regulate adaptive immune responses by production of cytokines such as IFN-
    D Q G   W K H   D G D S W L Y H   U H V S R Q V H   I H H G V   E D F N   W R   V X S S R U W   W K H   1 .   F H O O   U H V S R Q V H    I R U 
example via CD4+ T cell IL-2 secretion (1-3). Evaluation of this bi-directional 
relationship has contributed to our understanding of memory-like NK cell 
responses (reviewed in (4)).  
Cytokine pre-activated or cytokine-induced memory like (CIML) NK cells have 
been described in mouse and human in vitro cell culture models. NK cells pre-
activated with combinations of IL-12, IL-15 and IL-18 displayed enhanced 
proliferation and IFN-   S U R G X F W L R Q   D I W H U   F \ W R N L Q H   U H V W L P X O D W L R Q    W K L V   Z D V 
maintained for up to 12 weeks and through several cycles of cell division (5-7). 
Vaccination with whole inactivated or live attenuated viral vaccines generate 
CIML NK cells in vivo, with heightened potential for IFN- secretion after re-
encounter of pro-inflammatory cytokines (8-10). In particular, both seasonal 
influenza vaccination and in vitro pre-activation of human PBMC with inactivated 
influenza virus can enhance NK cell responses to cytokine restimulation for up to 
4 weeks (9). In mice, murine cytomegalovirus (MCMV) infection induces both 
 µ antigen-specific  ¶ memory NK cells (Ly49H recognition of m157) and CIML NK 
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cells, suggesting that diverse subsets of memory/memory-like NK cells can be 
induced by a single infection (11, 12). The pro-inflammatory cytokine IL-12 was 
 F U L W L F D O  L Q  0 & 0 9  L Q G X F H G  µantigen-specific  ¶ NK cell expansions and maintenance, 
the expansion of NKG2C+ NK cells in human cytomegalovirus (HCMV) infection 
and reactivation and in the generation of CIML NK cells, suggesting this cytokine 
may be a common requirement for the generation of memory-like NK cells (13-
15).  
In human PBMC, low concentrations of exogenous IL-15 (0.75ng/ml) enhance 
influenza virus-induced secretion of myeloid cell derived cytokines such as GM-
CSF, IFN-. , IL-12 and IL-     D Q G   W K L V    L Q   W X U Q    H Q K D Q F H V   F \ W R N L Q H-dependent NK 
cell activation (16). Moreover, NK cell IFN-   U H V S R Q V H V   W R   O R Z   F R Q F H Q W U D W L R Q V   R I 
IL-12 and IL-18 (12.5pg/ml and 10ng/ml respectively) are enhanced after 
influenza vaccination (9), suggesting that vaccine induced primed or co-
stimulated NK cells have a lower threshold for cytokine-induced activation. 
Whilst vaccine antigen driven NK cell recall responses are known to be 
dependent on vaccine specific T cell derived IL-2 and antibody (9, 10, 17, 18), 
the mechanisms of increased NK cell responses to innate cytokines after 
vaccination are not well understood. Our previous studies showed that IL-15 
could indirectly promote NK cell responses by boosting the in vitro production of 
accessory cell-derived cytokines in response to inactivated influenza H3N2 (16). 
We therefore hypothesised that IL-15 stimulation could also reveal whether a 
similar indirect effect could be promoted by active vaccination with seasonal 
trivalent or quadrivalent influenza vaccine (TIV, QIV). We examined IL-15 
stimulated accessory cell derived cytokine production in vitro before and after 
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vaccination and the associated impact on NK cell function. Restimulation of 
human PBMC cultures with low concentrations of IL-15 alone revealed enhanced 
production of both myeloid and lymphoid cell-derived cytokines four weeks after 
vaccine administration. Co-stimulation with IL-15 and influenza H3N2 resulted in 
further enhancement of cytokine production and in NK cell IFN-  and CD25 
upregulation in post-vaccination compared to baseline samples. These studies 
contribute to the understanding of vaccine induced pre-activation of innate 
immune cells, and of the in vivo mechanisms promoting the generation of CIML 
NK cells in humans. 
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3.3 Materials and Methods 
 
3.3.1 Study participants and sample collection 
 
Fifty-one healthy adult volunteers (median age 39y, range 24-66y; 41% male; 
41% HCMV seropositive by IgG ELISA (Biokit, Barcelona, Spain)) were recruited 
from amongst staff and students of the London School of Hygiene and Tropical 
Medicine (LSHTM). The study was approved by the LSHTM Ethical Review 
Committee (reference number 10336). All subjects received a single dose of 
2015-2016 inactivated TIV (n=37) or 2017-2018 inactivated QIV (n=14) by the 
intramuscular route (Split Virion BP, Sanofi Pasteur). Heparinised blood was 
collected prior to vaccination (baseline; day 0), and 3 days, 7 days and 30 days 
post-vaccination. Whole blood was also collected from non-vaccinated volunteers 
for use in additional experiments. PBMC were isolated using Histopaque 1077 
(Sigma-Aldrich, Gillingham, U.K.) gradient centrifugation and cryopreserved in 
liquid nitrogen. Plasma samples were stored at -80°C. 
 
3.3.2 Cell cultures 
 
Before use, cryopreserved cells were thawed, washed in RPMI 1640 
supplemented with 100U/ml penicillin/streptomycin and 20mM L-glutamine (Life 
Technologies, Thermo Fisher), and rested for 2 hours in the absence of 
exogenous cytokines. Cells were counted using a Countess II FL Automated Cell 
Counter (Invitrogen, Thermo Fisher); the median yield was 51% and median 
viability by trypan blue exclusion was 89%. PBMCs (4x105) were either stained 
immediately for ex vivo phenotyping or cultured for 6 or 18 hours with or without 
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    J  P O   L Q D F W L Y D W H G   Z K R O H   +  1    L Q I O X H Q ] D   Y L U X V    L Q I O X H Q ] D   $  9 L F W R U L D             
H3N2 (IVR-165); formalin inactivated, in PBSA buffer plus 1% (w/v) sucrose, 
National Institute for Biological Standards and Control, Potters Bar, U.K.), with or 
without 0.75ng/ml recombinant human IL-15 (PeproTech, London, U.K.) in RPMI 
plus 5% pooled human AB serum (Sigma-Aldrich). Additional cultures were 
stimulated with a high concentration of cytokines (HCC) consisting of IL-12 
(5ng/ml; PeproTech) and IL-18 (50ng/ml; R&D Systems, Oxford U.K.). 
For blocking experiments, the following antibodies were used; anti-IL-12 at 
    J  P O   % ’  % L R V F L H Q F H V   2 [ I R U G   8  . .) and mouse Ig  *   L V R W \ S H  F R Q W U R O  D W    J  P O 
final (eBiosciences, Thermo Fisher). There was no difference in NK cell activation 
in the presence or absence of isotype control antibody. GolgiStop (Monensin; 
1/1500 concentration; BD Biosciences) and GolgiPlug (Brefeldin A; 1/1000 final 
concentration; BD Biosciences) were added for the final 3 hours of all cell 
cultures. Culture supernatants were collected and stored at -80°C for Luminex 
analysis.  
 
3.3.3 Antibody-dependent NK cell activation assay 
 
96 well flat bottom tissue cultur  H  W U H D W H G  S O D W H V  Z H U H  F R D W H G  R Y H U Q L J K W  Z L W K    J  P O 
inactivated H3N2 virus at 4°C, washed and blocked with 5% FCS in RPMI 1640 
supplemented as above for 30 minutes. PBMC from fresh blood of one previously 
tested (non-vaccinated) donor with pre or post-vaccination serum from each 
participant at a final concentration of 0.1% (plus 4.9% FCS) were plated on the 
coated plates and incubated for 5 hours at 37°C. Cells were harvested into round-
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bottom plates by soaking and resuspending in cold PBS containing 0.5% FCS, 
0.05% sodium azide and 2mM EDTA for staining. 
 
3.3.4 Flow cytometry and Luminex 
 
PBMCs were stained in 96-well round-bottomed plates as described previously 
(16). Briefly, cells were incubated for 5 minutes with Fc Receptor (FcR) blocking 
Reagent (Miltenyi Biotec) and then with a viability marker (Fixable Viability Stain 
700; BD Biosciences) and antibodies to surface markers diluted in FACS buffer 
(PBS containing 0.5% FCS, 0.05% sodium azide and 2mM EDTA). Cells were 
then washed in FACS buffer, fixed and permeabilised using Cytofix/Cytoperm Kit 
(BD Biosciences) or Foxp3/Transcription Factor Fixation/Permeabilization Kit 
  H % L R V F L H Q F H V    D F F R U G L Q J   W R   W K H   P D Q X I D F W X U H U ¶ V   L Q V W U X F W L R Q V    & H O O V   Z H U H   W K H Q 
stained for intracellular markers with FcR blocking and washed again and finally, 
cells were resuspended for acquisition on a BD LSRII flow cytometer.  
Fluorophore-labelled antibodies used were: anti-CD3-V500 (clone UCHT1), anti-
CD56-PE-Cy7 (clone NCAM16.2), anti-CD107a-FITC (clone H4A3) (all BD 
Biosciences), anti-CD57-eFlour450 (clone TB01), anti-CD25  –PerCP-Cy5.5 
(clone BC96), anti-IL-     5. -PE (clone H44) (all eBiosciences), anti-IL-     5  -
PerCP-Cy5.5 (clone 622509) (R&D systems), anti-CD25  –FITC (clone BC96), 
anti-IFN- -APC (clone 4S.B3) and anti-Ki67-PEDazzle (clone Ki67) (all 
Biolegend, London, U.K).  Cells were acquired using FACSDiva software, data 
were analysed using FlowJo V10.4 (Tree Star, Oregon, U.S.A). FACS gates were 
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set using unstimulated cells or FMO controls. Samples with less than 100 NK cell 
events were excluded from analysis.  
Concentrations of GM-CSF, IFN-.    , ) 1 -   7 1 ) -.   , 3 -10, IL-     , / -10, IL-12p70, 
IL-15 and IL-2 in cell culture supernatants were determined by Luminex 
technology, kit number HCYTOMAG-60K-09 (Merck Millipore, Watford, U.K) 
using Bio-Plex software (Bio-Rad, Watford, U.K.) for data acquisition.  
 
3.3.5 Data analysis 
 
Statistical analysis was performed using GraphPad Prism version 7.04 
(GraphPad, California, U.S.A.). Differences in responses were analysed using 
Wilcoxon signed-rank test or one- Z D \   $ 1 2 9 $   ) U L H G P D Q   W H V W   Z L W K   ’ X Q Q ¶ V 
correction for multiple comparisons. Correlation analysis was performed using 
linear regression. Significance levels are assigned as *p < 0.05, **p < 0.01, ***p 
< 0.001, and ****p < 0.0001 for all tests. 
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3.4 Results 
 
3.4.1 Enhanced IL-15 stimulated cytokine production after influenza 
vaccination. 
 
Our previous study (16) revealed that IL-15 co-stimulation enhanced the 
production of myeloid cell-derived cytokines from influenza H3N2-stimulated 
PBMC. We therefore reasoned that influenza vaccination might also prime 
accessory cells for cytokine production which could be revealed on restimulation 
of PBMC with IL-15 in vitro. Baseline and day 30 post-vaccination PBMC from 
volunteers vaccinated with a single dose of 2015-2016 TIV were cultured in vitro 
for 18 hours with 0.75ng/ml exogenous IL-15, with or without inactivated H3N2 
virus or medium alone. Cytokine concentrations in cell culture supernatants were 
determined by Luminex (Figure 1). In line with our previous data in unvaccinated 
individuals (16), baseline samples showed significant induction of IL-10 
(p=0.0391) and IFN-  (p=0.006) in response to IL-15 alone (Figure 1b, g) and 
influenza H3N2 stimulation increased levels of IFN-. 2 (p=0.001), IL-12(p70) 
(p=0.002), TNF-.  (p=0.008), and IFN-  (p=0.009) compared to medium alone 
(Figure 1d-g). Co-stimulation of baseline, pre-vaccination samples with H3N2 and 
IL-15 further enhanced secretion of GM-CSF (p=0.0039), IL-      S               7 1 ) -
.  (p=0.0039) and IFN-  (p=0.005) compared either stimulus alone (Figure 1a, c, 
f, g).  
We then compared post-vaccination to pre-vaccination cytokine secretion in 
response to each stimulation condition alone or in combination. In vitro 
restimulation of PBMC with IL-15 alone significantly increased GM-CSF (3.6 fold), 
IL-10 (3.6 fold), IL-       .4 fold) and IFN-  (1.5 fold) secretion at 30 days post-
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vaccination compared to baseline (Figure 1a-c, g). An increase in median 
concentration of TNF-.  (baseline, 509.4pg/ml; day 30, 1169pg/ml) was also 
observed in response to IL-15 alone after vaccination (Figure 1f). Vaccination did 
not result in increased levels of cytokines in unstimulated (medium alone) 
cultures, indicating that enhancement of cytokine responses after vaccination 
was an active process, reliant both on in vivo priming and in vitro restimulation, 
and not due to residual activated cells in the cultures. Although H3N2 stimulated 
significant levels of IFN-. 2 and IL-12(p70) secretion, no enhancement post-
vaccination was observed to this stimulation (Figure 1d-e). However, when cells 
were co-stimulated with IL-15 and H3N2, significant increases in GM-CSF, IL-10, 
IL-       , ) 1 -. 2 and IFN-  were observed post-vaccination compared to baseline 
(Figure 1a-d, g). No enhancement in IL-2 was measured in cell culture 
supernatants in response to in vitro stimulation after vaccination (not shown). 
These data show that restimulation in vitro with low concentrations of exogenous 
IL-15 are sufficient to reveal enhanced cytokine secretion after vaccination in the 
absence of antigen specific stimuli. Whilst increased IFN-  secretion is consistent 
with enhanced NK cell activation, GM-CSF, IL-10 and IL-      D U H   L Q G L F D W L Y H   R I 
myeloid cell activation, suggesting that influenza vaccination primes both myeloid 
and lymphoid cells in vivo for increased cytokine production.  
 
3.4.2 Enhanced NK cell responses to IL-15 post-vaccination. 
 
To examine the effect of influenza vaccine-induced priming of innate immune 
cells on NK cell responses, baseline and 30 day post-vaccination PBMC were 
cultured for 6 or 18 hours in vitro with medium alone, IL-15 alone, H3N2 or H3N2 
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+ IL-15 and analysed for NK cell (CD56+CD3-) IFN-    & ’      D Q G   & ’     D 
expression by flow cytometry; the gating strategy is shown in Figure 2a-c. There 
were no significant differences between responses of individuals vaccinated with 
2015-2016 TIV or 2017-2018 QIV (not shown); all data were therefore pooled for 
analysis. NK cell IFN-   D Q G   & ’      D   Z H U H   L Q G X F H G  D I W H U     K R X U V   V W L P X O D W L R Q   Z L W K 
H3N2 (Figure 2a, b) and CD25 was upregulated after 18 hours (Figure 2c), NK 
cell activation was significantly higher after H3N2 + IL-15 co-stimulation 
compared to either H3N2 or IL-15 alone, consistent with our previous 
observations (Figure 2a-c) (16).  
Importantly, when PBMCs were stimulated with H3N2 + IL-15, significantly higher 
percentages of NK cells expressing IFN-   D W     K R X U V   P H G L D Q        L Q F U H D V H     
of 49 donors), and CD25 at 18 hours (median 7.8% increase; 30 of 48 donors) 
were detected among PBMCs collected 30 days after vaccination compared to 
baseline (Figure 2d, f). Similarly, after IL-15 stimulation, a higher percentage of 
NK cells expressed CD25 in day 30 post-vaccination PBMCs than in baseline 
PBMCs (Figure 2f). Conversely, there were no significant differences in levels 
(mean fluorescence intensity; MFI) of CD25 expression on CD25+ cells after in 
vitro stimulation (IL-15 alone: baseline median MFI 165, interquartile range (IQR) 
137-208; day 30 median 164, IQR 129-199; H3N2 + IL-15: baseline median 547, 
IQR 416-661; day 30 median 532, IQR 368-693; not shown) indicating that 
vaccination was increasing the frequencies of responsive NK cells rather than 
modulating the expression of CD25 expression per se. CD107a expression did 
not differ significantly between baseline and day 30 post-vaccination cells, 
irrespective of the restimulation conditions (Figure 2e). Finally, neither IFN-  
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CD107a (Supplementary Figure 1a, b) nor CD25 (Figure 2f) expression differed 
significantly between baseline and post-vaccination cells after restimulation with 
H3N2 alone.  
Whilst higher frequencies of IFN- + cells were observed among less differentiated 
(CD56bright and CD56dimCD57-) NK cells, both before and after vaccination, 
compared to more differentiated subsets (CD56dimCD57+) (Figure 2g), enhanced 
post-vaccination CD25 and IFN-    E X W   Q R W   & ’      D    U H V S onses to H3N2 + IL-15 
were observed across all NK cell subsets indicating that vaccination influences 
NK cell function independently of differentiation state (Figure 2g, h, i). In line with 
previous studies (8, 9, 19), we observed small but significant increases in IFN- + 
NK cells 30 days post-vaccination compared to baseline among cells 
restimulated with high concentrations of IL-12 and IL-18, consistent with an 
intrinsic vaccine-induced effect on NK cells (Supplementary Figure 1c-e). These 
data suggest that very low concentrations of IL-15 alone are sufficient to reveal 
vaccination mediated enhancement of total NK cell activation (CD25 expression) 
in post-vaccination cultures potentially through synergy with vaccine-primed 
cytokine secretion from accessory cells. 
TIV and QIV vaccination induced significant levels of H3N2 specific antibodies 
(Supplementary figure 2a), therefore, we measured antibody-dependent NK cell 
activation (whole PBMC from one non-vaccinated control donor) to inactivated 
H3N2 and pre or post-vaccination plasma from each vaccinated individual. 
Indeed we measured significantly higher NK cell CD107a and IFN-   H [ S U H V V L R Q 
in response to inactivated virus with post-vaccination plasma compared to 
baseline plasma (Supplementary Figure 2b). There was a weak positive 
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correlation (p=0.0006) between day 30 antibody concentration and NK cell IFN-
  V H F U H W L R Q   6 X S S O H P H Q W D U \  ) L J X U H    F   
 
3.4.3 Vaccine induced enhancement of polyfunctional NK cell responses 
requires IL-15 co-stimulation. 
 
IL-15 is a major contributor to CIML NK cell function and synergises with IL-12 
and IL-18 for polyfunctionality (20), suggesting that, in vivo, IL-15 may play an 
important role in maximising anti-viral NK cell activity. Here we examined whether 
vaccination would promote polyfunctional NK cell responses after restimulation 
with IL-15 alone or in combination with H3N2 (Figure 3). Frequencies of IFN-

+CD25+, CD107a+IFN- +, and CD107a+CD25+ polyfunctional NK cells were 
significantly higher in response to H3N2 + IL-15 than H3N2 alone or IL-15 alone 
both pre and post-vaccination (Figure 3a-c). Enhanced polyfunctional NK cell 
responses were observed after vaccination; significantly higher percentages of 
IFN- +CD25+ NK cells (median baseline, 0.38%; day 30, 0.73%) and an increase 
in median percentage of CD107a+IFN- + (baseline, 0.27%; day 30, 0.40%) and 
CD107a+CD25+ (baseline, 2.4%; day 30, 2.8%) were measured in response to 
H3N2 + IL-15 but not to either stimulus alone (Figure 3a-c). These data suggest 
that, consistent with viral induction of IFN-.    D Q G   , / -12(p70) shown in Figure 1, 
enhancement of polyfunctional NK cell frequencies requires viral induced signals. 
 
3.4.4 Post-vaccination NK cell responses are dependent on IL-12. 
 
Synergy between innate cytokines, IL-12, type I IFN and CD4+ T cell derived IL-
2 are required for enhanced NK cell responses after vaccination (9, 16, 17, 19). 
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Despite vaccination having no direct enhancement of IL-12 production per se 
compared to baseline samples (Figure 1) we assessed whether the enhancement 
of NK cell responses after vaccination was nonetheless dependent on IL-12. Pre 
and post-vaccination PBMCs were stimulated in vitro with H3N2 + IL-15 in the 
presence of anti-IL-12 blocking antibody or isotype control antibody and NK cell 
function was assessed. IL-12 blockade significantly reduced the percentages of 
IFN- + positive and CD25+IFN- + double-positive NK cells at baseline and ablated 
the vaccination-induced enhancement of CD25+IFN- + double-positive NK cells 
(Figure 4a). The relationship between NK cell function and IL-12(p70) secretion 
in 18 hour in vitro cultures was assessed by linear regression. Both NK cell IFN-
   H [ S U H V V L R Q   D Q G   & ’   +IFN- + polyfunctionality were loosely but significantly 
correlated with IL-12(p70) concentration at baseline (r2=0.19; p=0.014 and 
r2=0.13; p=0.03, respectively) (Figure 4b) but were more strongly correlated at 30 
days post-vaccination (r2=0.61, p=<0.0001 and r2=0.58, p=<0.0001, respectively) 
(Figure 4c). These data indicate that the enhancement of NK cell responses post-
vaccination were dependent on IL-12 but that the intrinsic ability of NK cells to 
respond to this cytokine may also be influenced by vaccination. 
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3.4.5 Altered ex vivo NK cell phenotype and cytokine receptor expression 
early after TIV vaccination. 
 
Enhanced cytokine-dependent NK cell responses observed after vaccination are 
restricted to less differentiated, cytokine responsive subsets (8-10, 19, 21). To 
determine how vaccination increases the functional potential of these less 
differentiated NK cells, including IL-12 responsiveness, we examined the effects 
of vaccination on NK cell phenotype at day 3, 7 and 30 post-vaccination by ex 
vivo analysis of expression of CD56, CD57, the proliferation marker Ki67, and 
cytokine receptors IL-12R2, IL-18R and CD25 (gating strategy is shown in 
Supplementary Figure 3a). We observed a transient expansion of the CD56bright 
NK cell subset, along with concomitant contraction of the CD56dim subset within 
the total NK cell population at 7 days post-vaccination when compared to baseline 
or day 30 (Figure 5a). This seems to be due to proliferation of CD56bright cells as 
demonstrated by a transient increase in the proportion of Ki67+CD56bright NK cells 
(Figure 5b) with no parallel effect on cell death (as monitored by viability dye) 
within both CD56bright and CD56dim NK cells across vaccination visits 
(Supplementary Figure 3b).  
We observed significant downregulation of surface IL-12 receptor (IL-12R2) 
expression on CD56dimCD57- cells 3 days after vaccination (Figure 5c), although 
we did not detect any significant vaccination-induced changes in IL-12R2 
expression in CD56bright or CD56dimCD57+ NK cells (Figure 5c). No changes in 
surface IL-18 receptor (IL-     5.   expression in any subset was observed 
(Supplementary Figure 3c). There was a small yet highly significant decline in the 
MFI of CD25 expression on both CD56bright and CD56dim NK cells post-vaccination 
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(Figure 5d). Taken together, these data show transient proliferation of less 
differentiated NK cells, and a small but significant downregulation of cytokine 
receptors (IL-12R2 and CD25) early after vaccination, consistent with vaccine 
induced responses to the cognate cytokines in vivo. 
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3.5 Discussion 
 
CIML NK cells have been described in a number of different in vitro models and 
after infection and vaccination (reviewed in (22) and (23)). Similarly to in vitro 
priming with cytokines, in vitro priming with inactivated H1N1 virus and TIV 
vaccination led to enhanced NK cell responses to cytokines alone (9), suggesting 
that anti-viral cytokine stimulation is sufficient to generate CIML NK cells. Here, 
in line with previous data, we demonstrate the generation of CIML NK cells by 
vaccination but furthermore, for the first time, we show that vaccination also 
primes for heightened secretion of myeloid cell-derived cytokines that can be 
induced by extremely low concentrations of IL-15 in vitro. Overall, our data 
suggest that influenza vaccination primes both myeloid cell cytokine secretion 
and intrinsic NK cell responsiveness, which together lead to the enhanced NK 
cell responses observed after influenza vaccination.  
These observations are in line with systems level analyses of the PBMC response 
to TIV influenza vaccination in which NK cell activation, type I IFN, serum IP-10 
(IFN- -induced protein) and DC activation signatures are seen within 48 hours 
(24, 25) and with innate cytokine secretion from PBMCs stimulated in vitro with 
inactivated influenza virus (16). Our study represents the first demonstration of 
enhanced myeloid cell-derived cytokine production after viral vaccination and is 
 U H P L Q L V F H Q W   R I   W K H   µtrained immunity ¶ described in human monocytes after 
Candida albicans infection or Bacille Calmette-Guérin (BCG) vaccination, where 
increased TNF-.    , / -     D Q G  IL-6 secretion occurred after secondary stimulation 
with the same or distinct stimuli (26, 27). Enhanced pro-inflammatory function in 
 µ trained  ¶ monocytes is associated with activation induced epigenetic modifications 
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(28, 29). Jegaskanda et al. recently reported that accessory cell IFN- .  L Q G X F H G  L Q 
response to influenza infection primed NK cells for enhanced responsiveness to 
antibody-dependent signals after a 12 hour rest period (without continued 
exposure). Consistent with our study, the authors measured increased Ki67 
expression on the pre-exposed NK cells (30). 
Although measurement of cytokines in supernatant after stimulation does not 
identify a specific cellular source, it is likely that the high levels of GM-CSF, IL-
10, IL-    D Q G  , ) 1 -. 2 measured here were derived from myeloid accessory cells, 
including monocytes, macrophages and DCs. As we have previously shown that 
IL-12 is induced in response to H3N2 in CD123-CD11c+ myeloid DCs (mDCs) 
(16), we suggest this cell subset may be responsible for the low but significant 
production of this cytokine. In contrast, IL-10 and TNF-.  are produced by CD14+ 
monocytes and IFN-.  and IFN-  D U H  S U R G X F H G  E \  F Rnventional and plasmacytoid 
DCs within hours of TIV vaccination (31, 32). This vaccine induced myeloid cell 
cytokine secretion enhancement may therefore demonstrate priming (or 
 µ W U D L Q L Q J ¶) of monocytes, or other innate myeloid cell populations in response to 
viral vaccination. 
Vaccine-induced enhanced cytokine secretion was revealed with low dose IL-15 
stimulation, without the need for vaccine antigen-specific stimulation. This same 
concentration of IL-15 also enhanced secretion of myeloid cell-derived cytokines, 
in particular IL-12 and IFN-.   L Q   F R P E L Q D W L R Q   Z L W K   +  1  ( 6). This suggests that 
pre-activation of these cells by the inactivated H3N2 virus within the vaccine 
leaves them with enhanced ability to respond to IL-15 and this effect is maintained 
for at least 30 days after initial stimulation. This enhanced cytokine secretion 
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capacity has a knock-on effect on NK cell activation, with significant upregulation 
of CD25 in post-vaccination cultures compared to baseline in response to IL-15. 
In contrast to our previous study, where vaccination promoted limited 
enhancement of NK cells in response to H1N1 virus alone (9), enhanced 
responsiveness of H3N2 vaccination-primed NK cells required IL-15.  This may 
be due to previous exposure to H3N2 by infection or vaccination leading to 
different levels of T cell help as suggested by comparing our previous study 
cohorts, lower overall induction of NK cell activation markers with H3N2 
compared to other influenza viruses (such as H1N1) (9) or differences in virus 
specific cytokine secretion profiles.  Production and trans-presentation of IL-15 is 
of particular significance in the lung during influenza infection, where local 
accumulation impacts T cell apoptosis, formation of IL-2-independent tissue 
resident memory T cells and recruitment of NK cells (33-36). Our previous study 
observed similar CIML NK cell generation with intranasal administration of live 
attenuated influenza vaccine (LAIV) (9), and thus the potential impacts of locally 
induced IL-15 in the lung after influenza vaccination or indeed infection merits 
further investigation. 
Frequencies of IFN-+ and IFN- +CD25+ NK cells were strongly correlated with 
IL-12 concentrations in cell supernatants, suggesting this cytokine is important 
for post-vaccination NK cell activation. Although, there was no evidence of 
enhanced secretion of IL-12(p70) after vaccination here (Figure 1), which may be 
due to immediate utilisation of secreted IL-12 in vitro. Similarly, we could not 
detect IL-2 in supernatants even though IL-2 (and IL-12) plays an essential role 
in NK cell responses to vaccination, supporting the suggestion that differential T 
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cell help is playing a role in the post-vaccination response to H3N2 (9, 17, 19). 
NK cells required both viral stimuli and IL-15 for enhanced polyfunctionality after 
vaccination, which is consistent with the need for combinations of two or more of 
IL-12, IL-15 and IL-18 in order to induce polyfunctionality in non-pre-activated and 
in vitro generated CIML NK cells, and IL-15 playing a major role in CIML NK cell 
mediated cytotoxicity (20). Vaccine induced changes in frequencies of 
polyfunctional NK cell cells ranged from 0.13% to 0.4%, representing up to 1/2500 
of total lymphocytes. Similar frequencies are observed for typical antigen specific 
T cell responses to whole antigens, indicating that the NK cell response could 
contribute meaningfully to vaccine induced immunity. 
CIML NK cells retain their characteristics through subsequent cell divisions, 
suggesting that their induction is not simply a short term priming effect but rather 
reflects an intrinsic change or differentiation state (37). Proliferation of less 
differentiated (CD56bright and CD56dimCD57-) NK cell subsets after vaccination is 
consistent with the previously demonstrated effects of vaccination on NK cells 
and with other routes for generation of CIML NK cells (5, 8, 9, 19). In addition, we 
measured significant down regulation of IL-12 receptor at day 3 after vaccination 
suggesting cytokine mediated NK cell activation in vivo; down-regulation of IL-
12R2 expression after vaccination would be consistent with IL-12-mediated 
receptor turnover, supporting a critical role for this cytokine in CIML NK cell 
generation. We previously measured weak but significant trends for NK cell 
function, in response to cytokine stimulation, to decline with age (38), however 
there was no significant tend for declining NK cell function or cytokine production 
post-vaccination in response to IL-15 +/- H3N2 with age. 
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In summary, we show for the first time that influenza vaccination primes PBMCs 
for heightened innate cytokine production, that this can be revealed by very low 
concentrations of IL-15, and that this - when combined with the generation of 
CIML NK cells - leads to enhanced NK cell responses after vaccination. Further 
work is required to determine the significance of this pathway in post-vaccination 
immunity to influenza virus. 
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3.7 Figures 
 
 
Figure 1: Influenza vaccination enhances IL-15 stimulated cytokine production.  
Baseline and 30 day post-vaccination samples of PBMC were cultured with medium (n=10), 
0.75ng/ml IL-15 alone (n=26), inactivated H3N2 (n=10) or H3N2 + IL-15 (n=26) for 18 hours and 
culture supernatants were collected. Concentrations (pg/ml) of GM-CSF (a), IL-10 (b), IL-       F ), 
IFN- . 2 (d), IL-12(p70) (e), TNF- .  (f), and IFN-   (g) in supernatant were determined by Luminex. 
Graphs show one dot per donor, with a bar representing median value. Comparisons between 
vaccination time points were made using Wilcoxon signed-rank test. *p < 0.05, **p < 0.01, *** p < 
0.001. 
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Figure 2: Enhanced NK cell responses to IL-15 post-vaccination. 
Baseline and 30 day post-vaccination PBMC samples from 2015-2016 TIV (n=37) or 2017-2018 
QIV (n=14) vaccinated individuals (all donors were combined for analysis), were stimulated in 
vitro with medium alone, IL-15 alone, H3N2 or H3N2 + IL-15. IFN-  , CD107a and CD25 
expression of CD56+CD3- NK cell activation was measured after 6 (IFN-      & ’     D    R U        K R X U V 
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(CD25) by flow cytometry. Plots show the gating strategy for IFN-       D     & ’     D    E    D Q G   & ’   
expression (c) from one representative donor at baseline. Numbers shown are the percentage of 
total NK cells positive for each marker. IFN-      G     & ’    D    H    L Q   U H V S R Q V H   W R   , / -15 and H3N2 + 
IL-15 and CD25 in response to all 4 conditions (f) is shown at baseline and 30 days post-
vaccination. IFN-      J    & ’     D   K   D Q G  & ’       L   L Q  U H V S R Q V H  to H3N2 + IL-15 attributed to NK cell 
differentiation subsets defined by CD56 and CD57 expression is also shown. Plots show one dot 
per donor with a bar representing median percentage. Comparisons between vaccination time 
points were made using Wilcoxon signed-rank test and between culture conditions by one-way 
 $ 1 2 9 $  Z L W K  ’ X Q Q ¶ V  F R U U H F W L R Q  I R U  P X O W L S O H  F R P S D U L V R Q V    S              S                   S                
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Figure 3: Vaccine induced 
enhancement of polyfunctional NK 
cell responses requires IL-15 co-
stimulation. 
Percentages of double positive IFN-

+CD25+ (a), CD107a+IFN-  + (b) and 
CD107a+CD25+ (c) NK cells at 
baseline and 30 days post-vaccination 
were determined by flow cytometry 
after 18 hour stimulation with medium 
alone, IL-15 alone, H3N2 or H3N2 + IL-
15 (n=51). Plots are one dot per donor 
with a bar representing median 
percentage. Comparisons between 
vaccination time points were made 
using Wilcoxon signed-rank test and 
between culture conditions by one-way 
 $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R Urection for 
multiple comparisons. *p < 0.05, ****p 
< 0.0001. 
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Figure 4: Post-vaccination NK cell responses are dependent on IL-12. 
Baseline and 30 day post-vaccination PBMC samples were stimulated in vitro with H3N2 + IL-15 
in the presence of an anti-IL-12 antibody for 18 hours, (a) percentage of IFN-  + and CD25+IFN-  + 
double positive NK cells were determined by flow cytometry (n=51). Graphs show median 
percentage with 95% confidence interval. The relationship between IFN-  + and CD25+IFN-  + 
double positive NK cells and IL-12(p70) production in response to H3N2 + IL-15 (no IL-12 
blocking) at 18 hours both before (b) and after (c) vaccination was determined by linear 
regression, goodness of fit was determined using r2 and significance was determined as p < 0.05. 
Comparisons between culture conditions and vaccination time points were made using Wilcoxon 
signed-rank test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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Figure 5: Altered ex vivo 
NK cell phenotype and 
cytokine receptor 
expression early after TIV 
vaccination. 
NK cell phenotype was 
measured ex vivo after 
2015-2016 TIV vaccination 
(n=37) at baseline, day 3, 
day 7 and day 30 post-
vaccination. Percentage of 
CD56bright and CD56dim NK 
cells (a), Ki67 (b), IL-12R  2 
(c) and CD25 MFI (d) were 
determined and attributed to 
NK cell differentiation 
subsets defined by CD56 
and CD57 expression. Graphs show box and whisker plots with 10th-90th percentile, comparison across vaccination visits was determined by one-way ANOVA 
 Z L W K  ’ X Q Q ¶ V  F R U U H F W L R Q  I R U  P X O W L S O H  F R P S D U L V R Q V     S               S                S                    S              
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3.8 Supplementary Figures 
 
 
Supplementary Figure 1: Post-vaccination NK cell responses to H3N2 alone or a high 
concentration of cytokines. 
Baseline and 30 day post-vaccination PBMC samples were stimulated in vitro with medium alone, 
H3N2 alone or a high concentration of IL-12 and IL-18 (HCC). IFN-      & ’     D   D Q G   & ’    
expression of CD56+CD3- NK cells was measured after 18 hours by flow cytometry. IFN-      D   D Q G 
CD107a expression (b) in response to medium and H3N2 alone is shown as one dot per donor 
with a bar at the median percentage. IFN-       F     & ’      D    G    D Q G   , ) 1 -  +CD25+ expression (e) in 
response to HCC is also shown with a line representing the median and interquartile range. 
Comparisons were made using Wilcoxon signed-rank test. *p < 0.05, ***p < 0.001, ****p < 0.0001.  
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Supplementary Figure 2: Antibody-dependent NK cell responses post-vaccination. 
Antibody level in baseline (0) and 30 day post-vaccination (30) plasma samples of participants 
vaccinated with TIV (n=37) and QIV (n=14) measured by ELISA (a). NK cell CD107a and IFN-     
expression in response to pre or post-vaccination plasma and plate bound inactivated H3N2 virus 
was measured in one non-vaccinated control donor (b). The correlation between antibody level 
and NK cell CD107a and IFN-     H [ S U H V V L R Q   D W        G D \ V   S R V W-vaccination (c). Comparisons were 
made using one-  Z D \   $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R U U H F W L R Q   I R U   P X O W L S O H   F R P S Drisons. *p < 0.05, **p < 
0.01, ****p < 0.0001. Correlation was determined by linear regression, goodness of fit was 
determined using r2 and significance was determined as p value below 0.05. AEU; arbitrary ELISA 
units.   
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Supplementary Figure 3: Ex vivo flow cytometry gating strategy. 
NK cell phenotype was measured ex vivo after 2015-2016 TIV vaccination (n=37) at baseline, 
day 3, day 7 and day 30 post-vaccination by flow cytometry. The flow cytometry gating strategy 
for CD56, live NK cells, Ki67, IL-12R2, CD25 and IL-18R .  expression from one representative 
donor is shown (baseline and day 7 only) (a). Percentage of live CD56bright and CD56dim NK cells 
(viability dye negative) (b) and CD56bright and CD56dim IL-18R MFI (c) across vaccination visits 
is shown as box and whisker plots with 10th-90th percentile. Comparison were determined by 
one-  Z D \   $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R U U H F W L R Q   I R U   P X O W L S O H   F R P S D U L V R Q V     S                S                  S     
0.001, ****p < 0.0001. 
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4.1 Abstract 
 
NK cells are activated by innate cytokines and viral ligands to kill virus-infected 
cells; these functions are enhanced during secondary immune responses and 
after vaccination by synergy with effector T cells and virus-specific antibodies. In 
human Ebola virus infection, clinical outcome is strongly associated with the 
initial, innate cytokine response but the role of NK cells in this process has not 
been examined. The novel prime-boost Adenovirus type 26.ZEBOV/Modified 
Vaccinia Ankara-BN-Filo vaccine regimen is a safe and immunogenic Ebola 
glycoprotein expressing vaccine, currently undergoing phase 3 trials. In this 
study, we analysed the NK cell response to Ad26.ZEBOV/MVA-BN-Filo 
vaccination, including NK cell phenotype and function ex vivo and in response to 
recombinant Ebola glycoprotein, before and after vaccination. We show in vivo/ex 
vivo proliferation and activation of NK cells after vaccination. Ebola glycoprotein-
induced activation of NK cells in vitro was dependent on accessory cells and TLR-
4-dependent innate cytokine secretion (predominantly from primary CD14+ 
monocytes) and enriched within less differentiated NK cell subsets. Optimal NK 
cell responses were dependent on IL-18 and IL-12, whilst IFN-  secretion was 
restricted by high concentrations of IL-10. This study furthers our understanding 
of innate immune responses to soluble Ebola glycoprotein and the impact of 
vaccination.  
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4.2 Introduction 
 
Ebola virus infection causes a rapid onset, severe acute haemorrhagic fever 
(Ebola virus disease, EVD) with mortality ranging from 25% to 90% depending 
on the outbreak (1). The search for an effective vaccine remains a high priority 
as regular disease outbreaks continue on the African continent. Ebola vaccine 
development has focussed on the viral glycoprotein (GP) which is the only protein 
exposed on the surface of the mature virus particle, is essential for viral entry into 
host cells and is highly immunogenic (2, 3). A prime-boost vaccination approach, 
priming with Adenovirus type 26 (Ad26) expressing the Zaire Ebola virus GP 
(ZEBOV) and boosting with Modified Vaccinia Ankara (MVA) expressing ZEBOV, 
Sudan Ebola virus (SEBOV) and Marburg Virus GP and Tai Forest Ebola virus 
nucleoprotein (MVA-BN-Filo), has been shown to be safe and immunogenic in 
phase 1 clinical trials. Eliciting high and sustained antibody titres and antigen 
specific T cell responses, phase 2 and 3 clinical trials of Ad26.ZEBOV/MVA-BN-
Filo are underway (4-6). 
Innate immune dysregulation underlies the pathophysiology of EVD, resulting in 
failure to activate essential effector cell functions and consequent uncontrolled 
virus replication, systemic virus dissemination and inflammation (3, 7). Ebola 
virus infects macrophages and DCs, impairs maturation and inhibits the type I 
IFN response, due in part to the presence of interferon inhibiting domains (IIDs) 
within the viral proteins, VP24 and VP35. This, in turn, leads to impairment of NK 
cell function: in vitro studies with human peripheral blood mononuclear cells 
(PBMC) have shown that DC maturation, type I IFN secretion and NK cell 
activation are all enhanced when these Ebola virus IIDs are mutated (8, 9). 
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Impairment of the type I IFN response is accompanied by an excessive pro-
inflammatory cytokine response (3, 10). In vitro studies have shown that the 
Ebola GP is a potent ligand for TLR-4, activating non-infected monocytic cell 
lines, monocyte-derived DCs and macrophages to produce cytokines such as 
TNF-.    , / -       , / -10, IL-6, IFN-    D Q G  IL-12 (11-15). Importantly, an initial type I 
IFN response accompanied by modest and transient IL-    D Q G   7 1 ) -.   V H F U H W L R Q 
correlates with survival among EVD patients, whereas high IL-10 associated with 
fatal outcome (10, 16, 17). This indicates that the very earliest interactions 
between the Ebola virus and the host immune system are critical for determining 
the outcome of infection.   
There is evidence that, if they can be appropriately activated, NK cells may play 
a role in vaccine-induced protection from EVD. For example, murine infection with 
Ebola virus fails to induce an NK cell response, whereas treatment of mice with 
Ebola GP virus-like particles (VLPs) confers complete protection against a lethal 
Ebola virus infection just 3 days later; this protection was lacking after in vivo NK 
cell ablation (7). Furthermore, NK cell cytotoxicity and IFN-  V H F U H W L R Q  K D Y H  E H H Q 
implicated in the prolonged survival of NK cell-sufficient mice immunised with the 
VSV-vectored Ebola GP vaccine compared to NK cell-depleted mice (18). In 
humans, upregulation of the activation markers NKG2D and CD38 on NK cells 
was noted within 24 hours of vaccination with the rVSV-ZEBOV vaccine (19). 
When taken together with evidence from non-human primates of partial 
protection against live virus within 3 days of vaccination and full protection within 
7 days, this suggests that NK cells may be able to mediate rapid and effective 
protection against Ebola virus (20, 21). Moreover, after vaccination, NK cells may 
synergise with anti-GP antibodies to clear virus-infected cells via antibody-
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dependent cellular cytotoxicity (ADCC) (22, 23). The ability of an Ebola virus 
vaccine to ensure appropriate NK cell activation upon subsequent exposure to 
Ebola virus is thus likely to be an important component of vaccine efficacy. 
Here, we evaluate the effect of Ad26.ZEBOV/MVA-BN-Filo prime-boost 
vaccination on accessory cell cytokine secretion, NK cell phenotype and NK cell 
effector function both ex vivo and in response to restimulation in vitro with soluble 
Ebola virus GP (EbovGP). We find that vaccination with Ad26.ZEBOV/MVA-BN-
Filo induces in vivo (ex vivo) proliferation and activation of less differentiated NK 
cell subsets. We also find that stimulation of PBMCs (collected either before or 
after vaccination) with EbovGP induces TLR-4 dependent secretion of high 
concentrations of inflammatory cytokines (mainly from CD14+ monocytes) and 
accessory cell-dependent NK cell activation. EbovGP induced NK cell activation 
was inhibited by neutralising antibodies to IL-18 (and IL-12) and was enhanced 
by IL-10 receptor blockade. These studies demonstrate a major role for peripheral 
blood monocyte cytokine secretion in control of NK cell effector function in 
response to EbovGP in unvaccinated and vaccinated individuals.  
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4.3 Results 
 
4.3.1 Robust in vivo/ex vivo NK cell responses to Ad26.ZEBOV/MVA-BN-
Filo vaccination. 
 
Vaccination with several anti-viral vaccines, including influenza, has been shown 
to promote NK cell activation and a realignment of subsets associated with 
functional differentiation (24-26). We therefore analysed the effect of 
Ad26.ZEBOV/MVA-BN-Filo vaccination on NK cell activation and subset 
distribution. Ex vivo flow cytometric analysis of CD56+CD3- NK cells from pre-
vaccination (visit 0), post-prime (visit 1) and post-boost (visit 2) samples was 
performed. NK cells were divided into CD56bright, CD56dimCD57- and 
CD56dimCD57+ (or total CD56dim) subsets (CD56bright representing the least 
differentiated and CD56dimCD57+ the most differentiated subset). The expression 
of Ki67 (a cell cycle marker of proliferation), IL-   5. -chain (CD25) and NK cell 
receptors NKG2A and NKG2C was analysed for each subset (the flow cytometry 
gating strategies are shown in Supplementary Figure 1a). Initially, samples from 
all five vaccination groups were pooled for analysis.  
When data for all vaccination groups were combined, there was a significant 
increase in the representation of CD56bright NK cells within total NK cells and a 
corresponding decrease in the frequency of CD56dim NK cells across vaccination 
visits (Figure 1a). CD56bright NK cells had the highest intrinsic capacity to 
proliferate, reflected in the higher percentage expression of Ki67 in this subset 
(Figure 1b), followed by CD56dimCD57- cells. There was a significant increase in 
the frequency of CD56bright Ki67+ and CD56dimCD57- Ki67+ NK cells between visit 
1 and visit 2, suggesting that proliferation of less differentiated NK cells may 
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explain their increasing frequency (as in Figure 1a). There was no significant 
change in the proportion of more highly differentiated (CD56dimCD57+) NK cells 
expressing Ki67 (Figure 1b). 
Consistent with the expression of the inhibitory receptor NKG2A on less 
differentiated NK cell subsets, a significant increase in frequency of NK cells 
expressing NKG2A was observed at visit 2, with no significant change in 
expression of the corresponding activating receptor, NKG2C (Figure 1c). There 
was a small but significant increase post-boost in the percentage of CD56dim (but 
not CD56bright) NK cells expressing CD25 (median 0.74% at visit 1; 0.88% at visit 
2) (Figure 1d). The proportion of CD25+ NK cells was positively correlated with 
the frequency of proliferating (Ki67+) cells at 21 days post-boost, further 
suggesting an association between NK cell activation and proliferation in 
response to vaccination (Figure 1e). No effect of vaccination was observed on 
the percentage or mean fluorescence intensity (MFI) of NK cells expressing CD16 
  W K H  O R Z  D I I L Q L W \  , J *  U H F H S W R U  , , ,   ) F 5 , , ,    6 X S S O H P H Q W D U \  ) L J X U H    E    7 K H V H  G D W D 
indicate proliferation of less differentiated NK cells in response to 
Ad26.ZEBOV/MVA-BN-Filo vaccination. 
Overall, no significant changes in ex vivo NK cell phenotype and function were 
observed after the primary vaccination but significant NK cell proliferation and 
CD25 expression were observed after the secondary (boost) vaccination but with 
a diversity of responses among individuals. To investigate any effects of the order 
and/or timing of the priming and boosting vaccinations, NK cell responses were 
reanalysed by vaccination group. Increasing CD56bright and decreasing CD56dim 
NK cell frequencies after vaccination was indicated by a trend in all groups except 
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group 4 and reached significance by one-way ANOVA between baseline and 
post-boost in groups 3 and 5 only (Supplementary Figure 2a, b). Furthermore, 
there was a significant increase in CD56bright Ki67+ and CD56dim CD25+ NK cells 
between baseline and post-boost in group 4 only (Supplementary Figure 2c, d). 
These data suggest that the Ad26 prime/MVA boost vaccine regimen induced a 
more robust NK cell response than MVA prime/Ad26 boost. However, these 
effects were small and may lack statistical significance due to a lack of power in 
this subgroup analysis.  
 
4.3.2 NK cell CD107a and CD25, but not IFN -   X S U H J X O D W L R Q  L Q  U H V S R Q V H  W R 
EbovGP stimulation in vitro . 
 
To determine the effect of Ad26.ZEBOV/MVA-BN-Filo vaccination on NK cell 
responses to soluble EbovGP, baseline, visit 1 and visit 2 PBMCs were cultured 
 I R U      D Q G        K R X U V   Z L W K       J  P O   ( E R Y * 3    ) U H T X H Q F L H V   R I   1 .   F H O O V   H [ S U H V V L Q J 
CD107a and IFN-    D W     K R X U V    R U   & ’      D Q G  & ’       D W      K R X U V    Z H U H   D Q D O \ V H G 
by flow cytometry (gating strategies are shown in Figure 2a). There were no 
significant differences in response to EbovGP between vaccination groups (not 
shown); therefore, all five vaccination groups were combined for analysis. In vitro 
stimulation with EbovGP induced a significant increase in the proportion of NK 
cells expressing CD107a (Figure 2b) and CD25 (Figure 2c) at the cell surface 
compared to unstimulated cultures (medium alone). EbovGP stimulation had no 
effect on NK cell IFN-   D W    R U      K R X U V   R U  & ’     H [ S U H V V L R Q   ) L J X U H   G   H    7 K H 
effect of EbovGP on markers of NK cell function did not differ across vaccination 
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visits (Figure 2b-e) suggesting the effect of EbovGP on NK cells is entirely innate 
and unaffected by vaccination.   
Given that there was no effect of vaccination on the NK response to EbovGP, the 
analysis of NK cell function by differentiation subset was restricted to the baseline 
data set (Figure 3). This analysis revealed that IFN-   V H F U H W L R Q   Z D V   U H V W U L F W H G   W R 
the less differentiated CD56bright and CD56dimCD57- subsets and that significant 
induction of IFN-  E \  ( E R Y * 3  Z D V  G H W H F W H G  R Q O \  Z L W K L Q  W K H  & ’  dimCD57- subset 
(Figure 3a). By contrast, CD107a and CD25 upregulation in response to EbovGP 
was seen in all NK cell subsets (Figure 3b, c), with a significantly higher CD25 
expression in the CD56bright subset compared to CD56dim subsets (Figure 3c). 
The majority of CD25+ NK cell events were CD56dimCD57- (60.5%) (Figure 3d). 
Overall, these data demonstrate that EbovGP induces markers associated with 
NK cell cytotoxicity (CD107a) and activation (CD25), with a much lesser impact 
on IFN-   V H F U H W L R Q    D Q G   W K D W   W K H V H   U H V S R Q V H V   V H H P   W R   E H   L Q Q D W H   D Q G   Q R W 
enhanced by vaccination.    
 
4.3.3 High concentrations of inflammatory cytokines induced by EbovGP 
in vitro. 
 
NK cells are able to respond to cytokines secreted from activated accessory cells 
in response to viral stimuli. To quantify cytokine production in response to 
EbovGP stimulation, baseline and 21-day post-boost vaccination PBMC samples 
were stimulated with EbovGP in vitro for 18 hours and cytokine concentrations in 
cell supernatants were measured by Luminex. EbovGP induced secretion of high 
concentrations of IL-10, IL-       , ) 1 -.     * 0 -CSF, TNF-.   D Q G   , ) 1 -   I U R P   3 % 0 & V 
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at baseline and post-boost samples compared to medium alone, where minimal 
concentrations were observed (Figure 4). Particularly high concentrations of IL-
10 (median 3151pg/ml at baseline), IL-      P H G L D Q         S J  P O   D W   E D V H O L Q H     * 0 -
CSF (median 461pg/ml at baseline) and TNF-.    P H G L D Q         S J  P O   D W   E D V H line) 
were measured in response to EbovGP (Figure 4a, b, d, e). IFN-.   V H F U H W L R Q  Z D V 
also significantly enhanced by EbovGP however the absolute concentrations of 
this cytokine were low (median 6.2pg/ml at baseline) compared to the other 
myeloid cell-derived cytokines (Figure 5c). Similarly, a low concentration of IL-
12(p70) (maximum 6.6pg/ml) was detectable by Luminex in only a small number 
of individuals (13 of 71 at baseline and 9 of 71 at post-boost; not shown). 
Conversely, there was no increase in IP-10 secretion over medium alone and IL-
15 was not detected (not shown). 
With the exception of a small but significant reduction in EbovGP-induced TNF-. 
concentration in cultures of post-boost PBMCs (4647pg/ml post-boost compared 
to 5542pg/ml at baseline) (Figure 4e), there was no effect of vaccination on 
cytokine concentrations. When vaccination groups were analysed separately, 
concentrations of GM-CSF in group 3, IFN-.   L Q  J U R X S    D Q G  , / -10 and TNF-.  L Q 
group 5 were significantly reduced at visit 2 compared to baseline (supplementary 
figure 3a, c, d, e) suggesting that reductions in cytokine responses were limited 
to the Ad26 prime/MVA boost regimen. In summary, EbovGP stimulated the 
release of high concentrations of IL-10, IL-      * 0 -CSF and TNF-.  I U R P  3 % 0 & V  
indicative of myeloid cell activation, with lower concentrations of IFN-.     , / -12 
and IFN-  G H W H F W H G  
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4.3.4 Myeloid accessory cell cytokine dependent NK cell activation. 
 
Vaccination independent activation of less differentiated, cytokine-responsive NK 
cell subsets accompanied by high levels of myeloid cell-derived cytokine 
secretion, led us to hypothesise that the NK cell response to EbovGP is a function 
of indirect NK cell activation. To test this hypothesis, we compared IFN-  
CD107a and CD25 expression among PBMCs and purified NK cells from healthy 
(non-vaccinated) control subjects (n=4) stimulated in vitro with EbovGP (Figure 
5a-c). Expression of CD107a, IFN-  D Q G  & ’     L Q  W K H  & ’   bright NK cell population 
(in which significant induction was measured) were determined by flow cytometry 
as before. IFN-    L Q     R I       G R Q R U V     & ’     D   L Q     R I       G R Q R U V    D Q G  & ’       L Q     R I 
4 donors) expression was markedly reduced in purified NK cells compared to 
PBMCs (Figure 5a-c) indicating that accessory cell-derived stimuli are required 
for optimal NK cell responses to EbovGP. 
To determine the precise nature of the accessory cell-dependent stimuli that drive 
NK cell responses to EbovGP, we stimulated whole PBMCs from (non-
vaccinated) control subjects with EbovGP in the presence of neutralising 
antibodies to IL-2, IL-12, IL-15, IL-18 and IFN-.  5      7 K H   E O R F N D G H   R I   , / -18 
significantly reduced the frequency and MFI of NK cell CD25 expression (Figure 
5d, e, Supplementary Figure 4a), with blockade of IL-12 also significantly 
reducing CD25 expression within the CD56bright NK cell subset (Figure 5f, g). 
CD107a expression was also impaired by IL-18 blockade, reflected in the 
CD56bright and CD56dimCD57- subsets (Figure 5h, Supplementary Figure 4a). 
There was no effect of IL-12 or IL-18 blockade on NK cell IFN-   H [ S U H V V L R Q 
(Figure 5i, Supplementary Figure 4a). Conversely, neutralisation of IL-2 or IL-15, 
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or IFN-.  5    E O R F N D G H    K D G   Q R   V L J Q L I L F D Q W   H I I H F W   R Q   1 .   F H O O   D F W L Y D W L R Q in any NK 
cell subset (not shown). In summary, these data suggest optimal NK cell CD25 
and CD107a expression in response to EbovGP stimulation is dependent on 
myeloid cell-derived IL-18 and IL-12. 
As both IL-12 and IL-18 were not amenable to detection by Luminex assay of cell 
culture supernatants, we next sought to measure these responses to EbovGP 
using high sensitivity ELISA for secreted IL-18 and flow cytometry for intracellular 
IL-12 (gating strategy shown in Supplementary Figure 5a). There was a 
significant increase in IL-18 measured in supernatant after 18 hours stimulation 
with EbovGP (median 47.6pg/ml, range 16.8-183.5pg/ml) (Figure 5j), which 
correlated significantly with increasing NK cell CD25 expression (Figure 5k). We 
were able to detect IL-12(p40)+ cells by flow cytometry with significantly higher 
frequencies of IL-12(p40)+ cells in CD14-CD11c+ myeloid DCs (mDC), total CD14- 
cells and CD14+ monocytes compared to medium alone, and the highest 
frequencies being observed in mDC (median 0.19%) and monocyte (median 
0.22%) populations (Figure 5l). 
 
4.3.5 Regulation of NK cell IFN -   S U R G X F W L R Q  E \   ( E R Y * 3  L Q G X F H G  , /-10. 
 
IL-10 is an essential immunoregulatory cytokine that is typically upregulated in 
response to inflammation (27). Having detected very high concentrations of IL-10 
in supernatants of EbovGP-stimulated PBMCs (Figure 4a) we explored the 
relationship between IL-10 production and NK cell function. NK cell IFN- 
expression significantly negatively correlated with IL-10 secretion in 18 hour 
cultures in both baseline (r=-0.331, p=0.0218) (Figure 6a) and 21 days post-boost 
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PBMC (r=-0.324, p=0.0157; not shown) suggesting that IL-10 induced by 
EbovGP might restrict the NK cell IFN-   U H V S R Q V H    7 K H U H I R U H    3 % 0 &   I U R P    Q R Q-
vaccinated) control subjects were cultured for 18 hours with EbovGP in the 
presence of a blocking monoclonal antibody to the IL-10 receptor (IL-10R) or the 
appropriate isotype control antibody. IL-10R blockade resulted in significantly 
higher frequencies of IFN- + (Figure 6b) and CD25+ (Figure 6c) NK cells (and a 
significant increase in CD25 MFI; median 349.5 with IL-10R blockade; 110.5 with 
isotype control; p=0.0002; not shown) compared to isotype control treated 
cultures. CD107a was significantly enhanced by IL-10R blockade in the 
CD56dimCD57+ NK cell subset only (Supplementary Figure 4b), and IL-10R 
blockade particularly enhanced IFN-  U H V S R Q V H V  L Q  & ’   bright and CD56dimCD57- 
NK cell populations (Supplementary Figure 4b). 
To determine the cellular source of the cytokines induced by EbovGP, PBMC 
were cultured with EbovGP for 18 hours, stained for intracellular IL-10, GM-CSF 
and TNF-.   D Q G   D Q D O \ V H G   E \   I O R Z   F \ W R P H W U \     J D W L Q J   V W U D W H J \   V K R Z Q   L Q 
Supplementary Figure 5a). IL-10 was expressed predominantly in CD14+ 
monocytes (median 6.0%) with little or no evidence of expression in B cells, 
mDCs, CD14-, NK cells or T cells (Figure 6e). Back-gating confirmed that the 
majority of IL-10+ cells were CD19-CD14+ monocytes (Figure 6f). GM-CSF 
expression was also essentially restricted to monocytes whereas mDCs and 
monocytes produced similar amounts of TNF-.   6 X S S O H P H Q W D U \  ) L J X U H    E   F    , Q 
summary, monocytes are the predominant source of inflammatory cytokines in 
response to EbovGP in primary peripheral blood and monocyte-derived IL-10 
negatively regulates NK cell IFN-   V H F U H W L R Q   D Q G   & ’      H [ S U H V V L R Q    7 K L V 
CHAPTER 4. EBOLA GP INDUCED NK CELL RESPONSES   
213 
 
immediate, robust IL-10 response helps to explain the lack of IFN-   H [ S U H V V L R Q 
by NK cells in response to EbovGP both before and after vaccination (Figure 2). 
 
4.3.6 EbovGP-induced NK cell activation is TLR-4 dependent. 
 
EbovGP stimulates cytokine secretion in human monocytic cell lines and in vitro 
generated monocyte-derived DCs and macrophages in a TLR-4-dependent 
fashion (11, 13-15). TLR-4 is expressed at high levels on human peripheral blood 
monocytes, as well as other myeloid lineage cells including macrophages and 
granulocytes (28). We therefore assessed the effect of blocking TLR-4 on 
cytokine secretion (measured by Luminex) and NK cell activation (by flow 
cytometry) in response to EbovGP within PBMC from (non-vaccinated) control 
subjects. TLR-4 blockade significantly reduced secretion of IL-10 (0.3 fold-
reduction; 7 of 7 donors) (Figure 7a), IL-      * 0 -CSF and IFN-  E X W  K D G  Q R  R Y H U D O O 
effect on IFN-.    R U   7 1 ) -.   V H F U H W L R Q    ) L J X U H    E     3 D U D O O H O   H I I H F W V   Z H U H   R E V H U Y H G 
among NK cells where there was a partial, but significant, decrease in 
frequencies of IFN- + (median 49.6% decrease frequency) and CD25+ (median 
14.6% decrease frequency) CD56bright NK cells in the presence of TLR-4 blocking 
antibodies (Figure 7c, d). Overall, these data indicate that NK cell activation by 
EbovGP is mediated, at least in part, via ligation of TLR-4 on primary human 
monocytes and the induction of accessory cytokines.  
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4.4 Discussion 
 
In the 2014-2015 Ebola virus outbreak in West Africa, almost 30,000 cases of 
EVD were reported with more than 11,000 deaths (29). In 2019, Ebola virus 
continues to be a considerable global health concern, with outbreaks currently in 
the Democratic Republic of the Congo. Detailed understanding of the immune 
response to Ebola virus infection, efficacy and mechanisms of protection induced 
by Ebola virus vaccines would greatly assist in efforts of prevention and 
containment of future outbreaks. We analysed the effect of the prime-boost 
regimen Ad26.ZEBOV/MVA-BN-Filo vaccine on human NK cell phenotype ex 
vivo and primary human innate cell function in response to soluble Ebola GP in 
vitro. We demonstrate NK cell activation, proliferation and expansion of less 
differentiated NK cells up to 21 days after boost vaccination. We have found that 
CD14+ monocytes are key responders to Ebola virus GP, rapidly producing a 
range of inflammatory cytokines in a TLR-4-dependent manner. This led to NK 
cell activation (CD25 expression) and function (degranulation); dependent on 
myeloid cell-derived IL-12 and IL-18. However, this potentially crucial, rapid NK 
cell effector response is almost completely abrogated by the very high levels of 
IL-10 that are secreted as part of the acute myeloid cell response to EbovGP.  
Activation and proliferation of NK cells after vaccination has been demonstrated 
with both inactivated and live attenuated vaccines. Jost et al. demonstrated 
upregulation of CD69 and CD25 and increased numbers of CD56bright NK cells at 
day 4 post-influenza vaccination (25) and Marquardt et al. observed heightened 
NK cell Ki67 expression (peaking at day 10) after yellow fever vaccination (26). 
We have previously reported increased percentages and proliferation of 
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CD56bright NK cells at day 3 and up to 4 weeks after influenza vaccination ((24) 
and unpublished data  – Chapter 3 of this thesis). Here, we detected heightened 
CD56bright NK cell proliferation up to 78 days after primary vaccination (21 days 
post-boost) and an increase in the proportion of CD56bright NK cells from as early 
as day 15 post-primary vaccination until at least 21-days post booster 
vaccination. Further, increased expression of CD25 by NK cells post-vaccination 
may indicate the potential for T cell derived IL-2 to contribute to NK cell 
proliferation and activation (24, 30, 31). Of potential relevance for future 
development of this vaccine, these responses were more robust after Ad26 
prime/MVA boost than after MVA prime/Ad26 boost. This work demonstrates - 
for the first time - activation of cytokine-responsive NK cells by a vectored, Ebola 
GP-expressing vaccine without the need for additional pathogen receptor-
mediated stimulation by adjuvant or the whole organism, although these 
experiments cannot exclude effects of the viral vectors. 
The pathogenesis of EVD is closely linked to the very high levels of pro-
inflammatory cytokines induced by the infection (10, 16, 17). We show for the first 
time within primary human PBMC cultures, that Ebola GP stimulated the 
secretion of high levels of IL-       * 0 -CSF and TNF-.    E R W K   E H I R U H   D Q G   D I W H U 
vaccination. This inflammatory response was accompanied by an equally rapid 
and potent IL-10 response and somewhat lower levels of IL-12, IL-18 and IFN-
.     7 K H V H   G D W D  - in a highly relevant ex vivo system  – corroborate previous 
observations from human cell lines and in vitro generated monocyte-derived DCs 
and macrophages (8, 11-13). The relatively low levels of important NK cell and T 
cell-activating cytokines together with the abundance of IL-10 suggest the 
generation of a tightly regulated cytokine environment within hours of exposure 
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to soluble EbovGP in vitro. Rapid production of IL-10 in response to a potent pro-
inflammatory stimulus is a well-described feature of the human homeostatic 
response; in preventing a life-threatening cytokine storm, this can also influence 
the emerging adaptive response (27). Indeed, pro and anti-inflammatory 
cytokines both indirectly correlate with survival after EVD indicating that IL-10 
itself, although associated with anti-inflammatory properties does not predict 
protection from disease (10). 
CD14+ monocytes were the main source of both inflammatory (GM-CSF, TNF-. 
and IL-12) and anti-inflammatory (IL-10) cytokines within hours of EbovGP 
stimulation. Both types of monocyte response and the downstream NK cell 
response were TLR-4-dependent confirming prior studies that the Ebola virus GP 
is recognised by TLR-4 on the surface of monocytes, inducing inflammatory 
cytokine secretion (11, 13, 15, 32). Interestingly, cytokine responses to EbovGP 
were lower in cells collected after Ad26 prime/MVA boost vaccination regimen 
than in baseline (pre-vaccination) cells. We wondered whether this might be due 
to neutralisation of EbovGP by vaccine-induced anti-GP antibodies, but cytokine 
responses did not differ significantly in control cultures in the presence of pooled 
pre or post-boost vaccination serum (data not shown) suggesting that vaccine 
induced antibody was not responsible for this difference. Moreover, the Ad26 
prime/MVA boost regimen induced lower anti-GP antibody titres 21 days post-
boost than did MVA prime/Ad26 boost, suggesting that monocyte cytokine 
responses are not related to antibody titre (4). This observation thus merits further 
investigation, perhaps indicating vaccine induced intrinsic control of Ebola GP-
induced inflammatory mediators. 
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EbovGP induces cytokine-dependent activation of peripheral blood NK cells in 
vitro, independent of prior Ad26.ZEBOV/MVA-BN-Filo vaccination. This innate 
response, which is particularly enriched in less differentiated NK cell subsets, is 
consistent with the proliferation and activation of the least differentiated, 
CD56bright NK cells after vaccination itself (measured ex vivo). This suggests that, 
as seen in vitro, Ebola GP within the vaccine potentially stimulates innate, 
cytokine-dependent NK cell activation in vivo.  Finally, in vitro, IL-18 and to a 
lesser extent, IL-12 from myeloid accessory cells were required for optimal NK 
cell degranulation and CD25 upregulation. This is the first demonstration of 
indirect, IL-18 and IL-12 dependent NK cell effector function in response to Ebola 
virus GP in human PBMC. 
It is well established that enhanced NK cell responses after vaccination, are 
mediated in part by IL-2 from antigen-specific T cells and vaccine induced 
antibody (24, 26, 30, 33-35). Moreover, incubation of NK cells with antigen-
antibody complexes cross-links and downregulates CD16 on the surface of NK 
cells (34, 36). However, in this study, despite evidence of moderate induction of 
IL-2+IFN- +TNF-. + triple positive T cells and anti-GP antibodies by 
Ad26.ZEBOV/MVA-BN-Filo vaccination (4), there was no enhancement of the NK 
cell response, or downregulation of CD16 in response to EbovGP, post-
vaccination compared to baseline (that is in the presence of 1% immune sera). 
This innate NK cell activation by EbovGP, combined with an apparent lack of 
enhancement of NK cell responses by the adaptive immune response, is in 
complete contrast to previous observations with yellow fever, BCG and influenza 
vaccination (24, 26, 35) and might plausibly be linked to the monocyte IL-10 
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response. In support of this hypothesis, a system-wide analysis of the immune 
response to the rVSV-ZEBOV Ebola vaccine suggested that vaccination-induced 
inflammatory monocytes negatively regulated the immune response (19). 
Additionally, IL-10 blockade can restore antigen-specific T cell-derived IL-2-
dependent activation of NK cells in other viral infection models (37, 38). NK  cell 
responses to Ebola GP, including IFN-  V H F U H W L R Q   Z H U H  D X J P H Q W H G  E \  O R Z  G R V H 
IL-15 co-stimulation (data not shown), previously shown to boost accessory cell 
IL-12 and IFN-.   V H F U H W L R Q   L Q   U H V S R Q V H   W R   L Q I O X H Q ] D   Y L U X V in vitro (39). This could 
suggest that boosting certain NK cell activating pro-inflammatory cytokines could 
override the effects of high concentrations of IL-10. 
In summary, for the first time, we have characterised the NK cell response to a 
novel Ebola virus GP-encoding, viral-vectored vaccine. We find that the robust 
TLR-4-dependent, monocyte-derived, innate cytokine response to Ebola GP both 
stimulates and moderates the NK cell effector response. This study contributes 
to the knowledge of Ebola vaccine induced immunity and the effect of Ebola GP 
on the innate immune system, aiding the continued development of novel Ebola 
vaccines.  
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4.5 Materials and Methods 
 
4.5.1 Study participants and samples 
 
Cryopreserved PBMCs (with corresponding serum samples) were obtained from 
participants enrolled in the EBL1001 single-centre, randomised, placebo-
controlled, observer blind trial conducted in Oxford, U.K. as described 
(ClinicalTrials.gov Identifier: NCT02313077) (4). Eligible, healthy adults (n=72), 
aged 18 to 50 years, were randomised into four groups, with a fifth group 
subsequently added by a protocol amendment, to receive the 
Ad26.ZEBOV/MVA-BN-Filo vaccine according to one of five vaccination 
schedules. The vaccine comprises monovalent Ad26.ZEBOV expressing the GP 
of the Ebola Zaire virus (Mayinga variant) (Crucell Holland N.V. (now Janssen 
Vaccines & Prevention B.V.), The Netherlands) and multivalent MVA-BN-Filo 
expressing the GP of the Sudan and Zaire Ebola viruses and Marburg virus 
together with Tai Forest virus nucleoprotein (Bavarian Nordic, Denmark). Groups 
1 and 2 received MVA-BN-Filo as prime on day 1 and Ad26.ZEBOV as boost on 
either day 29 or 57 respectively; groups 3, 4 and 5 received Ad26.ZEBOV as 
prime and MVA-BN-Filo as boost on days 29, 57 or 15 respectively.  
Samples were collected immediately prior to primary vaccination (baseline, visit 
0), post-prime (day 29, 57 or 15 depending on group; visit 1) and 21 days post-
boost (day 50, 78 or 36 depending on group; visit 2) (Table 1). HCMV serology 
was conducted on the baseline serum sample of each donor by HCMV IgG ELISA 
(BioKit, Barcelona, Spain): 26 of 72 volunteers (36%) were HCMV seropositive, 
44 were HCMV seronegative and two were indeterminate. Additional non-
vaccinated, healthy, adult volunteers (n=16) were recruited for subsequent in vitro 
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experiments from among staff and students at the London School of Hygiene and 
Tropical Medicine (LSHTM) using an anonymised volunteer database.  
 
  PBMC samples received for this study 
 Vaccine 
schedule 
Baseline 
(Visit 0) 
Post-prime 
(Visit 1) 
21d post-
boost 
(Visit 2) 
Group 1 (n=15) MVA-Ad26 Day 1 Day 29 Day 50 
Group 2 (n=15) MVA-Ad26 Day 1 Day 57 Day 78 
Group 3 (n=14) Ad26-MVA Day 1 Day 29 Day 50 
Group 4 (n=14) Ad26-MVA Day 1 Day 57 Day 78 
Group 5 (n=14) Ad26-MVA Day 1 Day 15 Day 36 
Table 1: Vaccination regimen and PBMC samples used in this study. 
MVA, MVA-BN-Filo; Ad26, Ad26.ZEBOV. 
 
4.5.2 In vitro cellular assays 
 
Cryopreserved PBMCs were thawed, washed in RPMI 1640 supplemented with 
100U/ml penicillin/streptomycin and 20mM L-glutamine (Gibco, ThermoFisher) 
and rested for 2 hours. Fresh PBMC were isolated from heparinised whole blood 
using Histopaque 1077 (Sigma-Aldrich, Gillingham, U.K.) gradient centrifugation. 
All cells were counted using Fastread counting slides (Immune Systems); the 
average cell yield after thaw was 5.8x106 per vial. Trial PBMC were stained 
immediately ex vivo or cultured in 96-well round-bottom plates in RPMI 1640 
supplemented as above and with 1% autologous (visit 0, 1 or 2) serum and 
      J  P O   S X U L I L H G   U H F R P E L Q D Q W   ( E R O D   Y L U X V GP (EbovGP), Mayinga variant, 
prepared in Hek293F cells (Crucell Holland B.V.) for 8 and 18 hours at 37°C. 
CHAPTER 4. EBOLA GP INDUCED NK CELL RESPONSES   
221 
 
For additional 18 hour experiments, fresh PBMC from non-trial donors were 
 V W L P X O D W H G   Z L W K    g/ml EbovGP in RPMI supplemented as above and with 5% 
FCS. The following blocking antibodies or isotype control antibodies were used, 
 D O O   D W     J  P O    D Q W L-I -2 (Becton Dickinson (BD) Biosciences, Oxford, U.K.), anti-
IL-10R (Biolegend), rat IgG2a isotype control (eBiosciences, ThermoFisher), anti-
IL-12 (BD Biosciences), anti-IL-15 (eBiosciences), anti-IL-18 (MBL, U.S.A), 
mouse IgG1 isotype control (eBiosciences). Anti-IFN-.  5     0 H U F N   0 L O O L S R U H  
Watford, U.K.) and mouse IgG2a isotype control (eBiosciences) were used at a 
 I L Q D O   F R Q F H Q W U D W L R Q   R I      J  P O  In vitro blockade of TLR-4 was performed in the 
 S U H V H Q F H   R I     J  P O   D Q W L-TLR-4 rabbit polyclonal anti-sera or isotype matched 
control reagent with irrelevant specificity (Invivogen, UK).  
To determine accessory cell dependency, NK cells were purified using NK Cell 
Isolation Kits (Miltenyi Biotec, Germany) and magnetic bead separation (MACS). 
Purified NK cells were on average 92.8% pure and were cultured as above for 18 
hours in 5% FCS.  GolgiPlug (Brefeldin A; 1/1000 final concentration; BD 
Biosciences) and GolgiStop (Monensin; 1/1500 concentration; BD Biosciences) 
were added to all in vitro cultures for the final 3 hours of culture. Cells were then 
stained with fluorophore labelled antibodies for flow cytometry and culture 
supernatants were collected and stored at -80°C for cytokine analysis by 
Luminex/ELISA. 
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4.5.3 Flow cytometry 
 
Cells were stained for surface markers including a viability marker (Fixable 
Viability Stain 700; BD Biosciences) in FACS buffer (PBS, 0.5% FCS, 0.05% 
sodium azide and 2mM EDTA) for 30 minutes in 96-well round bottom plates after 
blocking Fc receptors for 5 minutes with Fc Receptor (FcR) Blocking Reagent 
(Miltenyi Biotec). Cells were then washed in FACS buffer, fixed and 
permeabilised using Cytofix/Cytoperm Kit (BD Biosciences) or 
Foxp3/Transcription Factor Fixation/Permeabilisation Kit (eBiosciences) 
 D F F R U G L Q J   W R   W K H   P D Q X I D F W X U H U ¶ V   L Q V W U X F W L R Q V    & H O O V   Z H U H   W K H Q   V W D L Q H G   I R U 
intracellular markers with FcR blocking for 20 minutes and washed again. Finally 
cells were resuspended in FACS buffer and analysed using a BD LSRII flow 
cytometer. Cells were acquired using FACSDiva software and data were 
analysed using FlowJo V10 (Tree Star, Oregon, U.S.A). FACS gates were set 
using unstimulated cells or FMO controls. Samples with less than 100 NK cell 
events were excluded from the analysis (<4% of samples evenly distributed 
across all groups). 
The following fluorophore labelled antibodies were used: anti-CD3-V500 (clone 
UCHT1) (BD Biosciences), anti-CD56-BV605 (clone HCD56), anti-IFN- -BV785 
(clone 4S.B3), anti-IFN- -APC (clone 4S.B3), anti-CD25-BV785 (clone BC96), 
anti-CD11c-BV785 (clone 3.9), anti-CD14-AF700 (clone 63D3), anti-GM-CSF-
PE-Dazzle (clone BVD2-21C11), anti-TNF-. -FITC (clone MAb11), anti-IL-10-PE 
(clone JES3-9D7) (all Biolegend, London, U.K.). Anti-CD16-APC (clone CB16), 
anti-CD25-PerCPCy5.5 (clone BC96), anti-CD57-e450 (clone TB01), Ki67-
PerCP-eFluor710 (clone 20Raj1), anti-CD19-PECy7 (clone HIB19), anti-IL-12-
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eFlour660 (clone C8.6) (all eBiosciences), anti-NKG2A-PE-Vio770 (clone 
REA110) (Miltenyi Biotec), anti-NKG2C-PE (clone 134591) (R&D systems). Anti-
CD107a-FITC (clone H4A3) (BD Biosciences) was added to the culture at 2  l per 
100 l for the whole culture period.  
4.5.4 Luminex and IL-18 ELISA  
 
Concentrations of GM-CSF, IFN-.    , ) 1 -   7 1 ) -.   , 3 -10, IL-     , / -10, IL-12p70, 
IL-15 in cell culture supernatants were determined by Luminex technology (Merck 
Millipore) using the xPONENT 4.1 software for data acquisition. The 
concentration of IL-18 was determined by ELISA (R&D Systems). 
4.5.5 Statistics 
 
Statistical analysis was performed using GraphPad Prism version 7.04 
(GraphPad, California, U.S.A.). Functional responses were compared using 
Wilcoxon signed-rank test or one- Z D \   $ 1 2 9 $   ) U L H G P D Q   W H V W   Z L W K   ’ X Q Q ¶ V 
correction for multiple comparisons and correlations were made using linear 
 U H J U H V V L R Q   R U   V S H D U P D Q ¶ V   F R U U H O D W L R Q   D Q D O \ V L V    6 L J Q L I L F D Q F H   O H Y H O V   D U H   D V V L J Q H G 
as *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 for all tests. 
4.5.6 Study approval 
 
Written informed consent was received from all participants prior to inclusion in 
the study. The trial protocol and study documents were approved by the National 
Research Ethics Service (reference number 14/SC/1408) and the LSHTM 
Research Ethics Committee (reference number 14383).  
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4.7 Figures
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Figure 1: Robust NK cell 
responses to Ad26.ZEBOV/MVA-
BN-Filo vaccination ex vivo/in 
vivo. 
NK cell phenotype at baseline (visit 
0), visit 1 (day 29, 57 or 15 post-
prime) and visit 2 (21 days post-
boost) was analysed ex vivo by flow 
cytometry (gating strategy is shown 
in Supplementary Figure 1), n=72. 
Frequencies of CD56bright and 
CD56dim (a), CD56bright Ki67+, 
CD56dimCD57- Ki67+ and 
CD56dimCD57+ Ki67+ (b), NKG2A+ 
and NKG2C+ (c), CD56bright CD25+ 
and CD56dim CD25+ NK cells (d) 
were determined. The relationship 
between total NK cell CD25 and Ki67 expression at 21 days post-boost (e) was als  R  G H W H U P L Q H G  E \  6 S H D U P D Q ¶ V  F R H I I L F L H Q W   * U D S K V  V K R Z  E R [  D Q G  Z K L V N H U  S O R W V 
with median, interquartile range (IQR) (box) and 10th-90th percentile (whiskers). Comparisons across vaccination visits were performed using one-way ANOVA 
 Z L W K  ’ X Q Q ¶ V  F R U U H F W L R Q  I R U multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 2: NK cell CD107a and CD25, but not IFN -    H [ S U H V V L R Q  X S U H J X O D W L R Q  L Q  U H V S R Q V H  W R 
EbovGP stimulation in  vitro . 
Whole PBMC from baseline (visit 0), visit 1 (day 29, 57 or 15 post-prime) and visit 2 (21 days 
post-boost) were stimulated with EbovGP or left unstimulated (medium) for 8 and 18 hours, n=72. 
Cells were stained for NK cell activation markers and analysed by flow cytometry. Frequencies of 
CD107a and IFN-      P H D V X U H G   D W       K R X U V   R U   & ’      D Q G   & ’     P H D V X U H G   D W       K R X U V   Z H U H   J D W H G 
using medium alone controls, plots shown from one representative donor (a). Graphs show NK 
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cell CD107a (b), IFN-       F    & ’       G    D nd CD16 (d) expression as one point per donor with a line 
representing the median. Comparisons across vaccination visits were performed using one-way 
 $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R U U H F W L R Q   I R U   P X O W L S O H   F R P S D U L V R Q V   D Q G   E H W Z H H Q   F R Q G L W L R Q V   E \   :  L O F R [ R Q 
signed-rank test. ****p < 0.0001. 
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Figure 3: Less differentiated NK cells respond strongly to EbovGP stimulation in vitro. 
NK cell IFN-       D    D Q G   & ’     D    E     P H D V X U H G   D W      K R X U V   D Q G   & ’       F     P H D V X U H G   D W       K R X U V   L Q 
response to medium alone and EbovGP in baseline (visit 0) samples only was analysed according 
to NK cell differentiation subset determined by CD56 and CD57 expression (CD56bright, 
CD56dimCD57-, CD56dimCD57intermediate (int) and CD56dimCD57+), n=72. The proportion of CD25+ 
NK cell events per subset determined by back-gating is also shown as a pie chart (d). Graphs 
show one point per donor with a line representing the median. Comparisons across NK cell 
subsets were performed using one-  Z D \   $ 1 2 9 $  Z L W K  ’ X Q Q ¶ V  F R U U H F W L R Q  I R U  P X O W L S O H  F R P S D Uisons 
and between conditions by Wilcoxon signed-rank test. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001. 
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Figure 4: High concentrations of inflammatory cytokines induced by EbovGP stimulation 
in vitro. 
Supernatants were collected from baseline (visit 0) and post-boost (visit 2) PBMC after 18 hours 
stimulation with EbovGP and concentrations of IL-10 (a), IL-      E    , ) 1 - .     F    * 0 -CSF (d), TNF-
.    H   D Q G  , ) 1 -      I   Z H U H  G H W H U P L Q H G  E \  / X P L Q H [   Q       * U D S K V  V K R Z  R Q H  S R L Q W  S H U  Gonor with the 
median and IQR. Comparisons were performed using one-  Z D \   $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R U U H F W L R Q 
for multiple comparisons. *p < 0.05, ***p < 0.001, ****p < 0.0001. 
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Figure 5: Myeloid accessory cell cytokine-dependent NK cell activation.  
Non-vaccinated control PBMC or purified NK cells were stimulated with EbovGP or left 
unstimulated (medium). PBMC were also left unstimulated or stimulated with EbovGP in the 
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presence of blocking antibodies against IL-12 and IL-18 or appropriate isotype control (Iso.), NK 
cell function was analysed by flow cytometry, n=16. Graphs show CD56bright IFN-      & ’     D   D Q G 
CD25 expression (a-c), total NK cell CD25 percentage or MFI (d, e) or CD56bright CD25 percentage 
or MFI (f, g) and total NK cell CD107a and IFN-     H [ S U H V V L R Q    K    L     , / -18 in culture supernatant 
and intracellular IL-12 of unstimulated and EbovGP stimulated PBMC were determined by ELISA 
and flow cytometry respectively, the relationship between IL-18 and total NK cell CD25 expression 
was de W H U P L Q H G   E \   6 S H D U P D Q ¶ V   F R H I I L F L H Q W    M-l). IL-12(p40)+ B cells (CD19+), myeloid DC (mDC; 
CD19-CD14-CD11c+), total CD14- and total CD14+ cells were gated as per gating strategy in 
Supplementary Figure 5a. Graphs show box and whisker plots with median, IQR (box) and 10 th-
90th percentile (whiskers) or one point per donor. Comparisons were performed using Wilcoxon 
signed-rank test and correla  W L R Q V  Z H U H  G H W H U P L Q H G  X V L Q J  6 S H D U P D Q ¶ V  F R U U H O D W L R Q    S    .05, **p < 
0.01, ***p < 0.001, ****p < 0.0001. 
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Figure 6: Regulation of NK cell IFN -    S U R G X F W L R Q  E \  ( E R Y * 3  L Q G X F H G  , /-10. 
The correlation between NK cell IFN-     V H F U H W L R Q determined by intracellular staining and IL-10 
secretion measured by Luminex in response to EbovGP (in baseline trial samples) was 
 G H W H U P L Q H G   E \   6 S H D U P D Q ¶ V   F R H I I L F L H Q W    Q          D     1 R Q-vaccinated control PBMC were stimulated 
in the presence of blocking antibodies against IL-10R or isotype control, n=16 (b-f). Total NK cell 
IFN-       E     & ’     D    F    D Q G   & ’        G    H [ S U H V V L R Q   Z D V   G H W H U P L Q H G    , Q W U D F H O O X O D U   , / -10 was also 
measured by flow cytometry (gating strategy as per Supplementary Figure 5a) in B cells (CD19+), 
myeloid DC (mDC; CD19-CD14-CD11c+), total CD14- and total CD14+ cells, NK cells (CD3-CD56+) 
and T cells (CD3+) (e). The proportion of IL-10+ events per cell type determined by back-gating is 
also shown as a pie chart (f). Graphs show box and whisker plots with median, IQR (box) and 
10th-90th percentile (whiskers). Comparisons were performed using Wilcoxon signed-rank test. *p 
< 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. 
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Figure 7: EbovGP induced NK cell activation is dependent on interaction with TLR-4. 
Non-vaccinated control PBMC were stimulated in the presence of blocking antibodies against 
TLR-4 or isotype control, n=16. Supernatants were collected and concentrations of IL-10, IL-      
GM-CSF, IFN-      , ) 1 - .     D Q G   7 1 ) - .  were measured by Luminex. Graphs show IL-10 
concentration as one dot per donor (showing 7 of 16 with values below ELISA cut-off value of 
10,000pg/ml) (a) and IL-       * 0 -CSF, IFN-      , ) 1 - .    D Q G  7 1 ) - .   D V  I R O G  F K D Q J H   E H W Z H H Q  L V R W \ S H 
control and TLR-4 blockade (b). Expression of CD56bright NK cell IFN-       F    & ’        G    Z H U H 
determined after 18 hours by flow cytometry. Graphs show median with IQR or box and whisker 
plots with median, IQR (box) and 10th-90th percentile (whiskers). Comparisons between conditions 
were performed using Wilcoxon signed-rank test. *p < 0.05, ***p < 0.001, ****p < 0.0001. 
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4.8 Supplementary Figures 
 
 
 
Supplementary Figure 1: Flow cytometric gating strategy for ex vivo NK cell phenotype 
analysis. 
Plots demonstrate strategy for NK cell subset, NKG2A, NKG2C, Ki67, CD25 and CD16 gating in 
one representative donor (a). NK cell CD16 expression (percentage and MFI) at baseline (visit 
0), visit 1 (day 29, 57 or 15 post-prime) and visit 2 (21 days post-boost) after vaccination with 
Ad26.ZEBOV/MVA-BN-Filo was analysed (b). Graphs show box and whisker plots with median, 
interquartile range (box) and 10th-90th percentile (whiskers). Comparisons across vaccination 
visits were performed using one-way ANOVA with  ’ X Q Q ¶ V  F R U U H F W L R Q  I R U  P X O W L S O H  F R P S D U L V R Q V   
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Supplementary Figure 2: NK cell 
phenotype ex vivo according to 
vaccination regimen group. 
NK cell phenotype at baseline (visit 
0), visit 1 (day 29, 57 or 15 post-
prime) and visit 2 (21 days post-
boost) after vaccination with 
Ad26.ZEBOV/MVA-BN-Filo was 
analysed ex vivo by flow cytometry. 
Data was analysed according to 
vaccine regimen group (1-5) as 
indicated, n=15 (groups 1-2), n=14 (groups 3-5). Frequencies of CD56bright (a), CD56dim (b), CD56bright Ki67+ (c) and CD56dim CD25+ (d) NK cells were determined. 
Graphs show one point per donor with a line representing the median. Comparisons across vaccination visits were performed using one-way ANOVA with 
 ’ X Q Q ¶ V  F R U U H F W L R Q  I R U  P X O W L S O H  F R P S D U L V R Q V     S   0.05, **p < 0.01.
Group 1: MVA-Ad; boost d29 
Group 2: MVA-Ad; boost d57 
Group 3: Ad-MVA; boost d29 
Group 4: Ad-MVA; boost d57 
Group 5: Ad-MVA; boost d15 
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Supplementary Figure 3: 
Cytokine concentrations 
according to vaccination regimen 
group. 
Supernatants were collected from 
baseline (visit 0) and post-boost 
(visit 2) PBMC after 18 hours 
stimulation with EbovGP in vitro and 
concentrations of IL-10 (a), IL-1    b), 
IFN- .     c), GM-CSF (d), TNF- .    e) 
and IFN-      f) were determined by Luminex. Data was analysed according to vaccine regimen group (1-5) as indicated, n=15 (groups 1-2), n=14 (groups 3-5). 
Graphs show one point per donor with a line representing the median. Comparisons were performed using Wilcoxon signed-rank test. *p < 0.05.
Group 1: MVA-Ad; boost d29 
Group 2: MVA-Ad; boost d57 
Group 3: Ad-MVA; boost d29 
Group 4: Ad-MVA; boost d57 
Group 5: Ad-MVA; boost d15 
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Supplementary Figure 4: NK 
cell function in response to 
EbovGP and blocking 
antibodies according to NK cell 
subset. 
Non-vaccinated control PBMC 
were stimulated with EbovGP in 
the presence of blocking 
antibodies against IL-12, IL-18 
and IL-10R or appropriate isotype 
control, n=16. CD56bright, 
CD56dimCD57- and CD56dimCD57+ 
NK cell CD107a, IFN-     D Q G   & ’     
expression was determined by 
flow cytometry. Graphs show box 
and whisker plots with median, 
interquartile range (box) and 10th-
90th percentile (whiskers). 
Comparisons between conditions 
were performed using Wilcoxon 
signed-rank test. *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001. 
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Supplementary Figure 5: Intracellular cytokine staining gating strategy and GM -CSF and 
TNF- .  H [ S U H V V L R Q  
Intracellular IL-12, IL-10, GM-CSF and TNF- .  expression in response to EbovGP stimulation of 
non-vaccinated control PBMC was measured in B cells (CD19+), myeloid DC (mDC; CD19-CD14-
CD11c+), total CD14- and total CD14+ cells, NK cells (CD3-CD56+) and T cells (CD3+). Plots show 
gating strategy from one representative donor, and gates for intracellular cytokines in CD14+ 
monocytes. Graphs show box and whisker plots with median, interquartile range (box) and 10th-
90th percentile (whiskers). Comparisons were made between unstimulated and stimulated, using 
Wilcoxon signed-rank test. *p < 0.05, **p < 0.01, ****p < 0.0001. 
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5.1 Abstract 
 
Antibody Fc-mediated functions such as antibody-dependent cellular cytotoxicity 
contribute to vaccine-induced protection against viral infections. Weak 
neutralisation but strong Fc-mediated function of anti-Ebola glycoprotein 
antibodies suggest that Fc-dependent activation of effector cells, including NK 
cells, may be important for vaccine induced protection against Ebola virus 
infection. We analysed the impact of anti-Ebola glycoprotein antibody in the 
serum of U.K. based volunteers vaccinated with the novel prime-boost 
Adenovirus type 26.ZEBOV/Modified Vaccinia Ankara-BN-Filo vaccine regimen 
on primary human NK cell activation. We demonstrate induction of CD107a and 
IFN-  expression, with reciprocal downregulation of CD16, in more differentiated 
NK cell subsets in response to in vitro stimulation with Ebola glycoprotein and 
post-prime/post-boost vaccination serum. These responses varied significantly 
with vaccine regimen and, using a uniform responder cell preparation, NK cell 
activation was found to be strongly correlated with anti-glycoprotein antibody titre, 
suggesting at least partial dependence on antibody titre for optimal NK cell 
activation. Stimulation of NK cells from multiple donors with a standardised 
antigen/immune serum cocktail, revealed the impact of NK cell differentiation 
phenotype on antibody-dependent NK cell activation, with highly differentiated 
NKG2C+CD57+ NK cells being the most responsive. This study thus highlights 
the dual importance of vaccine-induced antibody titre and NK cell differentiation 
status in promoting Fc-mediated activation of NK cells after vaccination. Antibody 
mediated NK cell activation may be a useful readout for evaluating vaccine 
efficacy in different populations.  
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5.2 Introduction 
 
Determining correlates of protection for Ebola vaccines has proved difficult and 
ambiguous (1). Some anti-Ebola antibodies possess strong neutralising capacity 
(2, 3), however, antibodies with limited neutralising activity were protective in 
animal models and human in vitro culture systems suggesting that neutralisation 
alone presents an incomplete mechanistic picture of in vivo protection (3-5). In 
humans, Ebola specific antibodies induce antibody-dependent cellular 
cytotoxicity (ADCC) in peripheral blood NK cells and NK cell lines in vitro; in light 
of this, Fc-mediated function in anti-Ebola monoclonal antibody (mAb) therapy 
and vaccine induced protection is gaining in interest (5-7). Analysis of the primary 
response to the candidate Ebola vaccine, rVSV-ZEBOV, has revealed a 
correlation between early NK cell activation and anti-Ebola antibody titre in 
humans (8). Also, protection of non-human primates against Ebola virus 
challenge is associated with a low IgG2:IgG1 antibody isotype ratio, compatible 
with ADCC as a major mechanism of protection (9). In mice, experimental Ebola 
(or related filovirus) vaccines demonstrate induction of anti-glycoprotein (GP) 
antibodies with weak neutralising activity and robust ADCC function that was 
critical for protection (10-12). Taken together, these studies suggest Fc functions 
of anti-Ebola antibodies contribute to protection and may be exploited for 
improving vaccine and therapeutic mAb efficacy and as markers of vaccine 
induced immunity.  
NK cells, like other innate immune effector cells, express one or more Fc 
receptors (FcR) on their surface allowing activation of cell-mediated antibody-
dependent anti-viral functions (13). Antibody-dependent phagocytosis (ADP) of 
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virus or virally-infected cells by monocytes, macrophages and neutrophils, and 
ADCC mediated by NK cells, promote the clearance of infected cells, reducing 
viral load and viral dissemination. NK cell ADCC is principally mediated by 
crosslinking of Fc  RIIIa (CD16) by the Fc region of immunoglobulins  – typically 
subclasses IgG1 and IgG3 in humans  – which leads to activation of 
immunoreceptor tyrosine-based activation motifs (ITAM) and downstream 
pathway activation. Ultimately, killing proceeds by the release of lytic granules 
(containing granzyme B and perforin) from activated NK cells inducing apoptosis 
of virally infected cells. Cross-linking of CD16 by antibody induces its cleavage 
from the  NK cell surface (14-16), however, despite this NK cells can move on to 
kill multiple targets providing effective and rapid clearance of infected cells (17). 
Fc functions of broadly neutralising antibodies have been shown to be 
indispensable for protection against influenza virus infection (18, 19). However, 
the role of Ebola vaccine induced antibody-dependent NK cell functions is 
unknown. 
The novel Ad26.ZEBOV/MVA-BN-Filo prime-boost vaccine regimen has shown 
promising results in phase 1 trials; high levels of anti-Ebola GP specific antibody 
are sustained for at least 360 days (20-22). However, different vaccine regimens 
(differing in the order and timing of prime/boost) induce substantially different 
serum antibody titres in U.K. based volunteers at both post-prime and post-boost 
time points (21). Therefore, the purpose of this study was to assess the ability of 
post-Ad26.ZEBOV/MVA-BN-Filo vaccination sera to mediate antibody-
dependent NK cell function using a 6-hour in vitro ADCC assay with immobilised 
Ebola GP (EbovGP) as antigen. We observe robust, antibody-dependent 
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activation of NK cells in whole human peripheral blood mononuclear cell (PBMC) 
preparations cultured with EbovGP in the presence of serum from 
Ad26.ZEBOV/MVA-BN-Filo-vaccinated individuals. NK cell activation varied 
depending on vaccine regimen; NK cell degranulation and IFN-   V H F U H W L R Q 
correlated positively with mean antibody titres. Antibody-dependent NK cell 
activity also varied between NK cell donor consistent with NK cell differentiation 
phenotype influencing the potency of these responses.  
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5.3 Materials and Methods 
 
5.3.1 Study participants and samples 
 
Eligible, healthy volunteers (n=72, age range 18-50 years, 36% HCMV 
seropositive by IgG ELISA; Biokit, Barcelona, Spain) were recruited to take part 
in the EBL1001 (EBOVAC consortium) single-centre, randomised, placebo-
controlled, observer blind Ebola vaccine trial in Oxford, U.K.; see Milligan et al. 
for additional methodology (21) (ClinicalTrials.gov Identifier: NCT02313077). 
Active vaccination comprises monovalent Ad26.ZEBOV expressing the GP of the 
Ebola Zaire virus (Mayinga variant) and multivalent MVA-BN-Filo expressing the 
GP of the Sudan and Zaire Ebola viruses and Marburg virus together with Tai 
Forest virus nucleoprotein (NP) (Crucell Holland N.V. - now Janssen Vaccines & 
Prevention B.V., The Netherlands and Bavarian Nordic, Denmark). Participants 
were randomised to receive vaccinations as follows; groups 1 and 2 received 
MVA-BN-Filo as prime on day 1 and Ad26.ZEBOV as boost on either day 29 or 
57 respectively, groups 3, 4 and 5 received Ad26.ZEBOV as prime and MVA-BN-
Filo as boost on days 29, 57 or 15 respectively. 
Serum samples were obtained as shown in Table 1; anti-Ebola GP antibody 
concentrations were determined by ELISA as previously reported (21).  Additional 
whole blood samples were obtained from non-vaccinated volunteers from among 
staff and students of LSHTM. PBMC were isolated using Histopaque 1077 
gradient centrifugation and cryopreserved in liquid nitrogen or used immediately. 
Written informed consent was received from all participants prior to inclusion in 
the study. The trial protocol and study documents were approved by the National 
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Research Ethics Service (reference number 14/SC/1408) and the LSHTM 
Research Ethics Committee (reference number 14383). 
 
  Serum samples used in this study 
 Vaccine 
schedule 
Baseline 
(Visit 0) 
Post-prime 
(Visit 1) 
21d post-
boost 
(Visit 2) 
Group 1 (n=15) MVA-Ad26 Day 1 Day 29 Day 50 
Group 2 (n=15) MVA-Ad26 Day 1 Day 57 Day 78 
Group 3 (n=14) Ad26-MVA Day 1 Day 29 Day 50 
Group 4 (n=14) Ad26-MVA Day 1 Day 57 Day 78 
Group 5 (n=14) Ad26-MVA Day 1 Day 15 Day 36 
Table 1: Vaccination regimen and samples used in this study.  
MVA, MVA-BN-Filo; Ad26, Ad26.ZEBOV. 
 
5.3.2 In vitro culture assays 
 
For antibody- G H S H Q G H Q W   1 .   F H O O   D F W L Y D W L R Q   D V V D \ V         J  P O   S X U L I L H G   ( E R O D   * 3 
(EbovGP), Mayinga variant (Crucell Holland B.V.) was immobilised on 96 well, 
flat-bottom tissue culture plates overnight at 4°C, washed, blocked with 5% FCS 
in RPMI 1640 supplemented with 100U/ml penicillin/streptomycin and 20mM L-
glutamine (Gibco, ThermoFisher) for 30 minutes and washed again. Fresh PBMC 
from one individual (non-vaccinated) donor were washed in RPMI 1640 
supplemented as above and counted using a Countess II FL automated cell 
counter (Invitrogen, ThermoFisher). PBMC were seeded (3x105/well) onto the 
antigen-coated plates together with pre or post-vaccination serum at various 
concentrations (with total serum concentration made up to 5% with FCS), and 
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incubated for 6 hours at 37°C. Alternatively, cryopreserved PBMC from multiple 
(non-vaccinated) donors were thawed, washed and seeded onto the antigen-
coated plates with pooled pre or post-vaccination serum from vaccination group 
2 (MVA-BN-Filo prime and Ad26.ZEBOV boost at day 57). 
Anti-CD107a-FITC (clone H4A3; BD Biosciences) was added to the cultures (at 
2µl per well) for the entire culture period and GolgiStop (Monensin; 1/1500 
concentration; BD Biosciences) and GolgiPlug (Brefeldin A; 1/1000 final 
concentration; BD Biosciences) were added for the final 3 hours of culture. 
Positive control cultures comprised the CD20 expressing h  X P D Q   % X U N L W W V 
Lymphoma cell line (RAJI; ECACC, Salisbury, U.K.) in conjunction with 
monoclonal anti-CD20 (Rituximab; Ritxan®; Genentech, San Francisco, U.S.A.) 
at varying concentrations. In all cases, cells were harvested into round-bottom 
plates by soaking and resuspension in cold PBS (containing 0.5% FCS, 0.05% 
sodium azide and 2mM EDTA) for staining.  
 
5.3.3 Flow cytometry  
 
Cells were stained in 96-well round-bottom plates as described previously (23). 
Briefly, cells were blocked with Fc Receptor (FcR) Blocking Reagent (Miltenyi 
 % L R W H F K    * H U P D Q \    D F F R U G L Q J   W R   P D Q X I D F W X U H U ¶ V   L Q V W U X F W L R Q V   D Q G stained with 
fluorophore labelled antibodies for surface markers including viability marker 
(Fixable Viability Stain 700; BD Biosciences) in FACS buffer (PBS, 0.5% FCS, 
0.05% sodium azide and 2mM EDTA). Cells were washed in FACS buffer, fixed 
and permeabilised using Cytofix/Cytoperm Kit (BD Biosciences) according to the 
 P D Q X I D F W X U H U ¶ V  L Q V W U X F W L R Q V   & H O O V  Z H U H  W K H Q  V W D L Q H G  I R U  L Q W U D F H O O X O D U  P D U N H U V  Z L W K 
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further FcR blocking for 20 minutes and washed again. Finally cells were 
resuspended in FACS buffer and acquired using a BD LSRII flow cytometer. Cells 
were acquired using FACSDiva software, data were analysed using FlowJo V10 
(Tree Star, Oregon, U.S.A). FACS gates were set using unstimulated cells or 
FMO controls, samples with less than 100 NK cell events were excluded from the 
analysis. 
Fluorophore labelled antibodies used were: anti-CD3-V500 (clone UCHT1) (BD 
Biosciences), anti-CD56-BV605 (clone HCD56) and anti-IFN- -BV785 (clone 
45.B3) (Biolegend, London, U.K.), anti-CD16-APC (clone CB16), anti-CD57-e450 
(clone TB01) (eBiosciences) and anti-NKG2C-PE (clone 134591) (R&D 
systems). Cells were acquired using FACSDiva software, data were analysed 
using FlowJo V10 (Tree Star, Oregon, U.S.A).  
 
5.3.4 Statistics 
 
Statistical analysis was performed using GraphPad Prism version 7.04 
(GraphPad, California, U.S.A.). Functional responses were compared using 
Wilcoxon signed-rank test or one- Z D \   $ 1 2 9 $   ) U L H G P D Q   W H V W   Z L W K   ’ X Q Q ¶ V 
correction for multiple comparisons. Correlation analysis was performed using 
linear regression. Significance levels are assigned as *p, 0.05, **p, 0.01, ***p, 
0.001, and ****p, 0.0001 for all tests.  
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5.4 Results 
 
5.4.1 Ad26.ZEBOV/MVA-BN-Filo Ebola vaccine induced antibody-
dependent NK cell activation in vitro. 
 
To assess the effect of Ad26.ZEBOV/MVA-BN-Filo induced anti-GP antibody on 
antibody-dependent NK cell activation, whole PBMC from one non-vaccinated 
donor were cultured with plate bound EbovGP plus pre or post-vaccination serum 
for 6 hours. Initially, serial dilutions of pooled pre-vaccination (baseline) and post-
boost serum were performed and CD3-CD56+ NK cell CD107a surface 
expression was assayed by flow cytometry (gating strategy shown in Figure 1a 
and Supplementary Figure 1a). Significant NK cell expression of CD107a was 
induced with the lowest concentration (0.63%) of post-boost serum (1.32% 
CD107a+ NK cells compared to 0.055% with pre-immune serum) and the 
prevalence of CD107a+ NK cells increased with increasing concentrations of 
post-boost serum, consistent with an antibody-dependent response 
(Supplementary Figure 1b). A concentration of 5% post-boost serum was 
selected for use in for subsequent assays as it induced a strong CD107a 
response but a low background response to pre-vaccination serum or FCS 
control (11.1% CD107a+ NK cells with 5% post-boost serum;  0.54% CD107a+ 
with 5% pre-vaccination serum and 0.11% CD107a+ with 5% FCS) 
(Supplementary Figure 1b).  
NK cell CD107a, CD16 and IFN-  H [ S U H V V L Rn was then measured in response to 
5% serum collected pre (visit 0), post-prime (visit 1) or post-boost (visit 2) 
vaccination with Ad26.ZEBOV/MVA-BN-Filo from each individual study 
participant (n=72) (gating strategy shown in Figure 1a-c). Initially, data from all 
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five vaccination arms were combined for analysis. Significantly higher 
frequencies of CD107a+ NK cells were observed with post-prime serum 
compared to pre-vaccination serum and was further enhanced with post-boost 
serum (median 2.39% post-prime, 8.24% post-boost) (Figure 2a). CD56dim NK 
cell CD16 expression measured by mean fluorescence intensity (MFI) decreased 
significantly in cells cultured with post-prime serum and there was a further, more 
pronounced, decrease in CD16 expression in cells cultured with post-boost 
serum (median MFI 8990 post-prime, 4020 post-boost) (Figure 2b). Frequencies 
of NK cells producing IFN-   L Q   U H V S R Q V H   W R   S R V W-prime serum were low but 
significantly higher than in response to pre-vaccination serum, and again, this 
was dramatically increased with post-boost serum (median 0.28% post-prime, 
1.17% post-boost) (Figure 2c).  
The effect of Ad26.ZEBOV/MVA-BN-Filo-induced anti-GP antibody on antibody-
dependent NK cell activation was analysed according to NK cell differentiation 
subset (gating strategy is shown in Supplementary Figure 1c). The NK cell subset 
distribution of the single donor used in for this assay was 10.2% CD56bright, 28.3% 
CD56dimCD57-, 45.2% CD56dimCD57+ and 16.3% CD56dimCD57+NKG2C+ NK 
cells (Supplementary Figure 1d). NK cell CD107a expression was induced 
equally in less differentiated CD56bright and more differentiated CD56dim NK cell 
subsets and in subsets further subdivided into moderately and highly 
differentiated CD56dimCD57- and CD56dimCD57+(NKG2C+) cells, respectively 
(Figure 2d). This was consistent with significant CD16 downregulation observed 
in all NK cell subsets (Figure 2e). Basal CD16 expression increased with 
increasing differentiation status (CD56dimCD57- < CD56dimCD57+ < 
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CD56dimCD57+NKG2C+) and CD16 expression was maintained at higher MFI 
post-boost in the most differentiated subsets (Figure 2e). CD107a was induced 
within the CD56bright NK cell population in response to post-vaccination serum, 
however the overall contribution of this subset to total NK cell CD107a expression 
was significantly less than CD56dim subsets (less than 5%, p=<0.0001) (Figure 
2g). IFN-   H [ S U H V V L R Q   L Q   U H V S R Q V H   W R   S R V W-prime and post-boost serum was 
attributed to CD56dim NK cells and no increase in expression was measured in 
the least differentiated CD56bright NK cell subset (Figure 2f).  
The most highly differentiated CD56dimCD57+ and CD56dimCD57+NKG2C+ NK cell 
subsets showed the most extensive CD16 downregulation and contained the 
highest frequencies of IFN-  S U R G X F Lng cells (Figure 2e, f). Over half (58%) of all 
the NK cells producing IFN-   L Q   U H V S R Q V H   W R post-boost serum were 
CD56dimCD57+ NK cells, with 25% of IFN- + cells being CD56dimCD57+NKG2C+ 
(Figure 2h). Consistent with antibody-dependent activation of more differentiated 
NK cell subsets, anti-CD20 (Rituximab) and CD20-expressing RAJI cells also 
preferentially induced NK cell degranulation and IFN-   H [ S U H V V L R Q   L Q 
CD56dimCD57+ and CD56dimCD57+NKG2C+ cells (Supplementary Figure 2). 
These data suggest that anti-Ebola GP antibody induces antibody-dependent NK 
cell activation, including IFN-  V H F U H W L R Q, in more differentiated NK cell subsets. 
 
5.4.2 Variation in antibody-dependent NK cell activation by vaccine 
regimen. 
 
The anti-GP antibody titres in the serum samples of Ad26.ZEBOV/MVA-BN-Filo 
vaccinated individuals varied depending on the vaccination regimen (21). We 
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therefore analysed the impact of vaccine regimen on antibody-dependent NK cell 
activation. There was significant upregulation of CD107a, IFN-   D Q G 
downregulation of CD16 with post-boost serum in all groups compared to pre-
vaccination serum responses, however responses differed significantly between 
study arms (Figure 3a-c).  
Groups 1 and 2 (MVA prime/Ad26 boost) resulted in the strongest induction of 
CD107a and IFN-   H [ S U H V V L R Q   D Q G   W K H   O R Z H V W   & ’      0 ) ,   R I   D O O      J U R X S V    ) L J X U H 
3a-c). Serum collected after MVA prime alone did not induce NK cell activation, 
but significant induction of CD107a, IFN-  D Q G  G R Z Q U H J X O D W L R Q  R I  & ’    was seen 
with post-Ad26 boost serum (when compared to both pre-vaccination and post-
prime vaccination serum) (Figure 3a-c, Supplementary Table 1). By contrast, in 
groups 3, 4 and 5 (Ad26 prime/MVA boost) there was induction of NK cell 
responses to post-Ad26 prime serum and IFN-  (groups 3 and 4), CD107a and 
CD16 downregulation (group 4 only) were further enhanced by post-MVA boost 
serum (Figure 3a-c, Supplementary Table 1). Earlier MVA boost in group 3 and 
group 5 did not result in further significant NK activation over that with post-Ad26 
prime serum (except weak boosting of IFN-   L Q   J U R X S     and group 5 resulted in 
the weakest overall response (Figure 3a-c, Supplementary Table 1). This 
suggests that Ad26 prime induces sufficient titres of antibody for a robust NK cell 
response that is further increased by MVA boost, whilst MVA alone does not 
induce sufficient antibody (or antibody of the correct isotype or subclass) to 
mediate ADCC. This is in line with data on the effect of vaccine regimen on anti-
GP antibody concentration (21). 
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We next analysed the relationship between geometric mean anti-GP antibody 
titres (determined by Milligan et al. (21)) and median expression of NK cell 
activation markers. There was a significant positive correlation between post-
boost antibody concentration and median NK cell CD107a+ and IFN- + 
frequencies and a negative correlation with CD16 downregulation (Figure 3d-f). 
Both geometric mean antibody concentrations and NK cell ADCC responses 
were highest in groups 1 and 2 and lowest in group 5. Despite a large difference 
in antibody concentration between group 1 and 2 (MVA prime/Ad26 boost at day 
29 and day 57 respectively), NK cell CD107a expression and CD16 
downregulation were comparable (Figure 3d, e). Similarly, differences in antibody 
titres between group 3 and 4 (Ad26 prime/MVA boost at d29 and d57 
respectively) did not manifest as big differences in NK cell activation (Figure 3d, 
e). This suggests that sufficient antibody titres can be achieved with early (d29) 
boost to obtain optimal NK cell degranulation responses. By contrast, IFN- 
production, was very strongly correlated with antibody titre with no saturating 
effect of increasing mean antibody titre, suggesting that increasing levels of anti-
GP antibodies will be associated with stronger NK cell cytokine secretion (Figure 
3f). There was no significant correlation between antibody titre and NK cell 
function per group at post-prime time points (Supplementary Figure 3a-c), 
consistent with requirement of boost-vaccination for strong antibody-dependent 
NK cell responses.  
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5.4.3 Antibody-dependent activation varies by NK cell donor. 
 
The studies described above (Figures 1-3) employed a consistent source of 
PBMC from a single donor whilst varying the source of serum, such that variation 
in NK cell antibody-dependent activation between serum donor and vaccination 
group could be related to differences in antibody titre. In order to analyse the 
effect of donor variation, whole PBMC from non-vaccinated donors were cultured 
with plate bound EbovGP and pooled pre or post-boost vaccination serum 
samples from group 2 (MVA prime/Ad26 boost). NK cell CD107a (14 of 16 
responding), CD16 downregulation (16 of 16 donors responding) and IFN- (13 
of 16 donors responding) was induced with pooled post-boost serum compared 
to pooled pre-vaccination serum (Figure 4a-c). This suggests that cells from the 
majority of donors respond to Ad26.ZEBOV/MVA-BN-Filo-induced antibodies for 
NK cell activation and also indicates that, in addition to antibody titre, factors 
intrinsic to the responding NK cells influence individual ADCC responses.  
The extent of NK cell differentiation is influenced by age and infections such as 
human cytomegalovirus (HCMV) (24, 25). We therefore analysed NK cell 
activation in response to pooled post-boost vaccination serum according to NK 
cell differentiation subset. Amongst the individuals tested, frequencies of the most 
highly differentiated CD56dimCD57+NKG2C+ NK cells varied widely (with 5 of 16 
donors showing frequencies above 10%) and overall there was a wide range of 
frequencies of the different subsets (CD56bright range 1.8-18.6%; CD56dimCD57- 
17.6-68.1%; CD56dimCD57+ 7.9-66.1%; CD56dimCD57+NKG2C+ 0-32.5%) (Figure 
4d). NK cell CD107a+ expression after co-culture with antigen and post-boost 
sera was apparent in all NK cell subsets (Figure 4e), as was CD16 
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downregulation (Figure 4f). IFN-   Z D V   V L J Q L I L F D Q W O \   X S U H J X O D W H G in post-boost 
serum in CD56dimCD57- and CD56dimCD57+ subsets with the highest frequency 
of IFN-  expression being observed within the CD56dim NK cell subsets.  The 
individuals with a frequency of CD56dimCD57+NKG2C+ NK cells above 10% 
contributed the higher NK cell IFN-   S U R G X F W L R Q   R I   W K L V   V X E V H W (Figure 4g), and 
almost half (46.9%) of total NK cell IFN-  S U R G X F W L R Q  Z D V  D W W U L E X W H G  W R  W K L V  V X E V H W 
(Figure 4h). These data demonstrate that differences in NK cell differentiation 
status introduce additional inter-donor variation for in NK cell ADCC responses.  
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5.5 Discussion 
 
We have shown that antibodies to Ebola virus GP induced by the 
Ad26.ZEBOV/MVA-BN-Filo vaccine activate robust NK cell degranulation and 
IFN-  V H F U H W L R Q  Z L W K L Q 6 hours of co-culture with Ebola GP antigen. These NK cell 
responses are highly variable depending on vaccine regimen and are directly 
correlated with post-boost antibody titres. Furthermore, these antibody-
dependent NK cell responses are markedly enriched in (although not limited to) 
the more differentiated (CD56dim) NK cell subsets and differences between 
donors in the differentiation status of their NK cells therefore adds to the 
heterogeneity of ADCC responses seen post-vaccination. Thus, these data 
demonstrate that assessment of antibody-dependent NK cell effector function 
has potential as an informative correlate of vaccine efficacy.  
The strong positive correlation between post-boost antibody titre and NK cell 
activation suggests this is a robust read-out of antibody-dependent effector 
function that, to some extent, depends on antibody titre. Interestingly, NK cell 
CD107a expression did not further increase with higher antibody titres induced 
by delayed boost vaccination (d57) compared to earlier boost (d29) suggesting a 
threshold for maximum NK cell degranulation was reached. However, NK cell 
IFN-  H [ S U H V V L R Q  Z D V  K L J K H U  Z L W K  O D W H U  E R R V W   G     Fompared to the earlier boost 
(d29). The lack of correlation between antibody titre and NK cell responses after 
a single vaccine dose (i.e. post-prime) highlights a requirement for a two dose 
vaccine regimen to induce robust NK cell responses and may reflect effects of 
antibody affinity maturation and isotype/subclass switching in addition to any 
effects of overall antibody concentration.  
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Of interest, NK cell activation post-Ad26.ZEBOV/MVA-BN-Filo vaccination 
required relatively high serum concentrations. We have observed similar levels 
of NK cell degranulation with, for example, up to 40-fold lower concentrations of 
post-seasonal influenza vaccination serum (16); likely prior exposure to  influenza 
(and possibly prior vaccination) may result in production of higher anti-influenza 
antibody titres and induction of high avidity antibodies with a broad range of 
specificities. In addition, in the assays used here, only antibodies able to bind to 
the plate bound Ebola GP were able to contribute to the ADCC response; the 
contribution of antibodies to the Ebola virus nucleoprotein (contained in the MVA 
vaccine) was not assessed. 
Our data highlight a high level of variation in frequencies of activated NK cells 
subsets both within a single donor and between donors in response to post-
vaccination antibody. Many variables effect NK cell ADCC function including FcR 
polymorphisms (26), antibody glycosylation (27) and cytokine mediated 
regulation (28). Antibody binding epitopes can also affect the ADCC functional 
capacity of vaccine induced antibodies (3). Studies suggest that neutralising 
antibodies bind epitopes on the core of Ebola GP potentially inhibiting virion cell 
entry whereas antibodies with Fc function bind epitopes on the upper domains 
that are exposed on GP presented on the surface of infected cells and remain on 
the shed form of GP (6, 29). Ebola GP returning to the surface of the infected cell 
and the liberation of soluble GP for immune complex formation could present 
opportunities for NK cell ADCC. However, GP shed from infected cells has been 
shown to bind anti-GP antibodies and block, rather than facilitate, their activity 
(30).  
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More differentiated CD57hi (NKG2Chi) NK cells express high levels of CD16 on 
their surface, exhibit high antibody-dependent responses to viral antigens and 
display reduced responsiveness to cytokine stimulation, due in part to reduced 
cytokine receptor expression (16, 31-36). Our data is thus consistent with 
antibody-dependent NK cell activation. HCMV infection is highly prevalent, with 
seropositivity rates of up to 60% in adults in developed countries, near universal 
in developing countries, and strongly influences NK cell function in response to 
viral antigens (25, 37) (and reviewed in (38)). HCMV infection leads to the 
accumulation of highly differentiated NK cells expressing NKG2C with a mature 
(CD56dimCD57+    D Q G   µ D G D S W L Y H ¶   ) F0 5 -) phenotype. HCMV expanded 
populations of NK cells show enhanced IFN-   V H F U H W L R Q   L Q   U H V Sonse to antibody 
coated targets, owing to epigenetic modification of the IFN-   J H Q H  S U R P R W R U (36, 
39). HCMV serostatus therefore may impact antibody-dependent NK cell 
activation, and perhaps vaccine-induced protection after Ad26.ZEBOV/MVA-BN-
Filo vaccination. 
In separate studies, we demonstrated soluble EbovGP induced inflammatory 
cytokine secretion and cytokine-dependent activation of less differentiated NK 
cells, with high levels of IL-10 controlling NK cell IFN-   V H F U H W L R Q (unpublished 
data, Chapter 4 of this thesis). This present study, utilising plate bound antigen, 
suggests that anti-GP antibody in post-vaccination serum strongly activates NK 
cell CD107a and IFN-   V H F U H W L R Q   L Q   P Rre differentiated NK cell subsets via Fc-
dependent mechanisms. Frequencies of IFN- + NK cells measured in this study 
(median 1.17% at post-boost) may represent substantially higher percentages 
than Ebola GP-specific T cell IFN-  P H D V X U H G  E \  ( / , 6 3 2 7  S U H Y L R X sly (maximum 
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940 spot forming units/million PBMC (0.094%)) (21). This leads us to hypothesise 
that NK cell IFN-   L Q G X F H G  E \   $ ’ & &  L Q  U H V S R Q V H  W R  Y D F F L Q H  D Q W L E R G \    P D \   E H  R I 
increased importance during post-vaccination exposure to Ebola virus by limiting 
reliance on non-specific inflammatory mediators and associated downregulation 
by IL-10.  
In summary we have shown that vaccination with Ad26.ZEBOV/MVA-BN-Filo 
induces antibodies capable of inducing strong antibody-dependent NK cell 
activation that strongly correlated with antibody titre. This response varied widely 
between donors, was robust in the majority tested and was further enriched in, 
but not limited to, highly differentiated CD57+NKG2C+ NK cells. This study 
highlights NK cells as potential mediators of immunity to Ebola infection where 
responses are determined by both the level of vaccine induced antibody and by 
the differentiation status of effector NK cells. Antibody-dependent NK cell function 
may help better define the protective capacity of vaccine induced antibodies when 
combined with standard antibody level or neutralisation assays.  
CHAPTER 5. ANTIBODY-DEPENDENT NK CELL ACTIVATION 
 
270 
 
5.6 Acknowledgements 
 
This work was supported by a U.K. Medical Research Council Studentship in 
Vaccine Research (HRW). This project has received funding from the Innovative 
Medicines Initiative 2 Joint Undertaking (Grant 115861). This Joint Undertaking 
receives  V X S S R U W   I U R P   W K H   ( X U R S H D Q   8 Q L R Q ¶ V   + R U L ] R Q            5 H V H D U F K   D Q G 
Innovation Programme and Association.  
We also thank Carolynne Stanley for recruiting and obtaining consent from 
LSHTM study subjects and for blood sample collection.  
  
CHAPTER 5. ANTIBODY-DEPENDENT NK CELL ACTIVATION 
 
271 
 
5.7 Figures 
 
 
Figure 1: Gating strategy for NK cell CD107a, CD16 and IFN -    H [ S U H V V L R Q  
Flow cytometry plots show CD3-CD56+ NK cell (gating strategy shown in Supplementary Figure 
1a) CD107a (a), CD16 (b) and IFN-   (c) expression in response to 5% pre (visit 0), post-prime 
(visit 1) and post-boost (visit 2) vaccination serum and plate bound EbovGP antigen. Whole 
PBMC from one non-vaccinated single donor were used for NK cell activation assays in figures 
1-3, the NK cell differentiation phenotype of the donor is shown in Supplementary Figure 1c and 
d. 
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Figure 2: Antibody-dependent NK cell responses to plate bound EbovGP after 
Ad26.ZEBOV/MVA-BN-Filo vaccination.  
The median and 95% confidence interval of NK cell CD107a (a), CD56dimCD16 MFI (b) and IFN-
  (c) responses to each pre (visit 0), post-prime (visit 1) and post-boost (visit 2) vaccination serum 
sample are shown  – all vaccine arms combined (n=72). NK cell CD107a (d), CD16 (e) and IFN-   
(f) responses were analysed according to NK cell differentiation subset defined by CD56, CD57 
and NKG2C expression (gating strategy shown in Supplementary Figure 1c). Each individual 
donor serum sample is represented by a dot with a line at the median. The proportion of total NK 
cell CD107a (g) and IFN-   (h) expression (post-boost) attributed to each subset is shown as a pie 
graph with each slice representing the median. Comparisons across vaccination visits and 
between subsets was performed using one-  Z D \   $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R U U H F W L R Q   I R U   Pultiple 
comparisons. ****p < 0.0001. 
  
CHAPTER 5. ANTIBODY-DEPENDENT NK CELL ACTIVATION 
 
273 
 
 
Figure 3: NK cell activation varies with vaccine regimen. 
NK cell CD107a (a), CD56dimCD16 MFI (b) and IFN-   (c) expression was plotted according to 
vaccine regimen for pre (visit 0), post-prime (visit 1) and post-boost (visit 2) vaccination time 
points, graphs show median only. Comparisons between groups using one-way ANOVA with 
 ’ X Q Q ¶ V   F R U U H F W L R Q   I R U   P X O W L S O H   F R P S D U L V R Q V was performed and summarised in Supplemntary 
Table 1. Geometric mean anti-GP antibody concentration per study arm was correlated with 
median NK cell CD107a (d), CD16 (e) and IFN-   (f) expression, plots show one dot per group. 
Correlation was determined by linear regression and significance was defined as p < 0.05. 
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Figure 4: NK cell activation varies with NK cell donor. 
NK cell CD107a (a), CD56dimCD16 MFI (b) and IFN-   (c) expression (multiple non-vaccinated 
donors, n=16) in response to 5% pooled (group 2) pre and post-boost vaccination serum and 
plate bound EbovGP. The NK cell subset frequency distribution is shown for each donor (d). The 
NK cell CD107a (e), CD16 MFI (f) and IFN-   (g) responses were also analysed according to NK 
cell differentiation subset and the proportion of total NK cell IFN-   attributed to each subset is 
shown as a pie graph with each slice representing the median (h). Graphs show before and after 
plots with a line connecting each donor or one dot per donor with a line representing the median. 
Comparisons between pre and post serum responses was performed using Wilcoxon signed-rank 
test and between subsets using one-  Z D \   $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R U U H F W L R Q for multiple 
comparisons. *p < 0.05, **p < 0.01, ****p < 0.0001.  
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5.8 Supplementary Material 
 
Group  Visit  
P value  
CD107a (%) CD16 (MFI) IFN-  (%) 
1 
0 vs. 1 ns ns ns 
0 vs. 2 <0.0001 0.0002 0.0004 
1 vs. 2 0.001 0.0002 0.0004 
2 
0 vs. 1 ns ns ns 
0 vs. 2 0.003 <0.0001 0.0002 
1 vs. 2 0.0004 0.0008 0.0008 
3 
0 vs. 1 0.0421 0.0138 ns 
0 vs. 2 <0.0001 <0.0001 <0.0001 
1 vs. 2 ns ns 0.0322 
4 
0 vs. 1 ns 0.0245 ns 
0 vs. 2 <0.0001 <0.0001 <0.0001 
1 vs. 2 0.0138 0.0245 0.0075 
5 
0 vs. 1 0.0052 0.0024 0.011 
0 vs. 2 0.011 ns 0.0417 
1 vs. 2 ns ns ns 
Supplementary Table 1: Group wise statistical analysis.  
Statistical analysis of NK cell CD107a, CD16 and IFN-     H [ S U H V V L R Q   L Q   U H V S R Q Ve to plate bound 
EbovGP and pre (visit 0), post-prime (visit 1) and post-boost (visit 2) vaccination serum between 
visits within each group. One-  Z D \   $ 1 2 9 $   Z L W K   ’ X Q Q ¶ V   F R U U H F W L R Q   I R U   P X O W L S O H   F R P S D U L V R Q V  
significance defined as p < 0.05. ns, non-significant. 
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Supplementary Figure 1: NK cell gating strategy. 
CD3-CD56+ NK cells were gated for activation marker analysis (a). The effect of increasing 
concentrations of pooled baseline and post-boost serum on frequencies of CD107a+ NK cells in 
response to EbovGP (b). The gating strategy (c) and proportions (d) of NK cell differentiation 
subsets defined by CD56 and CD57 expression in the single PBMC donor used in Figures 1-3. 
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Supplementary Figure 2: The effect of increasing concentrations of Rituximab on NK cell 
activation.  
NK cell CD107a (a), CD16 MFI (b) and IFN-   (c) expression in response to CD20-expressing cell 
line (RAJI) and anti-CD20 antibody (Rituximab) was analysed by NK cell differentiation subset. 
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Supplementary Figure 3: Correlation between NK cell activation and antibody titre at post-
prime time point. 
Geometric mean anti-GP antibody concentration per group was correlated with the median NK 
cell CD107a (a), CD56dim CD16 MFI (b) and IFN-   (c) expression at the post-prime time point. 
Plots show one dot per group. Correlation was determined by linear regression and significance 
was defined as p < 0.05.  
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6.1 Summary of Findings 
 
The aim of this thesis was to investigate the effect of viral vaccination and 
restimulation with vaccine antigen and/or cytokines on human NK cell phenotype 
and function. I hypothesised that vaccination primes NK cells for enhanced 
responsiveness to innate cytokine stimulation leading to heightened effector 
responses post-vaccination. I have described a previously unappreciated 
mechanism of indirect NK cell functional enhancement by a very low 
concentration of IL-15. The effects of vaccination with whole inactivated influenza 
and vectored prime-boost Ebola vaccines on NK cell cytokine and antibody-
dependent activation have also been characterised. The specific cytokine 
signature secreted in response to vaccination and in vitro restimulation proved 
important in determining the magnitude and functional characteristics of the NK 
cell response after vaccination, therefore combined analysis of cytokine secretion 
and associated NK cell activation was performed throughout this project. This 
lead to key findings that vaccine induced priming within the myeloid accessory 
cell pool contributes to post-vaccination NK cell responses and that vaccine-
antigen induced IL-10 can suppress NK cell function. The findings presented in 
this thesis have furthered our understanding of NK cells as effectors of vaccine 
induced immunity. Here, I will summarise these and suggest directions for future 
work. 
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6.1.1 IL-15 Mediated Enhancement of NK Cell Function 
 
IL-15 is important for NK cell development, survival and activation, the potency 
of which has previously been attributed to both trans-presentation on 
neighbouring DCs and synergy with other innate cytokines. IL-15 is also known 
to recruit NK cells to the lung after influenza infection, enhance DC maturation 
and recruit and modulate activation of T cells (1-3). However the role of IL-15 in 
enhancing DC cytokine secretion has not been previously appreciated and linked 
to enhanced NK cell responses against viral challenge. 
I have shown that a very low dose of IL-15 (0.75ng/ml), which was unable to 
stimulate NK cells directly, enhanced NK cell responses to inactivated H3N2 
influenza virus by boosting accessory cell cytokine secretion. Table 1 
summarises the concentrations of cytokines measured by Luminex after H3N2 
vs H3N2 + IL-15 simulation in this study. IL-15 not only increased the frequency 
of responding NK cells but also increased the frequency of NK cells performing 
two or more functions (polyfunctional). This suggests a broadening of functional 
capacity against influenza virus, perhaps reflecting the increased concentrations 
of not only IL-12 (for enhanced IFN-γ secretion) but also IFN-α for the promotion 
of cytotoxicity. Interestingly, just under half (42-43%) of donors did not display 
enhanced IL-12 production in response to H3N2 + IL-15 compared with H3N2 
alone. This observation of ‘responders’ and ‘non-responders’ may reflect 
differences in the frequency of accessory cells amenable to IL-15 boosting, or 
differential responsiveness to IL-15 within the myeloid cell pool between donors. 
Recent influenza virus exposure or vaccination leading to differential T cell help 
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or indeed primed or trained innate immunity could introduce donor-donor 
variation of this kind. 
Although increases in functional NK cell percentages were small, this may 
represent a substantial proportion of the total lymphocyte response in peripheral 
blood and may be relevant in localised tissue environments such as the lung. The 
synergising concentrations of IL-15 employed here may be more physiologically 
relevant than the 5-fold higher concentrations typically used in NK cell in vitro 
culture (4). Increased concentrations of IL-15 (as well as IP-10, TNF, IL-10 and 
IFN-γ) have been measured in nasal lining fluid of live attenuated influenza 
vaccine (LAIV) vaccinated individuals demonstrating potential for this mechanism 
of NK cell enhancement in the lung after LAIV vaccination and indeed influenza 
infection (1, 5). It would be interesting to further investigate the effect of low doses 
of IL-15 on DC cytokine secretion, perhaps by measuring expression of IL-15 
receptor components, IL-15 trans-presentation or the role of DC/NK cell contact 
in peripheral blood, but also in the lung using LAIV vaccination as a model for 
infection.  Luminex analysis and immunophenotyping of nasal lining fluid and 
nasal cells applied in recent studies (5), may reveal whether these priming effects 
also have relevance in tissues after vaccination or infection. 
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Cytokine 
Median cytokine concentration 
(pg/ml)  
H3N2 H3N2 + IL-15 P value 
GM-CSF 13.9 27.9 <0.0001 
IFN-α2 1041 1271 0.0107 
IL-10 25.7 21.4 NS 
IL-12(p70) 5.1 8.9 <0.0001 
IL-1β 224 314.9 <0.0001 
TNF-α 902.2 1106 0.0341 
IFN-γ 139.2 806.3 <0.0001 
Table 1: Summary of cytokine concentrations secreted in vitro in response to H3N2 vs 
H3N2 + IL-15 stimulation of whole human PBMC.  
Data taken from chapter 2. Median concentration in pg/ml measured by Luminex (n=73). Red; 
increase over H3N2 alone. P value determined by Wilcoxon signed-rank test, significant values 
determined as p < 0.05. NS; not significant. 
 
It would be interesting to examine whether the impacts of IL-15 are unique to the 
signals induced by H3N2 (or other influenza viruses) or whether these are found 
in response to other viruses. In this context, I have found that co-stimulation of 
whole PBMC with EbovGP and 0.75ng/ml rhIL-15 also induced a heightened NK 
cell functional response compared to both IL-15 alone and EbovGP alone 
(Appendix Supplementary Figure 1). The frequency of IFN-γ+ NK cells was 
significantly higher in the presence of IL-15, which in the absence of IL-15 was 
not induced over medium alone. This suggested that consistent with whole 
inactivated H3N2 virus stimulation, IL-15 enhanced the in vitro NK cell response 
to soluble recombinant EbovGP, most likely indirectly via boosting innate cytokine 
secretion for synergistic responses. Measurement of the cytokine concentrations 
secreted in response to EbovGP + IL-15 compared with that induced by EbovGP 
alone would certainly help evaluate this observation further.  
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6.1.2 Influenza Vaccine Enhanced Innate Cytokine Secretion 
and NK Cell Function 
 
Previously, enhanced NK cell responses after influenza vaccination were 
demonstrated upon stimulation with vaccine strain influenza virus in vitro, this 
was dependent on antigen-specific T cell derived IL-2 and antibody (6, 7). Both 
in vitro and in vivo in mice, NK cells were primed in response to exogenous 
cytokine exposure (IL-12, IL-15 and IL-18) to mount more robust responses upon 
secondary exposure to innate cytokine stimulation (8, 9). NK cells were also 
primed by inactivated influenza vaccination in vivo enabling a heightened 
response to exogenous IL-12 and IL-18 stimulation in vitro in the absence of 
antigen stimulation; these cytokine primed or pre-activated NK cells are termed 
CIML NK cells (6, 10). In this thesis, I have shown that influenza vaccination 
primes both myeloid accessory cells and NK cells for enhanced cytokine 
secretion and activation in response to H3N2 and IL-15 stimulation, up to 30 days 
post-vaccination. These findings demonstrate that the function of vaccination 
primed NK cells, with increased responsiveness to innate cytokines (CIML NK 
cells), is further promoted in an environment with synergistic signals from 
enhanced accessory cell cytokine secretion and adaptive signals such as IL-2.  
The most interesting finding of this study was the response to low dose IL-15 
alone; I observed secretion of myeloid cell-derived cytokines such as GM-CSF, 
IL-10 and IL-1β in post-vaccination samples where little was induced at baseline. 
This was reflected in the NK cell response where there was significantly higher 
frequencies of CD25+ NK cells post-vaccination compared to baseline in 
response to IL-15 alone. Co-stimulation with H3N2 + IL-15 also revealed vaccine 
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enhanced cytokine secretion and NK cell function that was magnified over that of 
IL-15 alone. Table 2 summarises the concentrations of cytokines measured by 
Luminex in response to H3N2 + IL-15 simulation before and after vaccination in 
this study.  
It is likely that pro-inflammatory cytokines released after vaccination in response 
to PRR stimulation led to the generation of CIML NK cells that may be sensitive 
to even the smallest increases in cytokine concentrations (such as IL-12 and IFN-
α) induced by low dose IL-15 in vitro. This, in combination with the first finding 
(chapter 2), highlights an unappreciated role for very low doses of IL-15 in post-
vaccination anti-viral immunity in the context of pre-activated/primed or co-
stimulated innate immune cells. With this study, I have made some progress on 
assessing the functional differences in innate immune cells before and after 
vaccination. However, the mechanisms involved in vaccine-induced 
enhancement of innate immunity and their functional significance or contribution 
to vaccine-induced protection are not comprehensively understood. Further 
research could lead to improvements in the design of vaccine adjuvants, new 
vaccines or therapeutic strategies to boost (non-antigen specific) innate immunity 
through vaccination.  
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Cytokine 
Median cytokine concentration 
(pg/ml)  
Baseline Day 30 P value 
GM-CSF 68.1 132.7 0.0035 
IFN-α2 1113 1419 0.0263 
IL-10 160.7 411.6 0.0196 
IL-12(p70) 12.3 10.6 NS 
IL-1β 648.9 906.5 0.0386 
TNF-α 2067 2545 NS 
IFN-γ 737.9 2729 0.0006 
Table 2: Summary of cytokine concentrations secreted in vitro in response to H3N2 + IL-
15 stimulation before (baseline) and after (day 30) influenza vaccination.  
Data taken from chapter 3. Median concentration in pg/ml measured by Luminex (n=26). Red; 
increase over baseline. P value determined by Wilcoxon signed-rank test, significant values 
determined as p < 0.05. NS; not significant. 
 
Trained immunity, described in monocytes as induction of a non-specific memory, 
is underpinned by epigenetic modifications; histone trimethylation, keeping 
promotor regions open for rapid cytokine gene transcription, was increased up to 
3 months after BCG vaccination (with possible effects lasting up to 1 year) (11-
13). A study in which lower viremia upon yellow fever virus challenge was 
measured 1 month after BCG vaccination compared with unvaccinated controls 
suggested a role of non-specific trained immunity in protection against non-
related viral pathogens. In this study, monocyte-derived IL-1β was a crucial 
component of trained immunity (14). We measured enhanced IL-1β secretion in 
response to both IL-15 alone and H3N2 + IL-15 restimulation after influenza 
vaccination, perhaps suggesting the presence of trained monocytes in our 
system. Intracellular staining experiments suggested mDCs are important 
producers of IL-12 in response to influenza virus, and blocking experiments 
demonstrated IL-12 was critical for CIML NK cell function after influenza 
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vaccination. Yet trained immunity in DC subsets or indeed in response to viral 
stimuli has not been reported before. Whether it is possible for DC subsets to be 
trained in response to virus exposure during vaccination and undergo epigenetic 
modification resulting in lasting modulation would be an interesting avenue to 
explore.  
It is conceivable that epigenetic modifications are also involved in mediating 
heightened NK cell responsiveness to cytokines after vaccination. Promotor 
hypermethylation, was associated with signalling molecule SYK and FcεR1γ 
deficiency in HCMV driven expansions of ‘adaptive’ NK cells (15, 16). 
Demethylation, increasing gene accessibility, of the conserved non-coding 
sequences (CNS-1) of the IFNG locus in cytokine primed NK cells has also been 
demonstrated (17). CIML NK cells have comparable amounts of IFN-γ mRNA 
transcripts to naïve NK cells and the properties of CIML NK cells (enhanced IFN-
γ secretion) were maintained in daughter cells after proliferation suggesting post-
transcriptional/post-translational, heritable mechanisms (8, 9). However, 
epigenetic modifications have not yet been linked to enhanced cytokine 
responsiveness in NK cells after vaccination. Previous studies document the loss 
of influenza vaccine priming effects on NK cells by 12 weeks in U.K. based 
volunteers suggesting CIML NK cells, although perhaps retained after cellular 
proliferation, represent a transient state, with a currently unknown benefit (6). 
To further our understanding, RNA transcriptional analysis of unstimulated and 
IL-15 stimulated pre and post-influenza vaccinated PBMC from the study 
described in Chapter 3 is currently underway. This could identify changes in 
steady state gene expression which persist after vaccination, perhaps identifying 
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cell populations primed for rapid responsiveness to TLR signalling (myeloid) and 
inflammatory mediators (NK cells). Analysis of IL-15 stimulated pre and post-
vaccination PBMC could characterise the pathways upregulated by IL-15 in 
vaccine primed vs baseline samples. Cellular metabolism is also increasing in 
interest in regards to trained or pre-activated innate immune cells; studies have 
indicated a shift towards aerobic glycolysis in NK cells after cytokine stimulation 
and enhanced glycolysis in trained compared to naïve monocytes (18, 19). 
Assessing epigenetic modifications and glucose metabolism pathways in NK 
cells and accessory cells after viral vaccination would be of particular interest for 
future work. 
 
6.1.3 Altered NK Cell Phenotype after Vaccination 
 
Previous data on the effect of vaccination on human peripheral blood NK cells 
showed activation (CD69 and CD25 expression) and proliferation (Ki67 
expression) after live attenuated and whole inactivated vaccinations (6, 20, 21). I 
have demonstrated a transient change in NK cell phenotype after both inactivated 
influenza vaccination and vectored Ad26.ZEBOV/MVA-BN-Filo Ebola 
vaccination; the proliferative increase in frequency of CD56bright NK cells was a 
comparable effect of the two vaccines. As less differentiated NK cell subsets 
express a wider compliment of cytokine receptors including CD25, IL-12Rβ2 and 
IL-18Rα, a cytokine-dependent activation of the less differentiated subsets in vivo 
in response to vaccination could be responsible. This is remarkable in the context 
of a viral vectored vaccine vs a whole organism vaccine, in the absence of whole 
organism PAMPs or adjuvants for additional PRR signalling. In light of the 
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cytokine response to EbovGP alone, perhaps this is not so unexpected, however, 
we cannot rule out effects of the viral vectors (Ad26 and MVA), utilised in this 
Ebola vaccine. Pre-existing immunity (neutralising antibodies) to Ad26 is lower 
than other viral vectors such as Ad5, however internalisation and genome 
delivery may expose PAMPs such as viral DNA, eliciting an immune response 
(22). Similarly, the conformation and structure of the virally vectored Ebola GP 
expressed after vaccination is unknown. 
 
6.1.4 Characterisation of NK Cell Responses to Ebola GP 
Stimulation and Vaccination 
 
I have thoroughly investigated innate cytokine and antibody-dependent activation 
of NK cells in response to Ebola GP before and after Ad26.ZEBOV/MVA-BN-Filo 
Ebola vaccination. Soluble Ebola GP induces high levels of innate cytokines 
(TNF-α, IL-1β, IL-10, IL-6, IFN-β and IL-12) in monocytic cell lines, monocyte-
derived DCs and macrophages (23-26). However, the effect of this cytokine 
induction on cytokine-dependent NK cell function in primary whole human PBMC 
cultures has not been thoroughly evaluated. In this thesis, I measured whole 
human PBMC cytokine secretion in response to Ebola GP stimulation by 
Luminex, the cytokine signature and quantity was striking and merited further 
investigation. In comparison to H3N2 stimulation, EbovGP stimulated very high 
concentrations of GM-CSF, IL-10, IL-1β and TNF-α, but lower concentrations of 
IFN-α2 and IL-12(p70) (Table 3). This high level cytokine secretion (described as 
a cytokine storm) has been shown in the plasma of infected humans, and has 
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been likened to septic shock syndrome and pandemic 1918 influenza virus 
infection (27-29).  
 
Cytokine 
Median cytokine concentration 
(pg/ml) 
EbovGP H3N2 
GM-CSF 460.9 13.9 
IFN-α2 6.2 1041 
IL-10 3151 25.7 
IL-12(p70) ND 5.1 
IL-1β 3995 224 
TNF-α 5542 902.2 
IFN-γ 15.2 139.2 
Table 3: Comparison of cytokine concentrations secreted in vitro in response to H3N2 and 
EbovGP stimulation.  
Median concentration in pg/ml measured by Luminex (n=72 EbovGP, n=73 H3N2). Red; increase 
vs other antigen stimulation. ND; none detected. 
 
The findings of chapter 4 are consistent with others showing TLR-4 dependent 
recognition of Ebola GP by human innate immune cells of myeloid lineage, 
leading to the secretion of inflammatory cytokines (24, 26). I have shown human 
CD14+ monocytes in primary whole mononuclear cell preparations are key 
responders to soluble Ebola GP, where previous studies have been confined to 
human monocyte cell lines or in vitro differentiated DC and macrophages. Our 
study may be more relevant to vaccination (i.e. soluble GP in the absence of 
replicating virus) and subsequent environmental challenge, and also implicates 
CD14+ monocytes for future in vitro study of innate immune responses to Ebola 
GP. Moreover, I have shown for the first time that human NK cell upregulation of 
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CD25 and degranulation after Ebola GP stimulation in vitro is dependent on IL-
12 and IL-18 induced by the GP.  
TLR-4 activates two signalling pathways, the MyD88 and TRIF pathways, leading 
to activation of NF-κB (for pro-inflammatory cytokine production) and IRF3 (for 
type I IFN production) respectively, both have been shown to be activated in 
response to Ebola VLP stimulation in mice (30). IL-18 production requires 
inflammasome activation and caspase-1 dependent cleavage into the mature, 
bio-active form (31). In THP-1 cells (human monocytic cell line), IL-1β and IL-18 
were induced in response to Ebola GP stimulation via caspase-1 dependent 
NLRP3 inflammasome activation (25). NLRP3 inflammasome activity is thought 
to be primed by microbial ligand-dependent activation of NF-κB (via TLR 
engagement), and then activated by a secondary signal such as Ca2+ signalling, 
K+ efflux, reactive oxygen species (ROS) production or ATP (31). Although, in 
human monocytes, LPS induced TLR-4 signalling alone was shown to activate 
NLRP3 inflammasome activity without the need for a second signal (alternative 
inflammasome activation) (32). LPS induced IL-18 production in mouse bone 
marrow-derived macrophages was dependent on type I IFN signalling suggesting 
an indirect mechanism and requirement for additional cytokine stimulation (33), 
however, IFNαβR2 blockade did not reduce NK cell function in response to 
EbovGP in our in vitro system. IL-12 and the observed high levels of IL-10 are 
likely a result of direct TLR-4 signalling pathways. RNA transcriptional analysis of 
unstimulated and EbovGP stimulated whole PBMC and purified CD14+ 
monocytes to identify such pathways is underway. 
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Ad26.ZEBOV/MVA-BN-Filo vaccination, in contrast to influenza vaccination, did 
not lead to an enhancement in NK cell function or innate cytokine secretion in 
response to restimulation post-vaccination. Instead, NK cell activation in vitro, in 
particular IFN-γ secretion, was limited and highly regulated by monocyte derived 
IL-10. It is conceivable that EbovGP expression in vivo after vaccination causes 
a similarly tightly regulated immune environment, a hypothesis supported by 
monocyte-mediated negative regulation of the immune response to the rVSV-
ZEBOV Ebola vaccine (34). IL-10 supresses macrophage and DC cytokine 
secretion and T cell derived IL-2, factors important for CIML NK cell generation 
and enhanced NK cell function post-vaccination (35-37). This perhaps goes some 
way to explain the lack of CIML NK cell generation and NK cell recall responses 
to EbovGP stimulation in post-Ad26.ZEBOV/MVA-BN-Filo PBMC samples. It 
would therefore be interesting to analyse post-Ad26.ZEBOV/MVA-BN-Filo 
vaccination NK cell responses to EbovGP in the presence of IL-10 blockade. 
Vaccination did lead to lower median concentrations of some inflammatory 
cytokines (significantly so for TNF-α) in response to EbovGP compared to 
baseline (Table 4). Interestingly, this observation was limited to Ad26 prime/MVA 
boost groups that exhibited more robust T cell cytokine responses (IL-2+IFN-
γ+TNF-α+ triple positive) (38-40). As inflammatory cytokines are associated with 
increased likelihood of death in EVD (29), it may be preferable that there is no 
detectable post-vaccination enhancement of these responses. Furthermore, 
many of these responses (IL-1β, TNF-α and GM-CSF) are already of a log 
magnitude higher than those induced by H3N2 so may not be amenable to 
boosting. It is hoped that vaccine induced virus-specific immunity could limit 
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inflammatory responses upon challenge via the induction of neutralising or ADCC 
antibody function or via cytotoxic T cells restricting Ebola viral loads or by 
antibody blockade of Ebola GP stimulatory activity.  
 
Cytokine 
Median cytokine concentration 
(pg/ml)  
Baseline Post-boost P value 
GM-CSF 460.9 410.5 0.211 
IFN-α2 6.2 6.1 0.655 
IL-10 3151 2700 0.449 
IL-12(p70) ND ND  - 
IL-1β 3995 3428 0.341 
TNF-α 5542 4647 0.0232 
IFN-γ 15.2 19.5 0.111 
Table 4: Summary of cytokine concentrations secreted in vitro in response to EbovGP 
stimulation before (baseline) and after (post-boost) Ad26.ZEBOV/MVA-BN-Filo 
vaccination.  
Data taken from chapter 4. Median concentration in pg/ml measured by Luminex (n=26). Green; 
decrease over baseline. P value determined by Wilcoxon signed-rank test, significant values 
determined as p < 0.05. ND; none detected.  
 
In additional experiments, 5% pooled post-vaccination serum was unable to 
mimic the post-vaccination reduction in EbovGP induced inflammatory cytokine 
secretion in non-vaccinated, control PBMC, suggesting  that vaccine induced cell 
intrinsic changes rather than antibody-mediated blockade may be playing a role. 
Treatment of mice with an Ebola GP VLP vaccine that increased survival after 
Ebola challenge, attenuated viral replication and the Ebola-induced inflammatory 
cytokine response (41). This reduced inflammatory response was linked to robust 
type I IFN responses regulating cytokine secretion by inducing IL-10, supressing 
inflammasome activity and the formation of mature IL-1β and IL-18 (42). I did 
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observe a small but significant decrease in NK cell CD25 expression in control 
PBMC in the presence of post-boost serum compared to baseline serum 
suggesting possible antibody-mediated blockade of EbovGP interaction with 
TLR-4 (Appendix Supplementary Figure 2). Further studies on the effect of 
vaccine-induced antibody on cytokine secretion and NK cell function and the 
effect of IL-10 blockade on the inflammatory response would contribute to the 
understanding of these observations. 
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6.1.5 Antibody-Dependent NK Cell Activation after Vaccination 
 
I have also shown that anti-GP antibody in the serum of Ad26.ZEBOV/MVA-BN-
Filo vaccinated individuals induced robust antibody-dependent NK cell activation 
against immobilised EbovGP. This response strongly correlated with antibody 
titre suggesting this is a robust read out for Fc-dependent antibody induced by 
vaccination. Individual antibody level data has been requested from the vaccine 
consortium in order to perform more detailed correlations between antibody titre 
and NK cell function at an individual level. This study implicates antibody-
activated, more differentiated NK cells as important effectors of post-vaccination 
immunity against Ebola virus infection, not only for cytotoxicity but also for IFN-γ 
secretion when cytokine-dependent activation may be limited. I also found anti-
GP antibody-dependent NK cell responses varied widely between donors in the 
presence of a constant antibody source (pooled post-boost sera), which was 
partly due to differences in NK cell differentiation subset frequency. It would be 
interesting to analyse antibody-dependent NK cell function in multiple 
Ad26.ZEBOV/MVA-BN-Filo vaccinated individuals to determine the extent to 
which the combined impact of antibody titre and NK cell differentiation determines 
NK cell function. In this context, the impact of HCMV serostatus, which is 
associated with a polarisation towards antibody-dependent responses, can also 
be assessed.  
Both the production of innate inflammatory mediators and the NK cell functional 
differentiation profile are altered by age (43). The frequency of CD56dimCD57+ NK 
cells increases over a lifetime, with a reciprocal decrease in CD56bright NK cells; 
overall, NK cell IFN-γ secretion and responses to innate cytokine stimulation 
CHAPTER 6. DISCUSSION 
 
304 
 
reduces while cytotoxicity is maintained (44, 45). In African populations, where 
HCMV seropositivity is near universal by the age of three, this differentiation 
process proceeds rapidly in childhood (46). Therefore, further work is needed to 
evaluate the effect of infant vaccination in the context of higher levels of 
inflammatory cytokines and reduced NK cell differentiation and in African 
populations where both age an exposure to HCMV may influence the outcome of 
the effector NK cell response. The more refined antibody-dependent mechanisms 
may be preferential over the non-specific inflammatory cytokine-dependent 
mechanisms for NK cell activation to reduce viral loads and contribute IFN-γ. 
Figure 1 shows a schematic summary of EbovGP induced NK cell function. 
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Figure 1: Mechanisms for NK cell activation in response to Ebola GP challenge in a naïve 
and vaccinated individuals. 
Naïve donor; less differentiated NK cell (CD56bright) activation in response to monocyte (Mo) 
derived IL-12 and IL-18 released after to EbovGP TLR-4 stimulation. Monocyte derived IL-10 
mediated inhibition of NK cell IFN-γ secretion, most likely indirectly via suppression of further 
innate cytokine secretion (a). Post-vaccination; more differentiated NK cell (CD57+) activation in 
response to anti-GP antibody via CD16 crosslinking, perhaps independent of monocyte derived 
IL-12 and IL-18. Anti-GP antibody blockade of GP stimulatory effects via TLR-4 and/or IL-10 
mediated blockade of antigen-specific T cell activation may also play a role in regulating the post-
vaccination NK cell response (b).  
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6.2 Conclusions 
 
In conclusion, the generation of CIML NK cells by vaccination and subsequent 
memory-like NK cell recall responses upon restimulation is a process uniquely 
dependent on the cytokine signature secreted by the particular vaccine antigen 
involved and/or the type of vaccine administered. Although both vaccines studied 
during this thesis induced proliferation and expansion of less differentiated NK 
cells, this did not universally lead to vaccine-enhanced NK cell function. The 
utilisation of IL-15 to boost accessory cell cytokine secretion and therefore NK 
cell stimulation during vaccination could lead to better NK cell effector functions 
upon challenge, and perhaps cross-strain or universal protection. However, such 
boosting of innate immune function may only be beneficial in the context of certain 
viral infections and could be detrimental for others, including Ebola, which cause 
overt inflammatory responses. Finally, NK cell antibody-dependent activation in 
response to post-vaccination serum gathered as part of a vaccine trial, could be 
an informative and correlative readout of vaccine-induced antibody function and 
protection. 
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Figure for reviewers only; in 
relation to Chapter 2, page 126: No 
response to H3N2 or IL-15 in 
purified NK cell cultures. 
Purified NK cells or whole PBMC 
were cultured for 18 hours with 
inactivated H3N2 influenza virus with 
and without 0.75ng/ml IL-15. Plots 
snow box and whisker plots with 10th-
90th percentile. Paired statistical 
analysis by Wilcoxon signed-rank 
test. *p, 0.05, **p, 0.01, ***p, 0.001, 
****p, 0.0001. 
APPENDICES 
318 
 
 
 
Appendix Supplementary Figure 1: Nanogram concentrations of soluble IL-15 boosts the 
NK cell response to EbovGP. 
Whole PBMC from baseline (visit 0) were stimulated with 10μg/ml EbovGP alone, 0.75ng/ml IL-
15 alone, EbovGP plus IL-15 or left unstimulated (medium) for 18 hours, n=72. Cells were stained 
for NK cell activation markers and analysed by flow cytometry. Frequencies of IFN-γ+, CD107a+ 
and CD25+ NK cells were gated using medium alone controls; gating strategies are shown in 
Chapter 4, Figure 2a. Graphs show NK cell IFN-γ (a), CD107a (b) and CD25 (c) expression as 
box and whisker plots with median, interquartile range (IQR) (box) and 10th-90th percentile 
(whiskers). Comparisons across conditions were performed using one-way ANOVA with Dunn’s 
correction for multiple comparisons. ****p < 0.0001. 
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Appendix Supplementary Figure 2: Ad26.ZEBOV/MVA-BN-Filo vaccine-induced antibody 
mediated reduction in NK cell CD25 expression. 
Non-vaccinated control PBMC were stimulated with EbovGP or left unstimulated in the presence 
of pooled pre (baseline; visit 0) or post (post-boost; visit 2) vaccination serum for 18 hours, n=16. 
NK cell CD25 expression was determined by flow cytometry; gating strategies are shown in 
Chapter 4, Figure 2a. Graphs show CD56bright NK cell CD25 percentage (a) and MFI (b), 
CD56dimCD57- (c) and CD56dimCD57+ (d) CD25 percentage. Graphs show one point per donor 
with median and IQR. Comparisons between conditions were performed using Wilcoxon signed-
rank test. *p < 0.05, **p < 0.01, ****p < 0.0001. 
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Abstract
Vaccination has proved to be highly effective in reducing global
mortality and eliminating infectious diseases. Building on this
success will depend on the development of new and improved
vaccines, new methods to determine efficacy and optimum dosing
and new or refined adjuvant systems. NK cells are innate lymphoid
cells that respond rapidly during primary infection but also have
adaptive characteristics enabling them to integrate innate and
acquired immune responses. NK cells are activated after
vaccination against pathogens including influenza, yellow fever
and tuberculosis, and their subsequent maturation, proliferation
and effector function is dependent on myeloid accessory cell-
derived cytokines such as IL-12, IL-18 and type I interferons.
Activation of antigen-presenting cells by live attenuated or whole
inactivated vaccines, or by the use of adjuvants, leads to enhanced
and sustained NK cell activity, which in turn contributes to T cell
recruitment and memory cell formation. This review explores the
role of cytokine-activated NK cells as vaccine-induced effector cells
and in recall responses and their potential contribution to vaccine
and adjuvant development.
Keywords: accessory cell, cytokines, NK cell, vaccination.
INTRODUCTION
Vaccination is a cost-effective way of reducing the
burden of, eliminating and – in exceptional cases –
eradicating infectious diseases. Whilst a number of
effective vaccines are currently licenced, many highly
prevalent and complex diseases remain without
effective prophylactic vaccines. Protective titres of
neutralising antibodies and expanded populations
of effector and memory B and T lymphocytes
are viewed as measures of protection for many
vaccines. Currently, the generation of durable
antigen-specific memory forms the basis of vaccine
development and evaluation of vaccine efficacy.1,2
Developing vaccines to overcome pathogen
polymorphism and complexity demands new
approaches to vaccine design and evaluation; this in
turn requires the identification of novel correlates of
protection and determination of optimal dosing
schedules. The activation of Natural Killer (NK) cells
represents a potential route for further optimisation
of vaccination strategies by harnessing their role as
antipathogen effector cells which integrate innate
and acquired immune responses.
NK cells are large, granular, type 1 lymphoid
cells that express a wide variety of germline-
encoded receptors on their surface. Direct NK cell
activation is controlled by the balance between
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signals transduced by inhibitory and activating
receptors; NK cells are also activated indirectly by
innate cytokines such as type I interferons (IFN),
IL-12, IL-15 and IL-18, released from accessory
cells.3 Because NK cells do not rearrange receptors
to permit antigen-specific recognition, they are
normally classified as cells of the innate immune
system. NK cells are among the first cells to
respond during primary infection and contribute
to the early control of viral infections including
herpesviruses and influenza infections.4–8
However, NK cells can also augment and shape
the subsequent adaptive response by secretion of
cytokines (including IFN-c) and chemokines (such
as IP-10, MIP-1a and MIP-1b), reducing viral loads
by killing infected cells, inhibiting viral entry and
replication by production of chemokines which
compete for human immunodeficiency virus (HIV)
coreceptor CCR59 and by controlling expansion of
the CD4+ T cell compartment.10,11 In turn, the
secondary (adaptive) immune response can
activate NK cells via secretion of cytokines such as
IL-2 from CD4+ T cells and via FccRIIIa (CD16)-
dependent recognition of antigen-antibody
complexes.12–14
Several studies have shown that NK cells can
acquire some features of adaptive lymphocytes,
raising the possibility that the memory-like
properties of these cells could be induced or
enhanced by vaccination. Early examples of NK
cell adaptive features arose from mouse studies of
murine cytomegalovirus (MCMV) and hapten-
induced contact hypersensitivity. The MCMV viral
protein m157 on the surface of infected cells was
shown to recognise NK cell Ly49H receptor and
leads to clonal expansion of effector NK cells and
generation of a pool of self-renewing m157-
responsive NK cells; these cells respond robustly to
subsequent MCMV infection when transferred to
naive mice.15 NK cells from Rag2/ mice were
shown to transfer hapten-specific memory-like
responses (lasting up to 4 weeks) to naive mice
despite the absence of T and B cell immunity.16
More recently, virus antigen-specific NK cell killing
has been reported in rhesus macaques,17 and
there are suggestions of pathogen-specific
responses among human NK cells. These include
influenza hemagglutinin (HA) antigen recognition
by NK cell NKp46 and HLA-E stabilisation by
HCMV peptides for recognition by NK cell CD94/
NKG2C heterodimers.18–20
An increasing number of studies in humans
demonstrate activation of NK cells during recall
responses to pathogens in vaccinated subjects. In
vitro NK cell responses to components of the DTP
vaccine (diphtheria toxoid, tetanus toxoid and
whole cell inactivated pertussis), Bacille Calmette–
Guerin (BCG) and influenza vaccine are enhanced
after vaccination14,21–23 and heightened NK cell
IFN-c and degranulation responses have been
detected after vaccination against rabies.24 In
contrast to the memory responses described above,
these postvaccination responses are dependent on
vaccine-specific CD4+ memory T cells and, in
particular, their rapid secretion of IL-2.23,24
Although the ‘antigen-specificity’ of these
postvaccination NK cell responses resides in the
CD4+ T cell pool, the NK cells are also modified as a
result of vaccination. Innate cytokines, which can
be induced by live or killed whole pathogen
vaccines or by adjuvants, are potent NK cell
activators and can induce their differentiation into
cytokine-induced memory-like (CIML) NK cells. First
described as being generated by cytokine coculture
in vitro, CIML NK cells have an enhanced ability to
secrete IFN-c and become cytotoxic in response to
cytokine and MHC-devoid K562 cell restimulation
for up to 21 days after the initial stimulation.13,25–27
In vitro cytokine activation with IL-18 and IL-12 and/
or IL-15 induces expression of CD25, thereby
generating CIML NK cells with enhanced
responsiveness (demonstrated by IFN-c production
and cytotoxicity) to picomolar concentrations of
IL-2.28 More importantly perhaps, CIML NK cells can
be induced by vaccination in response to CD4+ T
cell-derived IL-2 and myeloid cell-derived IL-12 and
type I interferons, and have been implicated in the
enhancement of NK cell function ex vivo.13,24,29–33
Vaccination-induced CIML NK cells can be detected
for up to 12 weeks postvaccination in European
subjects13 and up to 6 months in west African
vaccines.33 Table 1 summarises the evidence for
vaccination-induced CIML NK cells.
Immature CD56bright and CD56dimCD57 NK cells
are more responsive to exogenous cytokines and
produce more IFN-c than do the more mature,
predominantly cytotoxic, CD56dimCD57+ NK cell
subset.34 Accordingly, vaccination-induced CIML
NK cells are restricted to the less differentiated
subsets of NK cells and their induction is accompanied
by proliferative expansion of the least mature
CD56bright NK cells and CD56dimCD57NKG2C/+
subsets.13,33 Enrichment of less differentiated NK
cells in lymph nodes and effector tissues could
influence the impact of CIML NK cells induced by
vaccination. The highest proportion of human
2018 | Vol. 7 | e1010
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immature CD56bright (CD16) NK cells are found in
the lymph nodes12,35 and produce IFN-c in
response to CD4+ T cell-derived IL-2, thereby
potentially influencing subsequent adaptive
responses.12 A higher percentage of adoptively
transferred pre-activated CIML NK cells were
found in the lymph nodes of mice compared to
control NK cells25 and localised in the bone
marrow, spleen and blood of mice and in the
bone marrow of patients with acute myeloid
leukaemia.27 The tissue localisation of NK cells
amenable to cytokine-mediated pre-activation
may also be crucial to functional outcomes.
Human liver, in contrast to secondary lymphoid
tissues, is enriched for resident CD56bright NK
cells with high natural cytotoxicity receptor and
NKG2D expression, strong target cell-mediated
degranulation but poor IFN-c production.36
Tissue-resident innate lymphoid cells (ILC) which
are phenotypically distinct from NK cells may,
however, also be sensitive to pre-activation by
vaccine-induced cytokines. Murine liver ILC-1, for
example, is highly sensitive to IL-12 stimulation
and produces more IFN-c at the sites of MCMV
infection.37 When taken together with the
emerging literature on the impact of persistent
viral infections (such as human cytomegalovirus
infection (HCMV); see below) on NK cell func-
tion,14 it is possible that differences between or
within human populations in proportions of
CIML NK cells (due to differences in recent infec-
tion and vaccination history) may contribute
to differences in vaccine immunogenicity and
effectiveness.33,38,39
Expanded populations of highly differentiated
NK cells in individuals chronically infected with
HCMV were first described more than a decade
ago.40 Many of these highly differentiated cells
were subsequently shown to have undergone key
intrinsic changes such as the loss of the signalling
molecules FceRc, SYK and EAT-2, associated with
stable epigenetic changes in the promotor regions
of genes involved in NK cell function, including
IFN-c.41–43 These ‘adaptive’ NK cells display
enhanced antibody-dependent cellular cytotoxicity
(ADCC) activity towards HCMV-infected target
cells suggesting they are specialised for
controlling virus reinfection or reactivation and
antigen-specific.44,45 However, despite the likely
dominance of such adaptive cells in populations
with endemic HCMV infection, the generation of
CIML from less differentiated NK cells persists
after vaccination33 (reviewed in ref. 46). It
appears, therefore, that there is a balance of CIML
and highly differentiated NK cell effectors which
may be altered by vaccination. Less differentiated
NK cells are shorter-lived, possess higher levels of
cytokine receptors and higher intrinsic
proliferative capacity; vaccination may simply
contribute to the homoeostatic maintenance of
these cells. The benefits of preferentially
expanding and generating CIML NK cells from
these subsets are unknown but could be more
functionally significant in young infants where
highly differentiated cytotoxic effectors are
lacking.47 On the other hand, loss of IL-12
responsiveness and independence of this cytokine
for IFN-c production is a well-known feature of
more differentiated NK cell effectors; more
focused antibody-driven responses may be
advantageous in restricting the potential for
inflammation associated damage in older
individuals.
In the remainder of this review, we explore in
more detail the potential role of NK cells,
activated by myeloid cell-derived cytokines or by
components of adaptive immunity (CD4+ T cell
IL-2 or pathogen-specific antibodies), as effectors
Table 1. Evidence of induction of human cytokine-induced memory-like (CIML) NK cells by vaccination
Pathogen Host species Vaccination
Increased
responsiveness
in vitro Duration of response References
Influenza Human TIV IL-12, IL-15, IL-18 3 months (UK) or
6 months (Gambia)
Goodier et al.60 and
Darboe et al.33
YFV Human YF-17D IL-12 15 days Marquardt et al.30
SIV Macaque Ad26 HIV-1,
DNA-Ad26
IL-12, IL-15 38 weeks Vargas-Inchaustegui et al.77
TB Human BCG IL-12, IL-18 ND Suliman et al.29
ND, not determined.
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of vaccination against a number of globally
important infectious diseases.
INFLUENZA
Seasonal influenza epidemics result in 3–5 million
cases of influenza globally and up to half a
million deaths every year as well as putting
intolerable pressure on health systems and
causing major economic losses.48 Annual variation
in the predominant circulating strains of influenza
viruses mitigates vaccine-induced or naturally
acquired cross-protective immunity, necessitating
annual revaccination of high-risk groups
(pregnant women, children of 6 months to
5 years and the elderly).48 A cross-protective
‘universal’ influenza vaccine is a major priority for
influenza vaccine development.
Influenza virus induces secretion of innate
cytokines (including IFN-a, IL-12 and IL-18) from
accessory cells such as macrophages and
dendritic cells (DCs); in turn, these cytokines
support the very rapid activation of NK cells
(within hours of infection).49,50 These activated NK
cells are cytotoxic, secrete IFN-c and upregulate
cytokine receptors such as CD25 (IL-2Ra)51 and
can reciprocally activate DCs, thereby promoting
T cell recruitment to sites of infection and
to lymph nodes.52 In vitro restimulation of
peripheral blood mononuclear cells (PBMC) from
trivalent influenza vaccine (TIV)-vaccinated
volunteers with inactivated influenza virus induces
much higher frequencies of IFN-c producing
and degranulating NK cells compared to restimu-
lation of prevaccination PBMC from the same
people.13,18,23,53 The heightened NK cell response
becomes evident as early as 2 weeks postvaccina-
tion but is normally lost by 12 weeks. Postvacci-
nation enhancement of NK cell IFN-c production
was dependent on IL-2 produced from CD4+ T
cells, whilst degranulation responses were
dependent on IL-2 and on the presence of anti-
influenza antibody.13,23 A costimulatory role for
innate myeloid cell-derived cytokines was also
demonstrated by partial inhibition of TIV restim-
ulation responses with IL-12, IL-18 and IFN-abR2
blockade.13
Indeed, consistent with the generation of CIML
NK cells, antigen-independent in vitro responses
to exogenous IL-12 and IL-18 were also elevated
for up to 3 months after influenza vaccination in
a UK study,13 but this response was detected for
up to 6 months in African subjects.33
Enhancement of NK cell responses after influenza
vaccination is therefore mediated by indirect
mechanisms involving antigen-specific cellular
CD4+ and humoral responses combined with a
shorter-lived CIML component. Such enhanced NK
cell function after seasonal influenza vaccination
may contribute to protective immunity to
influenza, but, given the dependence on antigen-
specific T cells and antibodies, does not in itself
overcome the need for regular revaccination.
However, the search for a ‘universal influenza
vaccine’ has identified the conserved ‘stalk’ of the
polymorphic HA molecule54 and other nonvaccine
antigens55 as possible targets of broadly
neutralising antibodies which mediate ADCC.56,57
Stalk-specific antibodies that mediate NK cell
ADCC are present after natural infection and after
vaccination with TIV or monovalent adjuvanted
H1N158 and nucleoprotein (NP)-specific ADCC-
mediating antibodies induced by seasonal
influenza vaccination demonstrate cross-reactivity
with H7N9 avian influenza NP.59 As mature
CD56dimCD57+ NK cells and HCMV-induced
‘adaptive’ NK cells are both potent mediators of
ADCC and preferentially respond to influenza
antigens after vaccination,60 NK cells may be of
particular importance as effectors of the next
generation of universal influenza vaccines.
YELLOW FEVER
The live attenuated yellow fever virus (YFV)
vaccine 17D is one of the most effective vaccines
developed to date; 99% of recipients are
protected for more than 10 years after a single
vaccination.61 For this reason, YF-17D has been
used as a tool to identify highly effective early
(innate) immune responses to acute viral infection
in humans.30,62 YFV infects and induces TLR-
mediated signalling in hepatocytes and cells of
the innate immune system such as monocytes and
DCs. In mouse models of YFV infection or YF-17D
vaccination, NK cells accumulate in the spleen and
are major producers of IFN-c.63,64 Induction of
innate cytokines such as IL-1a and chemokine
IP-10 (CXCL10), and upregulation of the early
activation and proliferation markers CD69 and
Ki-67 on NK cells are detected as early as 3 days
postvaccination in humans.30,62,65 NK cell
activation peaks at the same time as viral load,
6 days postvaccination and correlates directly with
a rise in plasma type I and type III interferons.
Thereafter, viral load and NK cell responses
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decline rapidly returning to baseline by day 10
and 15 postvaccination, respectively.30,65
In a study in Uganda, pre-existing IFN-c producing
NK cells in an activated immune microenvironment
were associated with lower viral loads and
subsequently reduced antibody titres after YF-17D
vaccination.38 NK cell IFN-c responses to YFV
correlated with increased in vitro responsiveness of
less differentiated NK cells to innate cytokines such
as IL-12 after vaccination30 suggesting that, as for
influenza vaccines, YF-17D-induced accessory cell-
derived cytokines may also induce development of
CIML NK cells. As in influenza vaccination, this
pre-activation state is short-lived suggesting that
there is no lasting imprint on the NK cell repertoire.
These transient innate responses (including NK
cells) may, however, synergise with antigen-specific
vaccine-induced responses resulting in the
formation of particularly durable and effective T
cell- and B cell-mediated immunity to YFV.30,65 A
more robust mechanistic understanding of the
induction and function of CIML NK cells during
infection or vaccination with YFV and other
flaviviruses will help to define their role.
HUMAN IMMUNODEFICIENCY VIRUS
HIV remains highly prevalent across the world
with 2.1 million new infections estimated in 2015;
lifelong treatment is required to prevent disease
and death, which places a considerable burden on
health systems worldwide.66 A prophylactic HIV
vaccine is of utmost priority. HLA-I and killer cell
immunoglobulin-like receptor (KIR) genotype and
NK cell education influence killing of HIV-1-
infected CD4+ T cells and are associated with the
rate of progression of HIV infection.67,68 In the
partially successful RV144 vaccine trial, IgG against
variable regions 1 and 2 of the HIV-1 envelope
glycoprotein was inversely correlated with the
rate of infection.69 Indeed, RV144 induced
isotypes IgG1 and IgG3 targeting the crown of the
V2 loop demonstrating the potential for NK cell
ADCC induction.70,71 NK cells from KIR3DL1/HLA-
Bw4+ or KIR2DL1/HLA-C2+ donors show higher
cytotoxicity against HIV-infected targets in the
presence of anti-HIV gp120 antibody, highlighting
the influence of NK cell education to HIV vaccine-
induced effector NK cells and potentially
contributing to individual variability in vaccine
outcomes.72,73 CD57+NKG2C+ memory-like NK cells
are expanded in HIV-1/HCMV co-infected
individuals, and these cells make a potential
contribution to control of viremia during primary
HIV infection.74,75 Together with evidence that
individuals with a degree of inherent resistance to
HIV – so-called elite controllers or slow
progressors – mount stronger antibody-mediated
NK cell activation and ADCC responses than more
susceptible individuals, these studies suggest that
NK cells may contribute to HIV protection and
control.76
NK cells have been implicated as antigen-
specific effector cells after vaccination or infection
of nonhuman primates with simian
immunodeficiency virus (SIV); target cells pulsed
with SIV vaccine antigen but not heterologous
antigens can be lysed in vitro by splenic and
hepatic NK cells from infected but not from
uninfected animals.17 These antigen-specific
responses could be detected for at least 5 years
after SIV DNA/adenovirus prime-boost vaccination,
suggesting that this memory-like response is long-
lived.17 By contrast, no significant potentiation of
circulating NK cell function was observed after SIV
infection or vaccination; rather, SIV infection
impaired the cytotoxic response of peripheral
blood NK cells.77 However, a trend towards
increasing in vitro NK cell CD107a expression in
response to IL-15 and IL-12 postvaccination
suggests that memory-like NK cells with enhanced
cytokine responsiveness may have been induced in
this study.77
In HIV patients, therapeutic HIV vaccination or
IL-2 treatment sustains or enhances NK cell
activity.32,78 Immunisation of chronically infected
patients with an adjuvanted HIV-1 Gp120/NefTat
subunit protein vaccine induces IL-2 from T helper
cells and an increase in NK cell IFN-c production
in vitro; NK cell IFN-c production was reduced by
depletion of CD4+ T cells and almost completely
abrogated after blocking both IL-2 and IL-12,
suggesting a role for accessory cells in full NK cell
effector functions after vaccination.32 These, and
other, studies highlight the potential of
therapeutic vaccination to restore NK cell function
during chronic HIV infection.32,79
EBOLA
Several vaccines are in development for the
prevention of Ebola virus disease (EVD). Two
vectored vaccines that express the glycoprotein
(GP) from the Zaire strain of Ebola (ZEBOV) and
use the recombinant vesicular stomatitis virus and
Chimp Adenovirus type 3 (rVSV-ZEBOV and
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ChAd3-ZEBOV, respectively) are the most
advanced of these.80 Ebola virus has a wide range
of host cell targets including macrophages and
DCs, infection of which aids viral dissemination
and crucially leads to immune dysregulation.81
Little is known about the role of NK cells in Ebola
virus infection but in vitro studies show IFN-
inhibiting domains (IIDs) within Ebola viral
proteins VP24 and VP35 interrupt DC maturation
and type I IFN signalling leading to somewhat
impaired NK cell activation and cytotoxicity.82
Disrupting either of these IIDs restores DC
maturation and NK cell activation as measured by
NKp46 and CD38 expression.82 Another study
showed that Ebola virus-like particles (VLPs)
lacking IIDs activated NK cells and led to lysis of
filovirus-infected autologous human DCs in
culture and pro-inflammatory cytokine release.83
Activation of the early inflammatory response
and release of cytokines such as IP-10, IL-1b, IL-6
and TNFa, correlated with survival from EVD in
humans81,84 and mice can be protected against
Ebola by adoptive transfer of NK cells from VP40
containing VLP-treated mice.85 Increased survival
of mice after postexposure vaccination with the
candidate vaccine rVSVΔG-EBOV is reversed by NK
cell depletion;86 postexposure vaccination
stimulated a burst of IFN-c release and type I IFN
secretion from accessory cells, potentially kick-
starting the antiviral response and overcoming the
blockade caused by IIDs.86 Postexposure antibody
therapy has also been shown to give effective
protection in animal models via ADCC activity.87,88
These studies implicate NK cells as important
effectors in protection against Ebola virus
infection and in vaccine-induced immunity and
raise the potential of indirect cytokine activation
of NK cells to restrict virus dissemination after
therapeutic vaccination.
MALARIA
The role of NK cells in natural immunity or
vaccine-induced protection against malaria
infection remains to be established.89 NK cell
activation has been described to varying degrees
in different experimental murine models90,91 and
NK cells have been shown to contribute directly
to the elimination of Plasmodium falciparum-
infected red blood cells (RBC) in a humanised
mouse model.92 In vitro studies of human PBMC
show NK cells are readily activated by
P. falciparum-infected RBC; the resulting NK cell
proliferation, IFN-c production, CD25 and CD69
expression were further demonstrated to be
dependent on IL-2 and accessory cell IL-12 and IL-
18 production and on cell–cell contact.93–96 In
humans, long-lasting NK cell activation has been
reported in controlled human malaria infection
(CHMI) studies; a decrease in peripheral blood NK
cell frequency early after infection suggests
migration of NK cells into the tissues, possibly the
liver.97–99
RTS,S/AS01 is the most promising vaccine tested
to date for human P. falciparum malaria. RTS,S
consists of recombinant circumsporozoite surface
protein (CSP) of P. falciparum fused to the
hepatitis B virus surface antigen (HBs) and
adjuvant delivery system (AS)01 formed into VLPs.
PBMC collected from a RTS,S randomised
controlled trial revealed postvaccination IL-2
secretion with IFN-c and CD69 upregulation on
NK cells in response to in vitro restimulation with
HBs or CSP. All responses were significantly higher
in RTS,S vaccines compared to control rabies
vaccinated subjects.31 A weak association has been
reported between IL-2 secreting CD4+ T cells and
time to parasitaemia, accompanied by an increase
in the proportion of CD56bright NK cells, higher
IFN-c and perforin expression, and protection
against malaria challenge in vaccine recipients has
also been reported.100 Interestingly, peripheral
blood NK cell gene expression signatures were
negatively correlated with RTS,S-induced malaria
protection, consistent with migration of activated
blood NK cells to the tissues,101 which implies that
peripheral NK cell responses to malaria play a
minimal role in vaccine responses.
TUBERCULOSIS
The live attenuated BCG vaccine is the only
vaccine currently licenced for the prevention of
tuberculosis disease (TB) caused by Mycobacterium
tuberculosis (M.tb) and is administered to over
120 million infants each year.102 NK cells are an
important component of the cellular immune
response to BCG, producing more than half of the
total IFN-c after vaccination in newborns and 2-
month-old infants.102
BCG, and other live vaccines such as measles
vaccine, have been shown to induce nonspecific
effects that are beneficial to the recipient and
reduce overall mortality in a community.103,104
Potential underlying mechanisms include T cell-
mediated cross-reactivity and/or ‘training’ or
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‘priming’ of innate immune cells, including
monocytes and NK cells. Increased expression of
pattern recognition receptors (PRR) in monocytes,
and higher levels of IFN-c, TNFa and IL-1b
secretion have been observed when PBMC from
BCG-vaccinated individuals are restimulated with
mycobacterial or unrelated antigens, compared to
prevaccination PBMCs.22 These effects persisted
for up to 12 months after BCG vaccination and
were partly attributed to epigenetic remodelling
of key cytokine gene loci and have been termed
‘trained immunity’. Similarly, increased NK cell
CD69 expression in response to Pam3Cys has been
reported in post-BCG vaccination samples from
infants and correlated with higher concentrations
of IL-12 secretion.105 Interestingly, no changes in
NK cell phenotype, maturation or IFN-c
production were reported in BCG-trained NK
cells,106 suggesting that they are not equivalent to
CIML NK cells.
Enhancement of NK cell IFN-c responses to BCG
has been reported after BCG vaccination of
patients with latent TB29 and in 5-week-old
infants who were BCG-vaccinated at birth
compared to unvaccinated controls;29 NK cell
responses were completely abrogated by
neutralisation of IL-12 and IL-18.29 Consistent with
studies of other whole organism vaccines, as
described above, these studies indicate that
enhanced responsiveness to cytokines is a key
feature of vaccine-mediated effects on NK cells.
THE ROLE OF VACCINE ADJUVANTS IN
PROMOTING NK CELL RESPONSES
Killed whole organism or live attenuated vaccines
are both highly immunogenic and particularly
effective at potentiating NK cell responses; both
of these traits likely reflect the presence of potent
pathogen-associated molecular patterns (PAMPs)
Figure 1. Accessory cell-dependent NK cell activation after vaccination. (a) Activation of APCs by live attenuated or inactivated whole organism
vaccines induces the release of costimulatory cytokines which in turn leads to NK cell activation including IFN-c release, degranulation and CD25
upregulation. (b) Adjuvants promote accessory cell function for subunit or vectored vaccines in the absence of vaccine-derived PAMPs. (c) Upon
secondary exposure, IL-2 from memory CD4+ T cells, antibody and the presence of CIML NK cells enable an enhanced response.
ª 2018 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of
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for PRR-mediated accessory cell activation. PAMP-
containing adjuvants are typically required to
improve the immunogenicity of subunit or
vectored vaccines, which lack these ligands.
Several studies have documented enhancement of
NK cell activation by adjuvants.32,107,108 IL-15-
matured DCs exposed in vitro to the TLR-4 agonist
AS04-adjuvanted human papilloma virus (HPV)
VLP vaccine can potentiate NK cell activation and
killing of HPV-infected cells compared to either IL-
4-matured DCs or VLP alone; this effect was
attributed to the superior cytokine-producing
ability of the DCs.109 Similarly, vaccination in the
presence of exogenous IL-15 enhances DC
maturation and protection against lethal
staphylococcal enterotoxin B challenge in mice
compared to vaccine alone.110
AS03, a squalene-based adjuvant, promotes
recruitment of antigen-presenting cells (APCs) and
antigen processing. A system-wide analysis of the
response to AS03-adjuvanted inactivated H5N1
influenza vaccine revealed a direct correlation
between IP-10, type I and II interferon production,
and enhanced NK cell activation and
proliferation.111,112 Similarly, a bursin-like peptide
shown to stimulate immune cells induced higher
levels of IL-2 and IL-4 and increased NK cell
frequencies and IFN-c secretion in mice vaccinated
with inactivated influenza H9N2 compared to
vaccine alone.113 Taken together, these studies
indicate that PRR-mediated activation and
maturation of accessory cells such as DCs by vaccine
adjuvants increase the production of costimulatory
cytokines leading to heightened NK cell activation.
Whether these NK cells share features of CIML NK
cells has not yet been formally tested.
CONCLUDING REMARKS
Although there is now considerable evidence of
enhanced NK cell responses after vaccination, the
functional importance of NK cells in vaccination-
induced immunity is rather difficult to evaluate.
The NK cell response to vaccination varies
depending on the type of vaccine, the cytokine
signature induced by the vaccine/adjuvant
combination and subsequent accessory cell
activation (Figure 1). The ability of NK cells to
respond to signals from both innate and adaptive
immune cells suggests that when one arm of the
immune response is impaired, such as T cell
responses in HIV infection or innate cell
dysregulation in EVD, NK cells may play an
important immune effector role, maximising the
impact of the remaining arm of the immune
system. Successful activation of APCs and induction
of an early inflammatory response by a vaccine
correlate with enhanced and sustained NK cell
activation and function. Importantly, NK cell
education by HLA-KIR or other receptor-ligand
combinations may well calibrate functional
capacity on induction by both adaptive and innate
pathways thereby driving individual variability in
vaccine-induced responses. The addition of
adjuvant systems to vaccines to increase accessory
cell activation and therefore augmenting NK cell
function including ADCC activity could play a role
in the future design of new vaccines, postexposure
therapy, therapeutic cancer vaccines, regimen
optimisation and evaluation of vaccine efficacy.
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IL-15 Promotes Polyfunctional NK Cell Responses to
Influenza by Boosting IL-12 Production
Helen R. Wagstaffe,* Carolyn M. Nielsen,*,† Eleanor M. Riley,*,‡ and Martin R. Goodier*
IL-15 is a key regulator of NK cell maintenance and proliferation and synergizes with other myeloid cell–derived cytokines to
enhance NK cell effector function. At low concentrations, trans-presentation of IL-15 by dendritic cells can activate NK cells,
whereas at higher concentrations it can act directly on NK cells, independently of accessory cells. In this study, we investigate the
potential for IL-15 to boost responses to influenza virus by promoting accessory cell function. We find that coculture of human
PBMCs with inactivated whole influenza virus (A/Victoria/361/2011) in the presence of very low concentrations of IL-15 results in
increased production of myeloid cell–derived cytokines, including IL-12, IFN-a2, GM-CSF, and IL-1b, and an increased fre-
quency of polyfunctional NK cells (defined by the expression of two or more of CD107a, IFN-g, and CD25). Neutralization
experiments demonstrate that IL-15–mediated enhancement of NK cell responses is primarily dependent on IL-12 and partially
dependent on IFN-abR1 signaling. Critically, IL-15 boosted the production of IL-12 in influenza-stimulated blood myeloid
dendritic cells. IL-15 costimulation also restored the ability of less-differentiated NK cells from human CMV-seropositive indi-
viduals to respond to influenza virus. These data suggest that very low concentrations of IL-15 play an important role in boosting
accessory cell function to support NK cell effector functions. The Journal of Immunology, 2018, 200: 2738–2747.
I
nterleukin-15 is essential for the survival, proliferation, and
functional integrity of NK cells and is being exploited to
enhance NK cell–mediated immunotherapies (1, 2). IL-15
augments NK cell expression of perforin, granzyme B, natural
cytotoxicity receptors NKp30 and NKp44 (3), and the activating
receptor NKG2D (4). The potency of IL-15, even at very low
concentrations, is due, in part, to its presence as a complex with
the a-chain of its own receptor (IL-15Ra) at the surface of APCs
(5), where it can be presented to the same cell (cis-presentation) or
to neighboring cells (trans-presentation), such as NK cells and
CD8+ T cells that express IL-15Rb and the common g-chain re-
ceptor (IL-15Rbgc) (6).
Dendritic cells (DCs) can be induced to present IL-15 at their
surface by microbial ligands signaling through TLR and by innate
cytokines, such as GM-CSF and type I IFN (7, 8). DC-mediated
NK cell activation is dependent, in part, on IL-15 that polarizes to
the DC–NK cell synapse during conjugate formation (9). Although
IL-15 is believed to mediate the majority of its effects via trans-
presentation by IL-15Ra, at high concentrations it can bind di-
rectly to IL-15Rbgc and, thereby, activate NK cells (10). Furthermore,
at very high concentrations, free IL-15 may bind to IL-15Ra
on neighboring cells for cis- or trans-presentation (5, 11). Low
concentrations of IL-15 alone induce negligible NK cell acti-
vation, but IL-15 is highly synergistic with other cytokines and
with recall Ags, such as influenza, for NK cell CD25 and IFN-g
expression (12, 13).
IL-15 trans-presentation is being explored for cancer im-
munotherapy; induction of constitutive expression of IL-15 and
IL-15Ra by DCs or the use of soluble IL-15/IL-15Ra complexes
has been shown to enhance NK cell antitumor activity in vitro and
in preclinical mouse studies (reviewed in Ref. 14). Another
strategy for NK cell immunotherapy includes activation of NK
cells with IL-12, IL-15, and IL-18 prior to adoptive transfer, which
reduces tumor growth in mice (15). Preactivation of PBMCs with
high concentrations of IL-15 can also restore impaired NK cell
cytotoxicity of SIV-infected macaques (16). Although these
studies are consistent with direct NK cell priming by IL-15 at high
concentration, or synergy with myeloid cell–derived cytokines at
low concentration, the potential for IL-15 to amplify the myeloid
cell response has not been thoroughly explored. However, one
study has shown that TLR-induced maturation of DCs is enhanced
in the presence of IL-15, leading to increased NK cell cytotoxicity
toward human papillomavirus (HPV)-infected cells (17).
We hypothesized that, in addition to NK cell activation by trans-
presentation and other direct effects, IL-15 could have indirect
effects on the response of human NK cells to viruses by promoting
NK cell–activating cytokines from accessory cells. We show that
very low concentrations of IL-15 (0.75 ng/ml) dramatically en-
hance the production of IL-12, IFN-a, IL-1b, and GM-CSF from
myeloid accessory cells in response to inactivated whole influenza
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virus (A/Victoria/361/2011) (H3N2) and that increased production
of IFN-a and, in particular, IL-12 is associated with heightened
and sustained activation of NK cells and polyfunctionality of the
responding NK cells. Furthermore, IL-15–mediated enhancement
preferentially boosts IL-12 production in myeloid DCs (mDCs)
compared with other blood DC populations and monocytes. These
studies suggest that IL-15–enhanced accessory cell function may
potentiate NK cell responses, providing an additional avenue of
interest for boosting NK cell effector responses in vaccination and
NK cell–mediated immunotherapy.
Materials and Methods
Study participants
Volunteers were recruited from the staff and students at the London School
of Hygiene and Tropical Medicine (n = 84) using an anonymized volunteer
database. The study was approved by the London School of Hygiene and
Tropical Medicine Research Ethics Committee (reference numbers 6237
and 6324). Human CMV (HCMV) serostatus was determined for each
donor with HCMV IgG ELISA (Biokit, Barcelona, Spain) using plasma
collected from heparinized whole blood. Donors ranged in age from 20 to
77 y, with a median age of 32 y. Twenty-nine (35%) of the donors were
male, and 48% were HCMV seropositive.
PBMC isolation and in vitro culture assays
PBMCswere isolated from heparinized whole blood using Histopaque 1077
(Sigma-Aldrich, Gillingham, U.K.) gradient centrifugation. Cells were
rested for 2 h and were used fresh (blocking experiments and IL-12 in-
tracellular staining) or were cryopreserved in liquid nitrogen (all other
experiments). Before use, frozen cells were thawed and washed in RPMI
1640 supplemented with 100 U/ml penicillin/streptomycin and 20 mM L-
glutamine (Life Technologies, Thermo Fisher). Cells were counted using a
Countess II FL Automated Cell Counter (Invitrogen, Thermo Fisher);
average viability after thaw was 86%. A total of 3 3 105 cells per well was
cultured in RPMI 1640 supplemented as above with 5% pooled human AB
serum for 6, 9, or 18 h at 37˚C in 96-well round-bottom plates with 2 mg/ml
H3N2 (IVR-165; National Institute for Biological Standards and Control,
Potters Bar, U.K.), with or without 0.75 ng/ml recombinant human IL-15
(PeproTech, London, U.K.). Concentrations were determined by prior ti-
tration; 2 mg/ml H3N2 was the lowest concentration to induce significant
NK cell IFN-g upregulation without the presence of additional cytokines,
and 0.75 ng/ml IL-15 was previously shown to be the lowest concentration
to synergize with other cytokines for NK cell activation, without significant
NK cell activation alone (13). Additional cultures were stimulated with a
high concentration of cytokines consisting of IL-12 (5 ng/ml; PeproTech)
and IL-18 (50 ng/ml; R&D Systems, Oxford U.K.). The following Abs
were used for blocking experiments: anti–IL-2 (3 mg/ml; BD Biosciences,
Oxford, U.K.), rat IgG2a isotype control (3 mg/ml; eBioscience, Thermo
Fisher), anti–IL-12 (3 mg/ml; BD Biosciences), anti–IFN-abR2 (1 mg/ml;
Merck Millipore, Watford, U.K.), and combined mouse IgG1 and IgG2a
isotype controls (3 mg/ml final; eBioscience). GolgiStop (monensin; 1/
1500 concentration) and GolgiPlug (brefeldin A; 1/1000 final concentra-
tion; both from BD Biosciences) were added for the final 3 h of culture.
Culture supernatants were collected and stored at 280˚C. For control
experiments, NK cells were purified (mean purity 87%) using an NK Cell
Isolation Kit (Miltenyi Biotec), and 2 3 105 cells were stimulated for 18 h
under the conditions described above for PBMC cultures. Cells were stained
with NK cell activation markers as before. For IL-12 intracellular staining
experiments, 2 3 106 cells per well were cultured as above for 18 h, with
GolgiStop and GolgiPlug for the final 5 h.
Flow cytometry and Luminex
Cells were stained in 96-well round-bottom plates for surface markers,
including viability marker (Fixable Viability Dye eFluor 780; eBioscience)
in FACS buffer (PBS containing 0.5% FCS, 0.05% sodium azide, and 2 mM
EDTA) for 30 min after blocking Fc receptors for 5 min with Fc Receptor
Blocking Reagent (Miltenyi Biotec). Cells were then washed in FACS
buffer and fixed and permeabilized using a BD Cytofix/Cytoperm Kit,
according to the manufacturer’s instructions. Cells were then stained for
intracellular markers with FcR blocking for 15 min and washed again;
finally, cells were resuspended in 300 ml of FACS buffer and transferred to
alpha tubes for acquisition on a BD LSR II flow cytometer. The following
fluorophore-labeled Abs were used: anti-CD3–V500 (clone UCHT1), anti-
CD56–PE–Cy7 (clone NCAM16.2), anti-CD107a–FITC (clone H4A3),
anti-HLA-DR–PE (clone TU36) (all from BD Biosciences), anti-
IFN-g–allophycocyanin (clone 45.B3), anti-CD86–Alexa Fluor 488 (clone
IT2.2), anti-CD11c–PerCP-Cy5.5 (clone 3.1), anti-CD16–PE/Dazzle (clone
3G8), anti-CD14–Alexa Fluor 700 (clone 63D3) (all from BioLegend,
London, U.K.), anti-CD25–PerCP-Cy5.5 (clone BC96), anti-CD57–eFluor
450 (clone TB01), anti-CD19–PE–Cy5 (clone HIB19), anti-CD123–eFluor
450 (clone 6H6), and anti–IL-12(p40)–eFluor 660 (clone C17.8) (all from
eBioscience). Cells were acquired using FACSDiva software, and data
were analyzed using FlowJo v10 (TreeStar, Ashland, OR). FACS gates
were set using unstimulated cells or fluorescence minus one controls, and
samples with ,100 NK cell events were excluded. Concentrations of GM-
CSF, IFN-a2, IFN-g, TNF-a, IP-10, IL-1b, IL-10, and IL-12p70 in cell
culture supernatants were determined using Luminex technology (Merck
Millipore) and Bio-Plex software (Bio-Rad, Watford, U.K.).
Statistics
Statistical analysis was performed using GraphPad Prism version 7.01
(GraphPad, La Jolla, CA). Functional responses were compared using the
Wilcoxon signed-rank test, and intergroup comparisons between HCMV-
seropositive and HCMV-seronegative individuals were performed using
the Mann–Whitney U test. Correlation analysis was performed using linear
regression. Significance levels are assigned as *p , 0.05, **p , 0.01,
***p , 0.001, and ****p , 0.0001 for all tests. Analysis and presentation
of polyfunctional NK cell data were performed using SPICE version 5.1
(downloaded from https://niaid.github.io/spice/).
Results
Nanogram concentrations of IL-15 boost and sustain
functional NK cell responses to H3N2
To determine the effect of a low concentration of exogenous IL-15
on the frequency and kinetics of NK cell responses to influenza,
IFN-g, CD107a, and CD25 were measured at 6, 9, and 18 h after
stimulation of human PBMCs with H3N2 in the presence or ab-
sence of 0.75 ng/ml recombinant human IL-15. The flow cytom-
etry gating strategy is shown in Fig. 1A–D. H3N2 alone induced
high frequencies of NK cells expressing each of the three acti-
vation markers, but there was no significant response to IL-15
alone. At all time points, the percentage of expression of all
markers was significantly higher when cells were cultured with
H3N2 plus IL-15 compared with cells cultured with H3N2 alone
(Fig. 1E–G), with each marker displaying distinctly different ki-
netics (frequencies of cells expressing CD107a, IFN-g, and CD25
peaking at 6, 9, and 18 h, respectively). A low frequency of NK
cells showed spontaneous degranulation (CD107a expression) at
early time points (Fig. 1E), whereas there was little or no IFN-g
production or CD25 induction in unstimulated cultures (Fig. 1F, 1G).
Increased responses to H3N2 in the presence of IL-15 were re-
flected in increased mean fluorescence intensities (MFIs) for all
NK cell functional markers at their optimal time points. A small,
but significant, increase was observed in CD107a MFI at 6 h
(H3N2 median 747 units, interquartile range [IQR] 718–776;
H3N2+IL-15 median 768 units, IQR 735–813, p# 0.0001), IFN-g
MFI increased substantially by 9 h (H3N2 median 681 units, IQR
523–814; H3N2+IL-15 median 1037 units, IQR 864–1179, p #
0.0001), and a significant shift in CD25 MFI was observed by 18 h
(H3N2 median 72.5 units, IQR 34.7–153.8; H3N2+IL-15 median
371.5 units, IQR 249–508, p # 0.0001). Thus, very low concen-
trations of IL-15 boost the NK cell response to H3N2 stimulation
and lead to sustained CD107a and IFN-g production compared
with untreated cultures.
NK cells are a heterogeneous population of cells; CD56bright
subsets are highly responsive to cytokines, whereas the more
mature CD56dimCD57+ subset is known to be less responsive to
cytokines but maintains cytotoxic function (18). Therefore, we
analyzed the response of each of these subsets to IL-15 (flow
cytometry gating strategy shown in Supplemental Fig. 1A). As
expected, the early degranulation response was highest in the
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most mature (CD56dimCD57+) subset and IFN-g production was
highest in the less mature (CD56dimCD572) subsets at the peak of each
response (Supplemental Fig. 1B, 1F). However, at 6 h, IL-15 had little
effect on degranulation in the CD56dimCD57+ NK cell population,
whereas, by 9 h, the heightened response in the presence of IL-15 was
pronounced within the CD56bright and CD56dim subsets (Supplemental
Fig. 1B, 1E). Enhancement of NK cell IFN-g and CD25 responses to
influenza by low concentrations of IL-15 was evident to a similar
extent in all NK cell subsets (Supplemental Fig. 1C–J).
IL-15 enhances NK cell polyfunctionality
Because IL-15 appeared to enhance all three NK cell functions to a
similar degree, we considered the possibility that this was due to a
fraction of NK cells being highly sensitive to the effects of IL-15
and responding in a polyfunctional manner. We examined coex-
pression of IFN-g with CD107a, CD25, or both at each time point
(flow cytometry gating strategy shown in Fig. 2A–C). No poly-
functional NK cells were detected in unstimulated cultures or in
cultures containing only IL-15 (Supplemental Fig. 2A–C). When
cells were cultured with H3N2 alone, very few double- or triple-
positive NK cells were detectable (Fig. 2D–F); however, after 6 or
9 h of culture with H3N2 plus IL-15, a considerable population of
NK cells was double positive for IFN-g and CD107a (Fig. 2D); by
18 h, cells coexpressing IFN-g and CD25 (Fig. 2E), together with
a small, but statistically significant, population of triple-positive
NK cells (Fig. 2F), were detectable. Importantly, influenza virus
stimulation in the presence of as little as 0.75 ng/ml IL-15 was
almost as effective at inducing polyfunctional NK cells as much
higher concentrations of a combination of IL-12 and IL-18 (5 and
50 ng/ml, respectively, Supplemental Fig. 2A–C). Polyfunctionality
of NK cells was also evident from the statistically significant cor-
relation between expression of the different functional markers by
NK cells cultured with H3N2 plus IL-15 compared with those
cultured with H3N2 alone (Supplemental Fig. 2D–I). Overall,
therefore, IL-15 significantly increased the frequency of poly-
functional NK cells responding to influenza virus.
FIGURE 1. Nanogram concentrations of IL-15 boost and sustain functional NK cell responses to H3N2. PBMCs were cultured in vitro for 6, 9, and
18 h in medium alone (unstimulated; n = 12), IL-15 alone (n = 12), H3N2 (n = 62), or H3N2 plus IL-15 (n = 62). (A) NK cells are gated as CD56+CD32
lymphocytes. Flow cytometry gating strategy for NK cell CD107a (B), IFN-g (C), and CD25 (D) responses after an 18-h in vitro culture in one
representative individual. Numbers shown are the percentage of total NK cells positive for each marker. Graphs show the percentage of the total NK cell
population expressing CD107a (E), IFN-g (F), or CD25 (G). Data are median and 95% confidence interval. ***p , 0.001, ****p , 0.0001 H3N2 alone
versus H3N2 plus IL-15 by the Wilcoxon signed-rank test.
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IL-15 enhances in vitro production of myeloid cell–derived
cytokines
Because NK cells respond to cytokines released from activated
accessory cells, such as DCs and monocytes, supernatants were
collected from cultures at 18 h, and cytokine concentrations were
measured by Luminex. H3N2 alone induced secretion of significant
concentrations of IL-12 (p70), IFN-a2, IFN-g, GM-CSF, IL-1b,
TNF-a, and IL-10 (Fig. 3A–G). However, addition of low con-
centrations of IL-15 to H3N2 resulted in further significant in-
creases in the secretion of all of these cytokines, with the
exception of IL-10 (Fig. 3G). IL-15–mediated enhancement of IL-
12 secretion was observed in 42 of 73 donors (57.5%), with an
average 2.1-fold increase in these individuals (Fig. 3A). IL-15
costimulation increased IFN-a2 secretion in 66% of individuals
compared with H3N2 alone, with a median 1.2-fold increase
(Fig. 3B), as well as enhanced IFN-g by an average of 5.6-fold
(Fig. 3C), consistent with IL-15 boosting of NK cell IFN-g re-
sponses (Fig. 1). In contrast, IL-15 alone induced only modest
increases in IFN-g and GM-CSF production (median increase of
only 8.18 pg/ml for IFN-g and an increase in GM-CSF in only 3 of
FIGURE 2. IL-15 enhances NK cell polyfunctionality. CD107a and CD25 expression of IFN-g–secreting NK cells was gated at 6 h (A), 9 h (B), or 18 h
(C). Plots show NK cell function in one representative donor; number is the percentage of the parent population after stimulation with H3N2 plus IL-15.
Frequencies of IFN-g+CD107a+ double-positive (D), IFN-g+CD25+ double-positive (E), and IFN-g+CD25+CD107a+ triple-positive (F) NK cells, after Ag
stimulation with IL-15 (gray) or without IL-15 (black), at each time point (n = 62). Graphs are box-and-whisker plots with 10–90th percentiles. (G) Median
distribution of triple-, double-, and single-positive NK cells after stimulation with H3N2 alone or H3N2 with IL-15 for 18 h are shown as pie charts as
the percentage of total NK cells (pie slice) and the proportion expressing each marker (pie arc). ****p , 0.0001, Wilcoxon signed-rank test.
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20 donors) compared with unstimulated cells (Fig. 3C, 3D), and
IL-15 alone had no effect on IL-12 (p70), IFN-a2, IL-1b, TNF-a,
or IL-10 secretion (Fig. 3A, 3B, 3E–G).
In the presence of H3N2 and IL-15, the percentage of NK cells
producing IFN-g at 18 h was significantly correlated with the
secreted concentrations of IL-12 and type I IFN (Fig. 3H–M).
However, there was no enhanced correlation between NK cells
producing IFN-g and GM-CSF, TNF-a, or IL-1b with IL-15
(GM-CSF: r = +0.385, r = +0.391 with IL-15; TNF-a: r = +0.231,
r = +0.285 with IL-15; IL-1b: r = +0.197, r = +0.331 with IL-15),
suggesting that IL-12 and/or IFN-a2 might be driving the en-
hanced NK cell IFN-g response. In summary, IL-15 dramatically
enhances the secretion of myeloid cell–derived cytokines, and the
secretion of two of these cytokines (IL-12 and IFN-a2) is strongly
correlated with NK cell function.
IL-12 is critical for IL-15–mediated enhancement of NK cell
responses and generation of polyfunctional NK cells
Because IL-12 and IFN-a2 were induced by coculturing PBMCs
with H3N2 and IL-15, and because enhanced NK cell function
was correlated with the concentrations of these two monokines,
we tested the hypothesis that the effects of IL-15 on NK cells were
mediated via IL-12 and/or type I IFNs. Neutralizing Abs against
IL-12, IFN-abR2, and IL-2 were added to cultures stimulated
with H3N2 (with and without IL-15) for 6, 9, and 18 h. All three
NK cell functional responses were reduced in the presence of
FIGURE 3. IL-15 enhances in vitro production of myeloid cell–derived cytokines. Supernatants were collected from whole PBMCs cultured with
medium (n = 20), IL-15 (n = 20), H3N2 (n = 73), or H3N2 with IL-15 (n = 73) for 18 h, and concentrations of IL-12p70 (A), IFN-a2 (B), IFN-g (C),
GM-CSF (D), IL-1b (E), TNF-a (F), and IL-10 (G) were determined by Luminex technology. The correlation between NK cell IFN-g production was
determined by intracellular cytokine staining, and the concentration of IL-12 (p70) (H and K), IFN-a2 (I and L), and IFN-g (J and M) was determined
by Luminex after stimulation with H3N2 (H–J) or H3N2 with IL-15 (K–M). (A–G) Graphs are before-and-after plots. *p , 0.05, ****p , 0.0001,
Wilcoxon signed-rank test. (H–M) Correlations were measured by linear regression, with statistical significance determined as a p value , 0.05.
2742 IL-15 PROMOTES NK CELL RESPONSES BY BOOSTING IL-12
blocking Ab to IL-12 by 18 h (Fig. 4A–F), as well as at the earlier
time point of 9 h (data not shown); in particular, the frequency of
CD107a- or IFN-g–producing cells induced by H3N2 plus IL-15
was reduced to that observed in the absence of IL-15 (Fig. 4A–E).
Degranulation was also dependent, in part, on type I IFNs, be-
cause blockade of the IFN-abR2 receptor led to a partial reduc-
tion in CD107a expression in cultures treated or not with IL-15
(Fig. 4A, 4D). Blocking IL-2 also reduced CD107a upregulation
after H3N2 stimulation, irrespective of the presence or absence of
IL-15 (Fig. 4A, 4D). However, although anti–IL-2 reduced the NK
cell IFN-g response to H3N2, no such reduction was seen in the
response to H3N2 plus IL-15, suggesting that IL-15 may be
substituting for IL-2 in this assay.
In addition to reducing the overall frequencies of CD107a+,
IFN-g+, and CD25+ NK cells, IL-12 blockade had a marked
effect on the induction of polyfunctional NK cells. IL-12 neutrali-
zation reduced the frequencies of double- and triple-positive NK
cells to the levels observed without IL-15 (Fig. 4G–J). These data
suggest that the heightened NK cell response to H3N2 and the
generation of polyfunctional NK cells in response to IL-15 are de-
pendent on accessory cell IL-12. Furthermore, correlations between
different NK cell functional markers (as seen in Supplemental
Fig. 2D–I) are also seen when NK cells are stimulated with
high concentrations of exogenous IL-12 and IL-18 (data not
shown). Stimulation of purified NK cells with H3N2 alone or with
IL-15 induced no significant activation, confirming an accessory
cell requirement for the virus-induced response and IL-15–medi-
ated enhancement (IFN-g percentage at 18 h: H3N2 median
0.29%, IQR 0.25–0.368%, H3N2+IL-15 median 0.465%, IQR
0.308–0.84; CD107a percentage at 18 h: H3N2 median 0.93%, IQR
0.605–1.293%, H3N2+IL-15 median 1.68%, IQR 0.75–2.475%).
IL-15 enhances IL-12 production by mDCs
To determine the source of IL-15–induced IL-12 within PBMCs,
stimulations were performed with H3N2 in the presence or ab-
sence of IL-15 for 18 h, and cells were stained for DC/monocyte
phenotypic markers and for intracellular IL-12(p40). DC pop-
ulations were gated as lineage2CD142HLA-DR+ cells and further
split into CD1232CD11c+ mDC and CD123+CD11c2 plasmacy-
toid DC (pDC) populations. The majority of IL-12–producing
cells were mDCs rather than pDCs, classical (CD14+CD162)
monocytes, or nonclassical (CD142CD16+) monocytes (Fig. 5A).
Up to 3.1% of mDCs expressed IL-12 in response to H3N2, and a
significantly higher proportion (4.5%) were IL-12+ with the
combination of H3N2 and IL-15 (a median 1.9-fold increase)
(Fig. 5A). Furthermore, IL-15–mediated enhancement of IL-12
production was observed only in DCs and was associated with
increased expression (MFI) of CD86 (Fig. 5B). Little to no IL-12
was detected in unstimulated mDCs or in those treated with IL-15
alone (Fig. 5C). Of the 14 individuals tested, 8 (57.1%) showed an
increase in IL-12 production by mDCs with H3N2 plus IL-15
compared with H3N2 alone, corresponding with the proportion
of responders determined by Luminex detection of IL-12 in su-
pernatant (Fig. 5D). Among these eight responders, there was also
an increase in the MFI of IL-12 staining of mDCs cultured with
H3N2 plus IL-15 compared with H3N2 alone (Fig. 5E). These
data suggest that IL-15 potentiates NK cell responses to H3N2 by
enhancing maturation (CD86 expression) and IL-12 production
specifically from mDCs.
Enhancement in NK cell function by IL-15 is observed in
HCMV-seropositive and -seronegative individuals
We (19, 20), and other investigators (21, 22) have reported
altered NK cell functions in HCMV-seropositive individuals.
HCMV-seropositive individuals also respond less well to exoge-
nous cytokines and vaccine Ags (including H3N2), and this is only
partially explained by accelerated NK cell differentiation (19, 20).
We again observed lower NK cell CD107a, IFN-g, and CD25
responses to H3N2 among HCMV-seropositive donors than
among HCMV-seronegative donors (Fig. 6). Low concentrations
of IL-15 enhanced the responses of HCMV-seropositive and
-seronegative subjects but could not fully restore the NK cell re-
sponse of HCMV-seropositive subjects to the level seen in HCMV-
seronegative subjects (Fig. 6A–C). Interestingly, however, IL-15
completely restored the IFN-g response of CD56bright and
CD56dimCD572 NK cells, but not CD56dimCD57+ cells, in
HCMV-seropositive individuals (Fig. 6E, 6H). This suggests that
IL-15 preferentially affects immature NK cells, normalizing their
IFN-g response to H3N2 to the level seen in HCMV-seronegative
individuals. With the exception of a reduced IFN-g response,
which may be accounted for by reduced production from NK cells
in seropositive individuals, there was no difference in the in vitro
production of lymphoid or myeloid cell–derived cytokines in re-
sponse to H3N2 between HCMV-seropositive and -seronegative
donors, irrespective of the presence or absence of IL-15
(Supplemental Fig. 3).
Discussion
Many studies of the effect of IL-15 on NK cell activation focus on
IL-15 trans-presentation or direct activation of NK cells with high
concentrations of IL-15 (typically between 5 and 50 ng/ml) in
combination with other cytokines (5, 10). Moreover, the synergy
between cytokines and pathogen-derived signals for NK cell ac-
tivation has typically been studied only for high concentrations of
cytokines acting on isolated NK cells, precluding consideration of
the potential indirect effects of the pathogen, the cytokines, or
both. To characterize more deeply the potential for synergy be-
tween IL-15 and pathogen-derived signals in NK cell activation,
we have conducted a comprehensive analysis of NK cell CD107a,
IFN-g, and CD25 expression and myeloid cell–derived cytokine
secretion in response to H3N2 in the presence or absence of an
extremely low concentration of IL-15.
Low concentrations of IL-15 enhanced the innate cytokine
response to influenza virus, and this increased cytokine (primarily
IL-12) was associated with potentiation of NK cell function. Im-
portantly, the concentrations of endogenous IL-12 induced by this
synergistic interaction between influenza virus and IL-15 are of the
same order of magnitude as the lowest concentrations of IL-12 that
we have previously shown to effectively synergize with IL-15 and
other common g-chain family cytokines for NK cell activation
in vitro (13). The measured concentration of IL-12 and the con-
centration of IL-15 used in this study are $5-fold lower than the
described effective concentrations for NK cell activation with
single cytokines and may be more physiologically relevant than
the higher concentrations previously studied in vitro. The low
in vitro concentration used in this study is within the range for the
maximal serum concentration achieved therapeutically in patients
with metastatic malignant melanoma or renal cancer after a low-
dose transfusion of 0.3 mg/kg/day recombinant human IL-15 and
which resulted in increases in innate cytokines (23).
In this article, we have shown that IL-15 preferentially enhances
virus-induced mDC maturation (measured by upregulation of
costimulatory marker CD86), as well as cytokine secretion,
compared with other DC subsets and monocytes and that, together,
this heightens and sustains NK cell activation. This role for mDCs
is fully in line with the known pathogen-recognition repertoire and
cytokine-production profile of mDCs (24, 25). Similarly, the
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essential role for DC-derived IL-12 in NK cell activation is in line
with published data, including data showing that IL-12 synergizes
with specific Ab for NK cell–mediated Ab-dependent cell–medi-
ated cytotoxicity of tumors (26, 27), that NK cell activation by
HPV-like particle–matured DCs is reversed by IL-12–blocking
Abs (28), and that exogenous IL-12 can restore NK cell function
FIGURE 4. IL-12 is critical for IL-15–mediated enhancement of NK cell responses and generation of polyfunctional NK cells. PBMCs were cultured for
6, 9, and 18 h with H3N2 (A–C) and H3N2 plus IL-15 (D–F) in the presence of IL-12–, IFN-abR2–, or IL-2–blocking Ab or the appropriate isotype control.
Graphs show CD107a (A and D), IFN-g (B and E), and CD25 (C and F) responses after an 18-h culture, and frequencies of IFN-g+CD107a+ (G), IFN-g+
CD25+ (H) double-positive and IFN-g+CD25+CD107a+ triple-positive (I) NK cells after 9 h (peak of IFN-g response) or 18 h (peak of CD25 response)
(n = 11). Graphs are box-and-whisker plots with 10–90th percentile. (J) Median distributions of triple-, double-, and single-positive NK cells after
stimulation with H3N2 and IL-15 for 18 h are shown as the percentage of total NK cells (pie slice) and the proportion expressing each marker (pie arc).
*p , 0.05, **p , 0.01, ***p , 0.001, Wilcoxon signed-rank test.
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in HIV-exposed, but uninfected, infants (29). Interestingly, IL-15
synergizes well in vitro with IL-12 and IL-18 but not with other
IL-2Rg-chain–dependent cytokines, including IL-2 and IL-21,
suggesting some redundancy between the latter pathways (13).
This is also consistent with our observation that neutralization of
endogenous IL-2 did not reduce NK cell IFN-g in response to
H3N2 and IL-15.
Enhancement of NK cell function by IL-15 is well established
(30). IL-15 has also been reported to enhance DC maturation
(measured by upregulation of CD40, CD86, and MHC class II ex-
pression) in mice (17, 31). In line with our observations in humans,
DCs cultured with HPV-like particle matured more efficiently in the
presence of IL-15, and this correlated with enhanced NK cell acti-
vation and killing of HPV-infected tumor cells (17). However, the role
of IL-15 enhancement of IL-12 production by peripheral DCs has not
been previously appreciated or linked to enhanced NK cell responses.
Interestingly, one study demonstrated that IL-15 enhancement of
IL-12 secretion by a PMA-activated U937 monocytic cell line was
FIGURE 5. IL-15 enhances IL-12 production by mDCs. PBMCs were cultured with H3N2 or H3N2 with IL-15 (n = 14) for 18 h, and cells were stained for DC
and monocyte phenotypic markers and intracellular IL-12. Single live cells were further gated as lineage (CD3, CD19, CD56) negative, classical (CD14+CD162),
and nonclassical (CD142CD16+) monocytes, all CD14+ and CD142 cells, all CD142HLA-DR+ DCs, mDCs (CD1232CD11c+), and pDCs (CD123+CD11c2).
IL-12+ events (A) and CD86 MFI (B) for each cell type was gated using fluorescence minus one controls and shown as one data point per donor; the horizontal line
represents the median. (C) Flow cytometry gating strategy for IL-12+ mDCs is shown in one representative individual; numbers denote the percentage
of IL-12+ mDCs. Before-and-after plots show the percentage of mDCs expressing IL-12 for each individual when stimulated with H3N2 +/2 IL-15 (D)
and the corresponding IL-12 MFI for each responder and nonresponder with IL-15 costimulation (E). *p , 0.05, Wilcoxon signed-rank test.
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associated with increased ability to kill intracellular Leishmania
parasites, suggestive of a potential role for such mechanisms in
protection against infection (32).
The cytotoxic and cytokine-producing roles of NK cells have
traditionally been ascribed to distinct NK cell subsets (CD56dim and
CD56bright, respectively), and this dichotomy has rather obscured the
potential for NK cells to perform both functions simultaneously
(i.e., to be polyfunctional). Nevertheless, polyfunctional CD56dim
CD62L+ NK cells (with dual ability to produce IFN-g and become
cytotoxic) can be induced by stimulation with high concentrations
(50 ng/ml) of IL-12 and IL-18 (33), and TLR stimulation induced
polyfunctional NK cells (expressing two or more of CD107a, IFN-g,
and TNF-a) in HIV-1–exposed seronegative, but not seropositive,
individuals (34). We defined polyfunctionality as simultaneous ex-
pression of two or more of IFN-g, CD107a, and CD25 by any NK
cell subset; no polyfunctional cells were induced by IL-15 alone, and
very few were detected in response to influenza virus alone. However,
stimulation with IL-15 and virus induced significant numbers of
double- and triple-positive NK cells, suggesting that synergy (likely at
the level of mDCs) between IL-15 and pattern recognition receptor
signaling may be necessary for the induction of polyfunctional NK
cells. This may be due, in part, to the dependence of NK cells on IL-
12 to drive IFN-g production and on IFN-a and IL-15 to drive cy-
totoxicity (2, 35).
Our observation that IL-15 restored the impaired responses of
HCMV-seropositive individuals only among the less differentiated
CD56bright and CD56dimCD572 NK cell subsets, as well as that
(with the exception of IFN-g production) there were no differ-
ences in cytokine production by PBMCs from HCMV-seropositive
and -seronegative donors, suggests that polyfunctionality may
arise from broadening the effector function of less mature NK
subsets rather than any effect on mature NK subsets. This effect is
entirely consistent with IL-12–mediated IL-15 enhancement of
NK cell responses, IL-12R expression, and, therefore, respon-
siveness being progressively lost during NK cell differentiation
and in adaptive NK cell subsets (18, 36). Moreover, these data
suggest that reduced NK cell responses in HCMV-seropositive
individuals are not due to an accessory cell defect but may
result from intrinsic changes in more-differentiated NK cells
(18, 22). This hypothesis, that IL-15 broadens the functional
response of immature NK cells, is further supported by evi-
dence that degranulation and IFN-g and TNF-a production
from CD56bright NK cells are potently enhanced by exposure to
multiple myeloma or acute myeloid leukemia target cells after
in vivo therapy with the IL-15R agonist ALT803 (37). The use
of an IL-15/IL-15Ra superagonist may further boost NK cell
responses to H3N2; however, this would be expected to act on
NK cells directly, because IL-15 is already complexed to its
receptor, therefore potentially bypassing accessory cell–de-
pendent effects.
In summary, we have revealed an unexpected impact of very
low concentrations of IL-15 on the production of cytokines, in
FIGURE 6. Enhancement in NK cell function by IL-15 is observed in HCMV-seropositive and -seronegative individuals. HCMV serostatus for each
individual was determined (n = 35 seropositive and n = 38 seronegative). CD107a (A), IFN-g (B), and CD25 (C) expression within each group after
stimulation with H3N2 or H3N2 plus IL-15 for 6, 9, or 18 h. NK cell responses attributed to each differentiation subset determined by the expression of
CD56 and CD57, CD56bright, CD56dimCD572, and CD56dimCD57+ were analyzed (flow cytometry gating strategy in Supplemental Fig. 1A). Graphs show
median with 95% confidence interval. CD107a (D and G), IFN-g (E and H), and CD25 (F and I) expression within each subset is shown for
HCMV-seropositive and -seronegative individuals; only the peak time point for each response is shown. Each dot represents an individual donor; the
horizontal line represents the median. *p , 0.05, **p , 0.01, ***p , 0.001, ****p , 0.0001, H3N2 versus H3N2 plus IL-15, Wilcoxon signed-rank test
(A–C), unpaired Mann–Whitney U test (D–I). ns, not significant.
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particular IL-12 from mDCs, which, in turn, plays a vital role in
boosting NK cell responses to influenza virus (summarized in
Supplemental Fig. 4). In addition to increasing the overall fre-
quencies of responding NK cells, IL-15 promotes the generation
of polyfunctional NK cells. These studies suggest that the use of
very low dose IL-15 may be a strategy for enhancing and
broadening NK cell effector function in immunotherapy and in
enhancing vaccine responses.
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